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ABSTRACT
Agonist-induced contraction of airways smooth muscle is mediated by
phosphoinositide hydrolysis and the production of the second messenger
inositol 1,4,5-trisphosphate (Ins(l,4,5)P3). Muscarinic receptor-stimulation of
bovine tracheal smooth muscle (BTSM) results in a transient increase in
Ins(l,4,5)P3 mass despite a sustained, non-desensitising hydrolysis of its
precursor phosphatidylinositol 4,5-bisphosphate (Ptdlns(4/5)P2). Hence the
rapid metabolism of Ins(l,4,5)P3 appears to be the major regulator of
Ins(l,4,5)P3 levels under agonist-stimulated conditions. A model system has
been developed to facilitate detailed study of the pathways involved in this
complex metabolism. BTSM slices were labelled to equilibrium with myo-
[3H]inositol in the presence of agonist and subsequent carbachol (CCh)- or
histamine (Hist)-stimulations carried out in the presence of lithium ions to
block InsPi breakdown. A delayed accumulation of [3H]Insl/3P and
[3H]Ins4P was observed under agonist-stimulated conditions. Moreover,
there was no demonstrable phosphoinositide hydrolysis either following
membrane-depolarisation, or secondary to a physiologically relevant
increase in intracellular calcium in this tissue. The model therefore provides
an appropriate system for the study of receptor-stimulated PtdIns(4,5)P2-
derived Ins(l,4,5)P3 metabolism. Cell-free experiments confirmed that
Ins(l,4,5)P3 is metabolised primarily by two different pathways - a 3-kinase
and a 5-phosphatase pathway - which yield mutually exclusive products.
H.P.L.C. separation of the individual [3H]inositol polyphosphate (InsPP)
isomers accumulating in BTSM slices enabled the 3-kinase and 5-
phosphatase metabolites to be quantified, and facilitated the determination
of flux of the inositol headgroup through these two pathways. The pattern
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of Ins(l/4,5)P3 metabolism varies during the lifetime of the agonist-
stimulated response: The 5-phosphatase enzyme is highly dominant
especially at early time-points following agonist-stimulation, whilst the 3-
kinase becomes increasingly important at later time-points. Several possible
regulators of the InsPP metabolising enzymes were studied in order to try
and elucidate the factors which may determine the fate of Ins(l,4,5)P3 in
BTSM. Kinetic analysis reveals that physiological concentrations of calcium
ions have no effect on the activity of the 5-phosphatase and 3-kinase
enzymes in crude BTSM extracts. It is generally thought that the 3-kinase
may be activated by Ca2+/calmodulin via an increase in its Vmax; however
this conclusion is based on studies pre-dating the discovery that 3-kinase
may be a substrate for the calcium-activated neutral protease calpain. The
inclusion of calpain inhibitors in my experiments may explain the conflicting
results. The metabolism of Ins(l,4,5)P3 in stimulated BTSM slices appears to
be agonist-specific such that the proportion of [3H]Ins(l,4,5)P3 entering the 3-
kinase pathway is greater in slices stimulated with Hist than with CCh. The
protein kinase C-activating phorbol ester phorbol dibutyrate has a more
potent inhibitory effect on the accumulation of [3H]InsPPs stimulated by
Hist (IC50 = 5 nM) than by CCh (IC50 = 230 nM). Similarly, the long-acting
{32-agonist salmeterol potently inhibits Hist-stimulated [3H]InsPP
accumulation (IC50 = 0.24 nM) but is without detectable effect on CCh-
stimulated [3H]InsPP formation. In addition to the well-characterised 3-
kinase and 5-phosphatase pathway metabolites, an agonist-stimulated
accumulation of a further [3H]InsP2, co-eluting with [3H]Ins(4,5)P2, was
observed. Accumulation of this isomer exhibited a bell-shaped lithium
concentration response curve and was maximal in the presence of 10 mM
LiCl. These data indicate the possible existence of a novel 1-phosphatase
enzyme for the removal of Ins(l,4,5)P3 in this tissue.
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Control of airways smooth muscle (ASM) tone is essential for regulating
airways calibre and hence the resistance of the airways. There is also
considerable evidence to suggest that airway wall remodelling, including
hypertrophy and hyperplasia of ASM is an important contributer to
airway responsiveness in asthmatic patients (Wiggs et al., 1992). A
variety of neurotransmitters (released from endogenous neurones),
hormones and peptides (either blood-borne or produced locally by pro¬
inflammatory cells) can elicit contraction of ASM following their binding
to, and stimulation of, surface receptors on the ASM cells. It is now well
established that excitation-contraction coupling is achieved principally by
a pharmacological process (i.e. pharmacomechanical coupling) rather
than an electrical response (i.e. electromechanical coupling). Hence
agonist stimulation of ASM is associated with the hydrolysis of a minor
membrane lipid component namely phosphatidylinositol 4,5-
bisphosphate (PtdIns(4,5)P2), resulting in the formation of the second
messengers inositol 1,4,5-trisphosphate (Ins(l,4,5)P3) and diacylglycerol
(DAG) (e.g. see Berridge, 1987; Rana and Hokin, 1990). DAG can activate
protein kinase C (PKC) (e.g. Hug and Sarre, 1993; Wilkinson and Hallam,
1994) while Ins(l,4,5)P3 can stimulate Ca2+ release from intracellular
stores to provide the activator Ca2+ necessary for the initiation of
contraction (see Berridge, 1993; Berridge and Irvine, 1989). The agonist-
stimulated contraction appears to be unaltered in asthmatic compared to
non-asthmatic subjects (Cerrina ct al., 1986; Coyle et al., 1990; Goldie et al.,
1986; Whicker et al., 1988). Nonetheless, the dominant role played by
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Ins(l,4,5)P3 in initiating agonist-mediated contraction in ASM
necessitates an understanding of the factors regulating Ins(l,4,5)P3
formation and metabolism in this tissue, and further research may
facilitate the generation of clinical modulators of the Ins(l,4,5)P3
response. Moreover, an understanding of the complex interplay between
phosphoinositide hydrolysis and other second messenger systems may
further our understanding of the mechanisms underlying both the
maintainance of contraction of ASM and the relaxant action of currently
used bronchodilators.
1.1 AIRWAYS SMOOTH MUSCLE PHYSIOLOGY
1.1.1 Structure of airways smooth muscle
In the foetus the trachealis consists of both outer (longitudinal) and
inner (transverse) portions together with a mucosal layer (the muscularis
mucosae) (Hakanson et al., 1976); however during development the outer
and mucosal layers are lost, and when fully developed only the
transverse layer - the muscularis transversus tracheae - remains. The
trachealis is classified as a multi-unit smooth muscle consisting of many
individual cell units (myocytes) each with their own nerve supply,
arranged into thick, non-branching, parallel-set bundles of smooth
muscle which connect the ends of the C-shaped tracheal cartilage rings.
The individual myocytes are typically 5-10 |im in diameter and 50-200 pm
long (Stephens, 1987) and the bundles are physically separated from each
other by spaces filled with connective tissue (Dixon and Small, 1983).
While several cell-cell communications exist within each bundle in the
form of intermediate junctions, the density of true gap junctions is very
low in this tissue; furthermore there are almost no communications
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linking the muscle cells bundles. The relative paucity of gap junctions
confers poor electrical conductivity on the trachealis muscle (Dixon and
Small, 1983) and the resting membrane potential (Em) is very stable (-45 -
-60 mV; Stephens, 1987) due to the strong rectifying properties of the
plasmalemma (Kirkpatrick, 1975). Following neuronal or
pharmacological stimulation ASM does not normally exhibit action
potentials; in contrast, the pattern of innervation and the poor electrical
conductivity of this tissue confer a slow, graded deplolarisation response
in which the difference between the resting Em and the mechanical
threshold is typically only ~ 5 mV (Stephens, 1987).
1.1.2 Innervation of the airways
The innervation of ASM is complex, consisting in most species of two
neuronal pathways mediating contraction and two linked to relaxation of
the muscle. The trachealis muscle is richly innervated with afferent
parasympathetic cholinergic neurones, stimulation of which results in
contraction of the muscle. These neurones provide the dominant control
of ASM tone, utilising acetylcholine (ACh) as a neurotransmitter. In
addition, stimulation of an excitatory non-adrenergic non-cholinergic
(eNANC) system can also facilitate contraction of ASM; the tachykinins
substance P, neurokinin-A and neuropeptide-B have been localised to
sensory afferent nerves and are believed to be the neurotransmitters for
eNANC (Hua et al., 1985; Lundberg et al., 1984). Conversely inhibitory
non-adrenergic non-cholinergic (iNANC) stimulation mediates
relaxation of ASM. The precise identification of the neurotransmitter for
this system remains uncertain, but strong candidates are vasointestinal
peptide and nitric oxide (Belvisi, 1992; Li and Rand, 1991; Matsuzaki et al.,
1980). Direct sympathetic (adrenergic) innervation of ASM, employing
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noradrenaline as a neurotransmitter appears to be species dependent;
while it has been demonstrated in a number of animal species (although
the innervation is often sparse), it appears to be entirely absent in man
(Cabezas et al., 1971; El-Bermani, 1987; O'Donnell and Saar, 1973; see
Richardson, 1979). Fibres from cervical sympathetic ganglia do penetrate
the airways however to supply vascular tissue, and have a regulatory
influence at the parasympathetic ganglia level (see Richardson, 1979). In
addition, ASM cells possess [3-adrenoceptors, predominantly (80-90 %) P2-
adrenoceptors, and hence can elicit relaxation in response to circulating
catecholamines (Barnes et al. 1983c; Popovich et al., 1984).
1.1.3 Muscarinic acetylcholine receptors in airways smooth muscle
Receptor-binding and autoradiographic studies have identified a high
density of muscarinic receptors in the smooth muscle layer of the trachea
and large airways from a number of animal species (Barnes et al., 1983a
and b; Basbaum et al., 1984; Cheng and Townley, 1982; Murlas et al., 1982;
Van Koppen et al., 1985). There appears to be a muscarinic receptor
gradient in the ASM of ferret lung as Barnes and colleagues (1983a and b)
noted a decrease in binding of the muscarinic ligand [3H]quinuclidinyl
benzilate (QNB) from the large to the small airways.
Original studies in other tissues, measuring the binding affinity of the
muscarinic antagonist pirenzepine, led to the division of muscarinic
receptors into three functional subclasses Mi .3 (Birdsall et al. 1980;
Hammer, 1980). The arrival of more specific muscarinic agonists and
antagonists however, has highlighted additional heterogeneity of the
originally described M2 subtype. A revised classification on the grounds
of several structural and pharmacological criteria identifies at least four
(Mi.4) receptor subtypes. The latter classification has now been
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substantiated by the cloning, sequencing and expression of distinct but
homologous genes (ml-m4) encoding these receptor subtypes (Bonner,
1989; Peralta et al., 1987). A fifth muscarinic receptor gene (m5) has also
been cloned from rat and human tissue but currently awaits its
pharmacological equivalent (M5) (Bonner et al., 1988; Liao et al., 1989).
Further heterogeneity of muscarinic receptors is suggested by Bognar and
colleagues (1992) who observed contraction of rabbit iris smooth muscle
following stimulation of a muscarinic receptor with an antagonist-
affinity profile distinct from Mi-4 receptors or indeed that of the m5 gene
product.
It is now evident that many smooth muscles co-express multiple
muscarinic receptor subtypes (e.g. Leiber et al., 1990; Mahesh et al., 1992).
Displacement of pH]QNB binding to ASM preparations by M2-selective
(AF-DX-116) and M3-selective (HHSiD and 4-DAMP) receptor antagonists
has identified both M2 and M3 receptor subtypes in this tissue, with the
former representing up to 89 % of the total muscarinic receptor pool
(Fernandes et al., 1992; Mahesh et al., 1992).
Expression of cloned muscarinic receptors has facilitated the
identification of the signal transduction mechanisms employed by the
receptor subtypes. Generally M3 receptors couple to stimulation of
phosphoinositide hydrolysis (e.g. Pinkas-Kramarski et al., 1988; Wess et
al., 1989) wheras activation of M2 receptors couple via a pertussis toxin-
sensitive G-protein (G;) to inhibtion of adenylyl cyclase (e.g. Ashkenazi et
al., 1987, 1989). In accordance with these data, activation of M3 receptors
in ASM results in the generation of contraction, secondary to
phosphoinositide hydrolysis (Roffel et ui, 1990a), however there is
considerable controversy concerning the role of the predominant M2
receptor pool. It has been suggsted that since M2 receptors are coupled to
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the inhibition of adenylyl cyclase their activation may explain (at least in
part) the relative resistance of muscarinic cholinoceptor-mediated
contraction to the relaxant effects of ^-adrenoceptor agonists (see Eglen et
al., 1994b and c). It has also been suggested however, that the extent of (3-
adrenoceptor mediated relaxation is controlled instead by the level of M3
receptor-mediated contractile tone (see Roffel et al., 1994).
Pre-junctional muscarinic autoreceptors may modulate ACh release,
thereby exerting a regulatory role on muscarinic receptor-mediated
contraction of ASM. Such inhibitory autoreceptors have been identified
in the pre-junctional neurones serving many smooth muscles including
human and guinea-pig airways (D'Agnostino et al., 1990; Minette and
Barnes, 1988). While there is some uncertainty over the identity of this
autoreceptor (either M2 or M4) current evidence favours an M2 or 'M2-
like' subtype (see Watson, 1994).
1.1.4 Non-muscarinic contractile receptors in airways smooth muscle
In addition to muscarinic cholinergic receptors, Hi histaminergic
receptors have been localised to the smooth muscle of both the small and
large airways where occupancy of the Hi receptor with histamine (Hist) is
closely related to the contractile response (Grandordy and Barnes, 1987).
A wide range of regulatory peptides which elicit a contractile response,
including substance P, tachykinins and gallanin, have also been identified
in ASM (see Polak and Bloom, 1986) although their signal transducing
mechanisms are less well characterised.
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1.2 MECHANISM OF AIRWAYS SMOOTH MUSCLE CONTRACTION
The force induced by ASM following agonist activation can be divided
into two components - a rapid initial increase in force (phasic
contraction), followed by a slower, maintained contractile phase (tonic
contraction). The mechanisms governing the generation and regulation
of these two contractile states may differ, and although great advances in
our understanding of force generation in smooth muscle have been
made in recent years, the mechanisms underlying force maintenance in
this tissue remain poorly understood.
1.2.1 Contractile proteins in airways smooth muscle
As in striated muscle, actin represents the major contractile protein
present in ASM. This protein is highly conserved in eukaryotic cells and
is readily demonstrable in smooth muscle (e.g. Fatigati and Murphy,
1984). Actin monomers (globular actin or G-actin) polymerise to form F
(filamentous)-actin with two linear chains of actin coiled into a right-
handed double helix. Each G-actin monomer contains a binding site for a
second contractile protein, myosin. This latter protein is present in
smooth muscle in much lower proportions than in striated muscle, being
some 10-20 fold less abundant than actin. Myosin is a hexameric protein,
comprising a single pair of heavy peptide chains folded into a globular
'head' and a 'tail', and two pairs of light chains (17 KDa and 20 KDa)
located at the head region. Myosin molecules combine to form thick,
bipolar filaments, each globular head containing actin-binding sites and
two Ca2+-stimulated, Mg2+-dependent ATPase activities (myosin
ATPase). Further actin-binding proteins which may play a role in
regulating contraction have been identified in smooth muscle including
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tropomyosin (Cummins and Perry, 1973; Fatigati and Murphy, 1984),
caldesmon (see Walsh, 1990) and calponin (Takahashi et al., 1988).
1.2.2 Force generation in airways smooth muscle
Evidence to support the increase in the free intracellular calcium
concentration ([Ca2+]j) as being the primary initiator of the contractile
response was first presented by Filo et al. (1965) in permeabilised vascular
smooth muscle preparations. This finding was later substantiated in
smooth muscle by Taylor (1989) and it is now recognised that a 4-10 fold
increase in free intracellular Ca2+ ([Ca2+]j) from a basal level of 70-180 nM
is necessary for the initiation of contraction (Felbel et al., 1988; Fujiwara et
al., 1988; Kotlikoff et al., 1987; Takuwa et al., 1988; Taylor and Stull, 1988;
Taylor et al., 1988).
In resting smooth muscle myosin forms weak contacts with actin
molecules, however following stimulation, the myosin heads form
transient, but tighter attachments to actin (cross-bridges) before
detachment and re-attachment to a G-actin monomer further along the
actin filament (cross-bridge cycling). The resulting sliding of the thick
and thin filaments over each other results in contraction, with the
magnitude of force related to the degree of interdigitation of the
filaments. The energy required for the cross-bridge cycling is provided by
ATP hydrolysis catalysed by the myosin ATPase, and hence force-
generation is dependent on activation of myosin ATPase. In contrast to
striated muscle in which myosin ATPase is constitutively active unless
regulated by the actin-binding proteins troponin and tropomyosin, a
mixture of partially purified smooth muscle actin and myosin exhibits
little myosin ATPase activity (see Giembycz, 1994). These data suggest the
presence in smooth muscle of a Ca2+-regulated factor responsible for the
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activation of myosin ATPase which is removed during the purification
procedure.
It is now known that activation of the calmodulin-dependent enzyme
myosin light chain kinase (MLCK) is both necessary and sufficient to
facilitate smooth muscle contraction (Itoh et al., 1989). MLCK is inactive
in the absence of Ca2+ ions, however it has a high affinity (Kj ~ 1 nM) for
Ca2+/calmodulin, and in the presence of raised [Ca2 + ]j forms a
Ca2+4:calmodulin:MLCK complex which exhibits phosphotransferase
activity (see Adelstein and Eisenberg, 1980). MLCK shows strict substrate
specificity for the 20 KDa light chain of myosin (LC20) which, when
phosphorylated, facilitates actin-mediated activation of myosin ATPase
(Kamm and Stull, 1985). Taylor et al. (1989) reported a direct correlation
between [Ca2 + ]j and LC20 phosphorylation irrespective of the source of
[Ca2+]j; furthermore the peak in LC20 phosphorylation precedes maximal
force generation (de Lanerolle et al., 1982; de Lanerolle and Stull, 1980;
Gerthoffer and Murphy, 1983; Kamm and Stull, 1985; Silver and Stull,
1984). These data indicate that LC20 phosphorylation, catalysed by
Ca2+ /calmodulin-activated MLCK, is the primary biochemical
determinant for force generation in ASM.
1.2.3 Force maintenance in airways smooth muscle
As described above contraction of ASM can be divided into a phasic and a
tonic component. These contractile states reflect a phasic and tonic [Ca2+]i
response whereby agonist stimulation results in a rapid and transient
[Ca2+]jpeak followed by a plateau of [Ca2+]j slightly above basal levels.
During the tonic phase of smooth muscle contraction the level of LC20
phosphorylation decreases from that associated with phasic contraction,
and plateaus at a concentration slightly above basal. Hence maintained
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tension can be achieved in ASM despite the [Ca2+]i and phosphorylated
LC20 concentrations being relatively low.
Force is maintained during tonic contraction, whereas shortening
velocity decreases rapidly from that obtained in phasic contraction to
reach a relatively low steady-state value. Since force is governed by the
number of attached cross-bridges, and shortening velocity is determined
by the rate of cross-bridge cycling, it would appear that in the maintained
contractile state cross-bridge cycling is dramatically slowed. Flence tonic
contractions are energetically economical, utilising relatively little ATP.
Much interest has focussed on the regulation of myosin phosphorylation
during tonic contraction in order to gain some insight into the factors
governing maintained force. The degree of myosin phosphorylation is
determined by the relative activities of MLCK and myosin light chain
phosphatase (MLCP). There is evidence to suggest that during tonic
contraction of smooth muscle MLCK may be phosphorylated by Ca2+-
calmodulin kinase (CaM kinase II) (Stull et ah, 1990), cyclic AMP-
dependent protein kinase (PKA) (Conti and Adelstein, 1981; Nishikawa et
al., 1984, 1985; Stull et al., 1990) and protein kinase C (Nishikawa et ah,
1985). Phosphorylation by the former two enzymes results in a decrease
in the affinity of MLCK for Ca2+/calmodulin and hence a decrease in its
activity. If this process occurs in vivo it may serve to limit cross-bridge
formation and hence decrease shortening velocity.
Several different MLCPs have been purified and characterised from
smooth muscle (see Cai et ah, 1994) some of which are tightly associated
with myosin filaments. It has been proposed that G-proteins may
decrease MLCP activity since G-protein receptor-linked contractile
agonists and GTPyS increase myosin phosphorylation and inhibit MLCP
in skinned vascular smooth muscle fibres (Kitazawa et ah, 1991a and b).
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In addition to the absolute level of myosin phosphorylation, a change in
the flux of phosphorylated LC20 may serve to regulate ASM tone, since it
has been observed that myosin kinase inhibitor, or MKI (an inhibitor of
both MLCK and MLCP), inhibits shortening velocity in skinned taenia
coli (Strauss et al., 1992). This data suggests that shortening velocity may
vary despite levels of LC20 phosphorylation remaining fairly constant.
While a direct relationship between LC20 phosphorylation and force
generation has been clearly demonstrated in ASM, correlative studies
have failed to demonstrate a tight temporal association between force,
shortening velocity and LC20 phosphorylation during maintained
contractions (Gunst et al., 1992; Merkel et al., 1990; Ozaki et al., 1990; Shieh
et al., 1991; Silver and Stull, 1984). Hence it has been proposed that
additional Ca2+-regulated mechanisms may be responsible for controlling
tonic contraction, and much research has focussed on the potential role of
the thin filament-associated proteins caldesmon and calponin in such a
process. Caldesmon can bind to calmodulin, myosin and tropomyosin.
When bound to the latter caldesmon is an effective inhibitor of myosin
ATPase (see Walsh, 1990). Phosphorylation of caldesmon in vitro
removes its inhibitory action on myosin ATPase (Adam et al., 1990). Like
caldesmon, calponin can bind to actin and tropomyosin and can inhibit
myosin ATPase activity (Abe et al., 1990; Winder and Walsh, 1990).
Phosphorylation of calponin by CaM kinase II or PKC reverses this
inhibiton (Winder and Walsh 1990) which can be restored by the action of
calponin phosphatase (Winder et al., 1992). A preliminary report suggests
that caldesmon may be phosphorylated during contraction of intact
tracheal smooth muscle (Pohl et al., 1991). Thus the phosphorylation
state of these thin filament-binding proteins may play a critical role in
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regulating smooth muscle contraction, although details of whether such
regulation is applicable in vivo remain to be determined.
PKC has been implicated as playing a major role in the maintenance of
smooth muscle contraction. Phorbol 12-myristate 13-acetate (PMA, 500
nM) can both activate PKC and induce tonic contraction, an effect which
is greatly enhanced by the presence of Ca2+-channel activators or Ca2 +
ionophores (Park and Rasmussen, 1985). In agreement, application of
low concentrations (< 1 |iM) of the phorbol esters PMA and 12-
deoxyphorbol 13-isobutyrate (DPB) induce contraction of rabbit trachea
which can be abolished by Ca2+ channel antagonists (Schramm and
Grunstein, 1989). The contraction evoked by low concentrations of
phorbol ester can be abolished by Ca2+ channel antagonists (Schramm and
Grunstein, 1989) indicating that PKC-induced contraction is mediated, at
least in part, by the activation of voltage-operated Ca2+ channels. The
tonic contraction induced by PKC activation is associated with
phosphorylation of the same proteins (including caldesmon) as those
observed during the tonic contraction induced by carbachol (CCh) (Park
and Rasmussen, 1986). It should be noted however that in the study of
Schramm and Grunstein (1989) the application of higher concentrations
of phorbol esters mediated ASM relaxation rather than contraction,
pointing to either a more complex role of PKC in regulating ASM
contraction or non-PKC-mediated effects at high phorbol ester
concentrations.
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1.3 SOURCE OF ACTIVATOR CALCIUM
ASM exhibits poor electrical conductivity and while a slow graded
membrane depolarisation is observed following agonist stimulation, this
effect is unlikely to account for the very rapid events leading to the
initiation of tone in this tissue. The use of fluorescent calcium probes
such as Fura-2 have facilitated temporal studies of the agonist-stimulated
[Ca2+]i response. The response is biphasic, consisting of a rapid, sharp rise
in [Ca2+]j which, in the continued presence of agonist falls to a plateau
level slightly above basal (Kotlikoff et al., 1987; Murray and Kotlikoff,
1991; Pannettieri et al., 1989; Senn et al., 1990; Shieh et al., 1991). It is now
established that the increase in [Ca2+]i responsible for force generation
(the initial transient increase in cytosolic Ca2+) in ASM arises from a non-
mitochondrial intracellular store (Twort and van Breemen, 1989),
whereas the influx of extracellular Ca2+ may be more important for the
maintenance of tone. Thus in ASM agonist-induced phasic contractions
are generally very resistant to the removal of extracellular Ca2+ and are
insensitive to dihydropyridine Ca2+ channel blockers; by contrast
depolarisation-induced contractions (or the tonic phase of agonist-
induced contractions) are more critically dependent on extracellular Ca2+
(Kirkpatrick, 1975; Ritchie et al., 1984; Weichman et al, 1982, 1983).
Electron probe X-ray microanalysis has identified the terminal cisternae
of the sarcoplasmic reticulm (SR) as the major source of activator Ca2+ in
smooth muscle (Bond et al., 1984; see Somlyo, 1981), and Bond et al. (1984)
have shown that this store contains sufficient Ca2+ to elicit maximal
contraction of guinea-pig portal vein. Recent studies in ASM have
highlighted a heterogeneity of the Ca2+ store, such that the available Ca2+
may be divided between multiple discrete pools released by Ins(l,4,5)P3,
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ryanodine or GTPyS, although passage of Ca2+ between the pools may
occur under some circumstances (Chopra et al., 1991).
1.3.1 The inositol 1,4,5-trisphosphate-sensitive calcium store
One of the most important mediators of intracellular Ca2+ release known
is Ins(l,4,5)P3, a water-soluble compound formed by phosphoinositidase
C-mediated hydrolysis of Ptdlns(4/5)P2 (see Berridge, 1993). Ins(l,4,5)P3
has been shown to release Ca2+ from a non-mitochondrial intracellular
store in permeabilised canine (Hashimoto et al., 1985), rabbit (Chopra et
al., 1991) and human (Twort and van Breemen, 1989) ASM preparations.
These studies show that application of exogenous Ins(l,4,5)P3 to
permeabilised tissue results in a rapid (90% release by 12 sec, Twort and
van Breemen, 1989) and concentration-dependent (EC50 = 0.8-2.3 pM;
maximal effect at 2-30 pM) release of intracellular Ca2+. A maximally
effective concentration of Ins(l,4,5)P3 released a high proportion (84 %) of
the ATP-dependent intracellular Ca2+ store in cultured human ASM
cells, a quantity which relates to that released in intact cells in response to
10 pM Hist (Twort and van Breemen, 1989).
A protein with highly specific binding properties for Ins(l,4,5)P3 has been
identified in many cell types including ASM (Chilvers et al., 1990b;
Schramm et al., 1992 and see Ferris and Snyder, 1992). Reconstitution
studies, in which the Ins(l,4,5)P3 binding proteins purified from rat
cerebellar membranes (Ferris et al., 1989) or aortic smooth muscle
(Mayrleitner et al., 1991) were incorporated into artificial membranes,
demonstrated that the Ins(l,4,5)P3 receptor protein has an intrinsic Ca2+
channel activity; moreover the binding affinity of a series of inositol
polyphosphates for this protein correlated with their ability to induce
45Ca2+ flux in these vesicles (Ferris et al., 1989). It has now been shown
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that the vicinal (4/5)-bisphosphate group is crucial for Ca2+-release
(Nahorski and Potter, 1989). In accordance with a role in Ins(l,4,5)P3-
mediated Ca2+ release from intracellular stores the receptor has been
localised predominantly to the endoplasmic reticulum (Mignery et al.,
1989; Ross et al. 1989), however recent studies have also identified an
Ins(l,4,5)P3 receptor in the nucleus (Malviya et al., 1990) and in some cells
an Ins(l,4,5)P3 receptor has been shown to be associated with the plasma
membrane (Khan et al., 1992; Kuno and Gardner, 1987). This latter
observation has prompted speculation for a direct role for Ins(l,4,5)P3 in
agonist-dependent Ca2+ influx. The plasma membrane-associated
Ins(l,4,5)P3 receptors exhibit less specificity for Ins(l,4,5)P3 over receptors
localised to the endoplasmic reticulum (Kalinoski et al., 1992) and
recently attention has therefore been drawn to the potential role of
Ins(l,3,4,5)P4 in Ca2+ influx (Irvine 1991).
The high density of Ins(l,4,5)P3 receptors found in cerebellar Purkinje
cells facilitated their purification and cloning (Danoff et al., 1991; Furuichi
et al., 1989; Nakagawa et al., 1991; Supattapone et al., 1988). More recent
cloning studies however, have identified four subtypes of receptor
(InsP3R-l-4) encoded by distinct but related genes, with the originally
described cerebellar receptor designated as InsP3R-l. Complete cDNA
sequences are also now available for both InsP3R-2 (Sudhof et al., 1991)
and InsP3R-3 (Blondel et al., 1993; Maranto, 1994), and a partial sequence
has been determined for I11SP3R-4 (Danoff et al., 1991). The mRNA
molecules for these Ins(l,4,5)P3 receptor isoforms are differentially
expressed in various tissues (Blondel et al., 1993; Mignery et al., 1990; Ross
et al., 1992) and a study of the Ins("l,4,5)P3-binding properties of the
receptors shows the neuronal sites generally display a lower affinity for
Ins(l,4,5)P3 (Kd = 20-70 nM) than peripheral receptors (K<j = 2-8 nM) (see
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Willcocks et al., 1990). Two major splice sequences, SI and SII, have been
identified within the InsP3R-l subtype leading to further heterogeneity of
Ins(l,4,5)P3 receptors with splice variants expressed in both a
developmentally- and tissue-specific manner (Danoff et al., 1991;
Nakagawa et al., 1991).
The Ins(l,4,5)P3 receptors exhibit extensive sequence and structural
similarity with the ryanodine receptor of skeletal and cardiac muscle
clustered around the transmembrane domains which form the Ca2+-
channel (Mignery et al., 1989; Takeshima et al., 1989). The native protein
exists as a tetramer (Maeda et al., 1991; Mignery et al., 1990) and hence
several forms of the receptor may exist in a single cell-type arising from
different combininations of Ins(l,4,5)P3 receptor monomers.
In many cell types Ins(l,4,5)P3-induced Ca2+ flux exhibits a biphasic
dependence on the cytoplasmic Ca2+ concentration with nanomolar and
micromolar [Ca2+]j potentiating and attenuating Ca2+ release respectively
(Bezprozvanny et al., 1991; Loomis-Husselbee and Dawson, 1993;
Missiaen et al., 1992, 1994). Initial studies by Worley et al. (1987) identified
an inhibitory effect of Ca2+ ions on Ins(l,4,5)P3 binding to the cerebellar
receptor, suggesting that the inhibitory effect of Ca2+ at high
concentrations might be due to regulation of ligand-binding to the
receptor. Danoff et al. (1988) however, observed that Ca2+ did not regulate
Ins(l,4,5)P3 binding to its receptor directly but required a secondary
protein termed calmedin. Moreover, Mignery et al. (1992), unable to
demonstrate such a Ca2+-mediated control of Ins(l,4,5)P3 binding in
cerebellum, proposed that calmedin may be a Ca2+-sensitive isoform of
PIC. The results observed by Worley et al. (1987) would therefore simply
reflect a Ca2+-stimulated production of endogenous Ins(l,4,5)P3 which
displaced radiolabeled [3H]Ins(l,4,5)P3 from the receptor. In agreement
31
with this proposal Chilvers et al. (1990b) showed Ins(l,4,5)P3 binding to
the BTSM receptor was unaffected by the Ca2+ ion concentration.
Ins(l/4/5)P3-induced Ca2+ release seems to occur in discrete quanta
(Bootman et al., 1992; Ferris et al., 1992), a phenomenon which may
reflect, in part, an interaction between luminal Ca2+ and Ins(l,4,5)P3
(Missiaen et al., 1992, 1994; Oldershaw and Taylor, 1993; Parys et al., 1993).
Depletion of Ca2+ stores reduces the affinity of the receptor for Ins(l,4,5)P3
(Oldershaw and Taylor, 1993) and increases the EC50 for Ca2+ release
(Nunn and Taylor, 1990). There is also some evidence to suggest that
luminal Ca2+ may modulate the regulatory effects of cytoplasmic Ca2+ on
the Ins(l,4,5)P3 receptor (Missiaen et al., 1992, 1994).
1.3.2 The ryanodine-sensitive calcium store
Ryanodine is a naturally occurring plant alkaloid which has been shown
to release Ca2+ from the SR of cardiac (Wier et al., 1985) and skeletal
(Sutko et al., 1985) muscle. A similar action of this compound has been
observed in airways smooth muscle (Chopra et al., 1991) although the
Ca2+ release effect is quantitatively much smaller. Since ryanodine
binding to its receptor is absolutely dependent on Ca2+ (e.g. Michelak et
al., 1988; Pessah et al., 1985) ryanodine receptors have been implicated in
Ca2+-induced Ca2+ release (see section 1.3.3). In cultured ASM cells pre-
treatment with a maximally effective concentration of ryanodine
abolishes Ca2+ release in response to GTPyS and caffeine suggesting that
the latter pools are a subset of the ryanodine-releasable Ca2+ pool (Chopra
et al., 1991). In addition ryanodine pre-treatment of these cells results in
an inhibition of any subsequent Ins(l,4,5)P3 response indicating that the
ryanodine releasable Ca2+ pool may be a subset of the Ins(l,4,5)P3
releasable pool.
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A further agent which which is now recognised to release Ca2+ from
ryanodine-sensitive stores is cyclic adenosine diphosphate-ribose (cADP-
ribose). The ability of this pyridine metabolite to mobilise Ca2+ was first
observed in sea urchin eggs (Clapper et al., 1987) and has more recently
been demonstrated in mammalian cells (Koshiyama et al., 1991;
Takasawa et al., 1993). Ca2+ mobilisation in response to cADP-ribose
occurs independently of Ins(l,4,5)P3 receptor-activation (see Galione,
1993) and since pretreatment with modulators of the ryanodine receptor
can regulate cADP-ribose-induced Ca2+ release (see Galione, 1992), this
agent has been proposed to mediate Ca2+ efflux from ryanodine-sensitive
sites. It is not known if cADP-ribose is formed following agonist
stimulation of ASM and hence the physiological relevance of this Ca2+-
release mechanism in this tissue is not clear.
1.3.3 Calcium-induced calcium release
Ca2 + -induced Ca2+ release (CICR) has been demonstrated in
permeabilised skeletal, cardiac and vascular smooth muscle where small
increases in the [Ca2+] of the bathing medium elicit substantial Ca2 +
release (Endo, 1975, 1977; Endo et al., 1970; Fabiato, 1983; Ford and
Podolski, 1970; Saida, 1981, 1982). A localised increase in [Ca2+]j has been
proposed to activate large conductance cation channels on the SR close to
the plasma membrane to mediate CICR which has been implicated as the
mechanism underlying the propagation of intracellular Ca2+ waves
(Berridge and Irvine, 1989). In other muscle types, caffeine appears to
release Ca2+ from intracellular stores by sensitising the CICR mechanism
(see Endo, 1977; lino, 1987; Leijten and van Breemen, 1984; see Martinosi,
1984). Although there is no direct evidence for CICR in ASM, the
presence of such a mechanism is suggested by the ability of caffeine to
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induce a slow release of Ca2+ in permeabilised cultured ASM cells
(Chopra et al., 1991).
1.3.4 The guanine-nucleotide-sensitive calcium store
The ability of guanine-nucleotides to release intracellular calicum was
originally observed in hepatic and neuronal cells (Chueh and Gill, 1986;
Dawson, 1989; Gill et al., 1986). A similar action of GTPyS, independent of
G-protein activation of phosphoinositidase C and hence Ins(l,4,5)P3
formation, has more recently been observed in cultured ASM cells
(Chopra et al., 1991). Studies in the DDT} MF-2 smooth muscle cell line
suggest that GTP acts to translocate Ca2+ from an Ins(l,4,5)P3-insensitive
to an Ins(l,4,5)P3-sensitive compartment (Ghosh et al., 1989; Mullaney et
al., 1988). While the presence of such a mechanism in ASM is
questionable since GTPyS-induced Ca2+ release (unlike Ins(l,4,5)P3-
mediated Ca2+ release) is unaffected by heparin (Chopra et al., 1989), the
GTPyS-sensitive pool does appear to communicate with the Ins(l,4,5)P3-
sensitive pool and may be able to regulate its size.
In addition to storing Ca2+ which may be released into the cytosol
following agonist stimulation, in non-excitable cells the SR may also
serve to regulate Ca2+ influx into the cell. A model has been proposed
(the capacitative model) in which depletion of intracellular Ca2+ stores
can, through an unknown mechanism, increase the permeability of the
plasma membrane to Ca2+ ions (Putney, 1986, 1991). In support of such a
mechanism, Randriamampita and Tsien (1993) have isolated a putative
messenger from Jurkat cells which is released into the cytosol from
intracellular organelles following depletion of Ca2+ stores. The
messenger can induce Ca2+ influx when applied exogenously to
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macrophages, astrocytoma cells and fibroblasts and hence has been
termed calcium influx factor, or CIF. This small molecular weight (< 500
Da) molecule is negatively charged and appears to contain both a
phosphate group (essential for stimulation of Ca2+ influx) and two
hydroxyl groups on adjacent carbon atoms. In addition, independent data
from electrophysiological experiments in Xenopus oocytes identify a
plasma membrane Ca2+ current which is activated by a diffusible factor
following depletion of intracelluar Ca2+ stores, and is inhibited by a
phosphatase (Parekh et al., 1993). The capacitative model of Ca2+ entry
provides a possible mechanism for agonist-stimulated Ca2+ influx
(secondary to intracellular Ca2+ release), and may be important in the
maintenance of contraction in ASM.
1.4 INVOLVEMENT OF PHOSPHOINOSITIDE HYDROLYSIS IN
PHARMACOMECHANICAL COUPLING IN AIRWAYS SMOOTH
MUSCLE
Michell (1975) was the first to propose a link between agonist-stimulated
phosphoinositide metabolism and Ca2+-signalling, based on the
following observations from a variety of tissues:-
1. Certain receptors controlled the activation of inositol lipid
metabolism in many tissues regardless of the cellular response.
2. These receptors did not generally activate adenylyl cyclase and the
post-receptor signalling mechanism for these receptors was
unknown.
3. Stimulation of these receptors always appeared to cause an increase
in [Ca2+]i.
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4. Studies in adrenal medulla, platelets and parotid gland suggested
that the inositol lipid metabolism was not secondary to the rise in
[Ca2+]j.
5. Receptor stimulation caused tissues to become partially depleted of
Ptdlns.
6. Inositol lipid breakdown occured with a rapidity to that required of
a signalling reaction.
7. Inositol lipid breakdown showed a concentration-response curve
that corresponded to receptor occupation by the applied agonist
rather than the functional effect.
Dawson (1971) demonstrated that a phosphoinositide-specific
phospholipase C (PIC) was responsible for this phosphoinositide
metabolism leading to the formation of DAG and water-soluble inositol
phosphates (InsPs). Durrel et al. (1969) suggested that in guinea-pig brain
the polyphosphoinositides may also be metabolised in addition to Ptdlns -
a finding that was later substantiated in iris smooth muscle by Abdel-Latif
and collegues, (see Abdel-Latif, 1986). All of these proposals are now well
accepted as a means of agonist-stimulated second messenger formation
(see Berridge, 1987; Rana and Hokin, 1990). PtdIns(4,5)P2, formed by the
sequential actions of a 4- and 5-kinase on Ptdlns, is recognised to be the
primary substrate for PIC resulting in the formation of DAG and
Ins(l,4,5)P3. DAG remains within the plane of the membrane and can
activate certain PKC isoforms and hence facilitate phosphorylation of a
range of effector molecules (see Wilkinson and Hallam, 1994), whereas
Ins(l,4,5)P3 is released into the cytosol and can facilitate intracellular Ca2+
release by binding to its specific receptor on the ER (see Berridge, 1993).
The identification of Ins(l,3,4,5)P4 and Ins(l,3,4)P3 isomers in tissue
extracts was thought initially to suggest the presence of additional 3-
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phosphorylated phosphoinositides from which these compounds might
be derived (Batty et al., 1985; Downes et al., 1986; Nahorski and Batty, 1986;
Nahorski et al., 1986). Although a series of 3-phosphorylated
phosphoinositides (PtdIns3P, PtdIns(3,4)P2 and PtdIns(3,4,5)P3) have now
been identified in membranes from a variety of cell types (see Stephens et
al., 1993), they appear to represent minor phosphoinositide components
that are resistant to hydrolysis by PIC (Lips et al., 1989; Serunian et al.,
1989). Recently, much research has been focussed on the role of these 3-
phosphorylated phosphoinositides leading to the proposal that they may
represent components of a separate phosphoinositide signalling pathway,
whereby PtdIns(4,5)P2 is phosphorylated by a 3-kinase to yield
PtdIns(3,4,5)P2 (Stephens et al., 1991b). PtdIns(3,4,5)P3 has now been
implicated in a variety of cellular processes including cell growth (Fantl et
al., 1993; Valius and Kaslauskas, 1993), chemotaxis and cytoskeletal
rearrangement (Eberle et al., 1990), glucose transport (Okada et al., 1994a)
and neutrophil respiratory burst activity (e.g. Eberle et al., 1990; Okada et
al., 1994b). The precise second messenger function of PtdIns(3,4,5)P3
however remains uncertain.
Chilvers et al. (1991a) could not detect any isomeric heterogeneity of the
PtdInsP2 pool in BTSM which appeared to consist solely of PtdIns(4,5)P2-
Conversely analysis of the PtdlnsPi pool by these authors showed the
presence of both the dominant PtdIns4P isomer and a minor (17 %)
PtdlnsPi constituent identified as PtdIns3P. As yet however, no evidence
exists to suggest the presence of higher 3-phosphorylated
phosphoinositides in ASM.
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1.4.1 Contractile agonist-stimulated phosphoinositide metabolism in
airways smooth muscle
The involvement of phosphoinositide hydrolysis in the coupling of
contractile receptor stimulation to Ca2+ release and ASM contraction was
first suggested in a study by Baron et al. (1984). These authors noted
enhanced [32P]Pj incorporation into Ptdlns following CCh stimulation of
canine trachealis, accompanied by an overall decrease in Ptdlns mass and
a parallel increase in the accumulation of DAG and its metabolite
phosphatidate (PtdOH). A similar agonist-stimulated incorporation of
[3H]inositol into Ptdlns, PtdlnsP and PtdInsP2 has also been observed in
tracheal smooth muscle (Baron et at., 1989; Chilvers et al., 1989a). Studies
in [3H]inositol-labelled BTSM have demonstrated a rapid (ti/2 = 14 sec)
and sustained, CCh-stimulated decrease in the mass of PtdInsP2 (Takuwa
et al., 1986) and more specifically PtdIns(4,5)P2 (Chilvers et al., 1991a). The
former study (Takuwa et al., 1986) demonstrated that in tracheal smooth
muscle, as in most other tissues, PtdInsP2 appears to be the major
membrane phosphoinositide hydrolysed following agonist stimulation.
Accumulation of [3H]InsPs in the presence of 5-10 mM LiCl (a potent,
non-competitive inhibitor of the inositol monophosphatase - see section
1.5.1) has also been used as an index of phosphoinositide hydrolysis in
[3H]inositol pre-labelled ASM. Using this approach, agonist-stimulated
[3H]InsP accumulation has been observed in response to a variety of
contractile stimuli including full and partial muscarinic agonists
(Chilvers et al., 1989a, 1990a; Duncan et al., 1987; Hall and Hill, 1988;
Meurs et al., 1988; Offer et al., 1991; Roffel et al., 1990a), histamine (Hall
and Hill, 1988), bradykinin (Chilvers et al., 1989a), 5-hydroxytryptamine
(Lemoine et al., 1988), endothelin (Hay, 1990), leukotrienes C4, D4 and E4
(Grandordy et al., 1987; Mong et al., 1988), substance P and neurokinins A
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and B (Grandordy et al., 1988). A similar finding was also observed
following both electrical field stimulation of [3H]inositol-labelled BTSM
strips (Miller-Hance et al., 1988), and co-incubation of [3H]inositol-labelled
canine ASM membranes with histamine and GTP (Murray et al., 1989).
1.4.2 Agonist-stimulated inositol 1,4,5-trisphosphate accumulation in
airways smooth muscle
[3H]Ins(l,4,5)P3 has been shown to mediate Ca2+ release from intracellular
stores in permeabilised canine tracheal smooth muscle cells (Hashimoto
et al., 1985). To substantiate a role for this second messenger in
stimulating the release of activator Ca2+ for the contractile response,
Duncan et al. (1987) demonstrated a rapid (1 sec) ACh-stimulated
accumulation of [3H]InsP3 in canine ASM which preceded the detectable
onset of contraction. Similarly, increases in [3H]InsP3 in bovine ASM
have been detected as early as 500 msec following electrical field
stimulation (Miller-Hance et al., 1988).
One of the major defects of these early studies however was the failure to
identify the precise isomeric composition of [3H]InsP3. Using both
H.P.L.C. and enzymic methods the [3H]InsP3 fraction accumulating in
bovine tissue has been shown to consist of both [3H]Ins(l,4,5)P3 and
[3H]Ins(l,3,4)P3 with the latter isomer predominating even at early time-
points after agonist stimulation (Chilvers et al., 1990a; Kennedy et al.,
1989). Nonetheless, Chilvers et al. (1990a) demonstrated a rapid (albeit
transient) increase in [3H]Ins(l,4,5)P3 in BTSM strips following
stimulation with CCh. In agreement, subsequent studies utilising a
specific radioreceptor binding assay for the determination of Ins(l,4,5)P3
mass (Palmer et al., 1989) identified a substantial CCh-stimulated increase
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in Ins(l,4/5)P3 mass, apparent by 2 sec, peaking after 5 sec and returning to
basal and sub-basal levels by 30 sec in BTSM (Chilvers et ah, 1989b).
Rosenberg and co-workers (1991) demonstrated a relationship between
both the EC50 and magnitude of the CCh-stimulated Ins(l,4,5)P3 response
and differences in the contractile response observed between immature
and adult rabbit ASM. Furthermore, a direct relationship has been
observed between [3H]InsP formation and contraction induced by a range
of muscarinic agonists in bovine trachealis (Meurs et ah, 1988). Hence
stimulation of Ins(l,4,5)P3 production in ASM appears to occur with a
time- and concentration dependence compatible with the contractile
response. While Ins(l,4,5)P3 has not been shown directly to mimic
contraction in ASM, such experiments have been carried out in vascular
and gastric smooth muscle where liberation of caged Ins(l,4,5)P3 can elicit
contraction in permeabilised tissue (Bitar et ah, 1986; Somlyo et ah, 1985,
1992; Walker et ah, 1987).
Therefore much evidence has accumulated to implicate the receptor-
mediated generation of Ins(l,4,5)P3 in pharmacomechanical coupling in
ASM. This compound is generated rapidly enough and with a
concentration-dependence consistent with the contractile reponse, and by
binding to its specific receptor on the SR can elicit sufficient Ca2+ release
to initiate contraction. Also in support of a second messenger role for
Ins(l,4,5)P3, it should be noted that inhibition of Ins(l,4,5)P3 generation by
phorbol esters (Baba et ah, 1989) and cAMP (see section 1.6.3) is associated
with an attenuation of agonist-induced contraction.
In BTSM, CCh-stimulated hydrolysis of PtdIns(4,5)P2 appears to persist (>
20 min) in the continued presence of agonist (Chilvers et ah, 1991a),
hence the transient Ins(l,4,5)P3 accumulation response observed in this
tissue must reflect extensive agonist-stimulated metabolism of
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Ins(l,4/5)P3- Such rapid metabolism is to be expected of a putative second
messenger. An alternative pattern of agonist-stimulated [3H]Ins(l,4,5)P3
formation however, has been observed in rabbit tracheal smooth muscle
where endothelin-1 stimulated a sustained, rather than transient,
increase in Ins(l,4,5)P3 accumulation (Grunstein et al., 1991). The
mechanisms underlying such agonist- and/or species-specific differences
in the Ins(l,4,5)P3 response in this tissue are unclear. They may reflect
intrinsic differences in the enzymes present in the tissues (e.g. the PIC
isozymes recruited by the receptors) or in the regulation of these enzymes
(e.g. the use of different G-proteins to couple the receptors to PIC) (see
sections 1.4.3 and 1.4.4). Alternatively the contrasting receptor-mediated
Ins(l,4,5)P3 responses may arise as a result of differential feedback or
crosstalk mechanisms from other signal transducing pathways, which
could affect both the production and metabolism of Ins(l,4,5)P3.
1.4.3 Phosphoinositidase C studies in airways smooth muscle
Studies in various tissues have identified four, and possibly five,
biochemically, structurally and immunologically distinct subclasses of PIC
enzymes (a, p, y, 5 and e) (see Crooke and Bennett, 1989; Meldrum et al.,
1991; Rhee et al., 1989, 1991). Hornma et al. (1989) identified mRNA
encoding at least four discrete PIC isozymes in rat lung homogenates.
Two groups have subsequently reported partial resolution of at least three
peaks of PIC activity in soluble fractions of bovine, porcine and canine
trachealis (Chilvers et al., 1992; Murray et al., 1991b). The enzyme activity
in all three peaks in bovine trachealis was found to be Ca2+-dependent.
Furthermore, the ability of platelet-derived growth factors PDGF-AB and
PDGF-BB to stimulate [3H]InsP generation and antisense PIC-pi cDNA to
inhibit agonist-stimulated phosphoinositide hydrolysis in ASM suggests
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the presence of at least PIC-y and PIC-(3i isozymes in this tissue (see
Chilvers, 1994).
1.4.4 Involvement of G-proteins in agonist-stimulated phosphoinositide
hydrolysis in airways smooth muscle
G-proteins, or guanine-nucleotide-binding proteins, are a large family of
hetrotrimeric proteins (consisting of a, [3 and y subunits) which serve to
couple a wide range of receptors to their effector enzymes (for review see
Helper and Gilman, 1992). Under resting conditions the a subunit is
bound to GDP which can slowly dissociate and be exchanged for GTP.
Interaction of the G-protein with agonist-bound receptor dramatically
enhances the rate of GDP/GTP transfer and following GTP binding the G-
protein dissociates into a-GTP and (3y subunits. Until recently, the
released a-GTP has been thought to be the principal modulator of effector
enzymes, however evidence has accumulated indicating the importance
of the (3y subunit in regulation of certain responses, most notably
stimulation of PLC-P2 (Boyer et al., 1992; Camps et al., 1992) and binding
of receptor kinases, leading ultimately to receptor desensitisation
(Kameyama et al., 1993; Koch et al., 1993). Termination of a-GTP
mediated responses follows GTP hydrolysis by the intrinsic GTPase
activity of the a subunit.
The first suggestion that G-proteins might be involved in receptor-
mediated phosphoinositide signalling was provided by the observation
that guanine nucleotides could alter the binding affinity of agonists
linked to Ca2+-mobilising receptors in human astrocytoma cells (Evans et
al., 1985). This observation has been substantiated in ASM where
muscarinic agonist binding affinity is regulated by a range of stable GTP
analogues (Grandordy et al., 1986; Lucchesi et al., 1990). GTPyS has since
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been observed to directly stimulate phosphoinositide hydrolysis in ASM
membranes and permeabilised ASM cells (Grunstein et al., 1991; Murray
et al., 1989). The ability of fluoroaluminate (a non-selective G-protein
activator which mimics the y-phosphate of GTP) to elicit concentration-
dependent contractions and [3H]InsP formation in BTSM provided
further evidence for the involvement of G-proteins in coupling receptors
to PIC activation (Hall et al., 1990a). While the precise identity of the G-
protein(s) involved in phosphoinositide signalling in ASM remains to be
determined, the inability of pertussis toxin to modulate high affinity
oxotremorine binding (Lucchesi et al., 1990) or to affect CCh-, Hist- or
bradykinin-stimulated [3H]InsP accumulation in ASM (Chilvers, 1991;
Pyne and Pyne, 1992) implies the involvement of a member of the
recently identified pertussis toxin-insensitive Gq subclass (Gq/i 1/14/15/16)
of G-proteins (Strathmann and Simon, 1990). Furthermore Pyne and
Pyne (1992) have detected the a subunit of Gq/Gn in guinea-pig tracheal
smooth muscle using specific peptide-directed antibodies. By contrast,
leukotriene-D4-stimulated [3H]InsP accumulation in guinea-pig tracheal
smooth muscle cells is pertussis-toxin-sensitive, although it should be
noted that this effect was observed at a very high concentration (10
|ig/ml) of pertussis toxin (Howard et al., 1992). This data may suggest
either the presence of more than one PIC isozyme coupled differentially
to discrete G-proteins, or the recruitment alternative G-protein isoforms
in response to activation of different receptors in guinea-pig ASM.
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1.5 INOSITOL 1,4,5-TRISPHOSPHATE METABOLISM
As detailed above, CCh stimulation of BTSM results in a transient
accumulation of Ins(l,4,5)P3 despite ongoing hydrolysis of PtdIns(4,5)P2,
indicating a rapid agonist-stimulated metabolism of Ins(l,4,5)P3 in this
tissue. Studies in other tissues show that the immediate and
downstream metabolism of Ins(l,4,5)P3 is highly complex, resulting in
the formation of a large array of InsPP isomers (for reviews see Majerus et
ah, 1988; Shears 1989, 1991, 1992). In some cases subsecond oscillations of
Ins(l,4,5)P3 and Ins(l,3,4,5)P4 have been observed (e.g. Breer et ah, 1990;
Raha et ah, 1993). In mammalian cells the metabolism of Ins(l,4,5)P3
proceeds predominantly via two main pathways involving the
Ins(l,4,5)P3 3-kinase and Ins(l,4,5)P3 5-phosphatase enzymes. These '3-
kinase' and '5-phosphatase' pathways are shown in figure 1.5 and
outlined below. The possible regulatory mechanisms governing the
activities of these enzymes are presented in chapter three.
1.5.1 The 5-phosphatase pathway
A Mg2+-dependent inositol polyphosphate 5-phosphatase enzyme has
been identified in many cell types which can specifically remove a
phosphate group from the 5-position of the inositol ring of Ins(l,4,5)P3,
Ins(l,3,4,5)P4, Ins(l:2cyc,4,5)P3 and Ins(4,5)P2 (e.g. Downes et ah, 1982;
Mitchell et ah, 1989; Takimoto et ah, 1989). In the majority of tissues
studied the enzyme appears to be predominantly membrane bound,
forming tight (probably hydrophobic) interactions with the membrane -
in particular the plasma membrane, and can be liberated following
treatment with detergent (Downes et ah, 1982; Hansbro et ah, 1994;
























Figure1.5Pathwaysofinositol1,4,5-trisp osphateform i nandet b l sm
Two distinct soluble 5-phosphatase activities have been identified in a
variety of tissues including brain (Erneux et al., 1989; Hansen et al., 1987),
skeletal muscle (Hansbro et al., 1994), and neutrophils (Kennedy et al.,
1990). These isoforms were originally designated, according to their
substrate specificity, as Type I (hydrolyses both Ins(l,4,5)P3 and
Ins(l,3,4,5)P4) and Type II (very low affinity for Ins(l,3,4,5)P4 and therefore
in vivo probably metabolises only Ins(l,4,5)P3) (Hansen et al., 1987). The
Type I 5-phosphatases generally have a molecular mass of 40-45 KDa and
are smaller than the Type II enzymes (70-160 KDa). However the
possibility of a further 5-phosphatase isoform has been suggested by the
presence in platelets (Mitchell et al., 1989; Ross et al., 1991) and
erythrocytes (Hodgkin et al., 1994) of a 5-phosphatase activity which can
hydrolyse both Ins(l,4,5)P3 and Ins(l,3,4,5)P4 but which has a higher
molecular mass (70-75 KDa) than the previously identified Type I
enzymes. Hodgkin and co-workers (1994) noted that these enzymes had
lower affinity for Ins(l,4,5)P3 than their smaller 40-45 KDa counterparts,
leading to the conclusion that they may represent a third isoform
designated as Type lb (the 40-45 KDa isoform was redesignated as Type la).
Further evidence to suggest that these isoforms may be distinct enzymes
was provided by Ross et al. (1991) who demonstrated that human platelet
Type la and Type lb enzymes are immunologically distinct. To date, Type
lb 5-phosphatase activity has only been identified in platelets and
erythrocytes, suggesting that they may be restricted to cells of
haematopoietic lineage.
In general, where the membrane-associated 5-phosphatase has been
studied, it has been found to be very similar, both physically and
biochemically to the Type la enzyme (e.g. Erneux et al., 1989; Hodgkin et
al., 1994; Laxminarayan et al., 1993, 1994; Takimoto et al., 1989), and
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Verjans et al. (1990) have shown that these two activities are
immunologically indistinguishable.
Following dephosphorylation of Ins(l,4,5)P3 to Ins(l,4)P2, the latter
compound is further dephosphorylated by a 1-phosphatase to Ins(4)P
(Balla et al., 1986). This enzyme has been purified from bovine brain and
found to have a molecular mass of 44 KDa (Inhorn and Majerus, 1987,
1988). It specifically removes the 1-phosphate from both Ins(l,4)P2 and
Ins(l,3,4)P3, is Mg2+-dependent and is inhibited by lithium ions. The
product of this reaction - Ins4P - is metabolised to free inositol by a
monophosphatase enzyme (Gee et al., 1988) which can additionally utilise
Ins3P, Ins4P, Ins5P and Ins6P as substrates. Lithium is a potent (Kj <
ImM), uncompetitive inhibitor of the monophosphatase enzyme (Gee et
al., 1988; Hallcher and Sherman, 1980) and therefore prevents the
generation of free inositol and traps inositol monophosphates within the
cytosolic fraction of the cell.
1.5.2 The 3-kinase pathway
An Ins(l,4,5)P3 3-kinase enzyme which phosphorylates Ins(l,4,5)P3 to
Ins(l,3,4,5)P4 has been purified and cloned from both brain (Choi et al.,
1990; Johanson et al., 1988; Lee et al., 1990; Sim et al., 1990; Takazawa et al.,
1989, 1990b, 1991a and b) and platelets (Lin et al., 1990) and shown to have
a molecular mass of approximately 50 KDa. Takazawa et al. (1991a and b)
identified two isozymes in a human hippocampus cDNA library with
calculated molecular masses of 50,988 and 53,451 Da. Other Ins(l,4,5)P3 3-
kinase activities with a lower molecular weight have also been identified
(Lin et al., 1990; Takazawa et al., 1989, Lee et al., 1990); however these
proteins may represent proteolysis products of the higher molecular
weight enzyme (Lee et al., 1990). Indeed Takazawa et al. (1991a)
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demonstrated that a truncated 3-kinase cDNA transcript from human
hippocampus encoded an active protein which when expressed in E. coli
had a molecular mass of 36-38 KDa. These smaller, active 3-kinase
proteins can be formed in vivo by calpain digestion (Lee et al., 1990). The
presence of a further 3-kinase isozyme is suggested from studies in
porcine aortic smooth muscle, in which a higher molecular weight
(93,000 Da, calculated by SDS-PAGE) 3-kinase activity has been purified
(Yamaguchi et al., 1988). The molecular mass of this protein estimated by
gel-filtration agrees with that above, indicating the protein is a monomer
and not simply a dimer of two 50,000 Da subunits.
The most generally accepted and well-characterised route of Ins(l,3,4,5)P4
metabolism is by a Type I 5-phosphatase, as described in section 1.5.1, to
form Ins(l,3,4)P3. Phosphorylation of Ins(l,3,4,5)P4 by a novel 6-kinase
identified in turkey erythrocytes and Chlamydomonas eugametos (Irvine
et al., 1992) or dephosphorylation by a 3-phosphatase (e.g. Hughes and
Shears, 1990; Nogimori et al., 1991) may represent additional albeit more
minor routes of Ins(l,3,4,5)P4 metabolism. However it is unknown how
widespread the former enzyme is in the animal kingdom, and the latter
enzyme appears to be localised to the endoplasmic reticulum and not to
be active within the cytosolic compartment under in vivo conditions (Ali
et al., 1993).
The metabolism of Ins(l,3,4)P3 can also proceed through multiple
pathways. Two dephosphorylation pathways have been identified in
which Ins(l,3,4)P3 may be metabolised to either Ins(l,3)P2 by a 4-
phosphatase (Bansal et al, 1987, 1990; Guse et al., 1989), or to Ins(3,4)P2 by
the same 1-phosphatase that degrades Ins(l,4)P2- As noted above, this
enzyme is inhibited by lithium ions; the potency of inhibiton is greater
when Ins(l,3,4)P3 is used as a substrate compared to Ins(l,4)P2 (K; < 1 mM
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and ~ 6 mM respectively). The metabolism of Ins(l/3)P2 proceeds by the
action of a 3-phosphatase (Bansal et al., 1987; Caldwell et al., 1991) to
produce InslP, while Ins(3/4)P2 is metabolised to Ins3P by the same 4-
phosphatase that dephosphorylates Ins(l,3,4)P3 (Bansal et al., 1990). As
detailed above (section 1.5.1), both InslP and Ins3P are finally
dephosphorylated to free inositol by the inositol monophosphatase
enzyme.
An additional route of Ins(l,3,4)P3 metabolism, demonstrated in a variety
of cell types, is phosphorylation by a 6-kinase (e.g. Balla et al., 1987;
Hansen et al., 1988; Hughes et al., 1989; Shears et al., 1987a).
The Ins(l,4,5)P3 3-kinase and 5-phosphatase enzymes therefore provide
mechanisms for both the removal of Ins(l,4,5)P3 and the recycling of
inositol back into the phosphoinositide pool. There are several reasons
however, why the differential routing of Ins(l,4,5)P3 metabolism through
the 3-kinase and 5-phosphatase pathways may be important. The 5-
phosphatase pathway is generally thought to be simply an inactivating
pathway, since Ins(l,4)P2 does not mobilise Ca2+ from intracellular stores
(Berridge and Irvine, 1989). By contrast, the 3-kinase pathway may
provide additional second messengers.
A topic of much debate over recent years has been the involvement of
Ins(l,3,4,5)P4 in Ca2+ entry. Such an action has been the subject of a great
deal of controversy (see Irvine, 1991), nonetheless, the proposed second
messenger role for Ins(l,3,4,5)P4 acting, either alone or in concert with
Ins(l,4,5)P3, to facilitate Ca2+ entry into the cell (e.g. Changya et al., 1989;
De Lisle et al., 1992; Irvine and Moor, 1986; Luckhoff and Clapham, 1992)
is substantiated by the presence of specific intracellular binding sites for
Ins(l,3,4,5)P4 (Bradford and Irvine, 1987; Enyedi and Williams, 1988;
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Theibert et al., 1990). Ins(l,3,4,5)P4 has also been implicated in
intracellular Ca2+ release (Joseph et al., 1989; Ely et al., 1990; Gawler et al.,
1990).
The 6-kinase route of Ins(l,3,4)P3 metabolism may provide even more
functional inositol polyphosphate molecules. For example Ins(l,3,4,6)P4
is a substrate for the synthesis of Ins(l,3,4,5,6)P5 (Balla et al., 1989) and
InsP6 (Ji et al., 1989; Stephens et al., 1991a). Due to the apparently slow
metabolism of these latter compounds (i.e. their labelling to isotopic
equilibrium with [3H]inositol takes several days) and their almost
unchanging mass, Ins(l,3,4,5,6)P5 and InsP6 were originally thought to be
metabolically inert. Passive roles have therefore been suggested for these
highly polar inositol phosphates, for example as Ca2+ chelators (Luttrell,
1992) or antioxidants (Graf and Eaton, 1990). More recently however, a
rapid, PLC-stimulated accumulation of the Ins(l,3,4,5,6)P5 metabolite
Ins(3,4,5,6)P4 has been demonstrated (Balla et al., 1989; Barker et al., 1992;
Menniti et al., 1990; Stephens et al., 1988) and in [3H]inositol labelling
studies the specific activity of this compound following [3H]inositol-
labelling always co-varies with [3H]Ins(l,3,4,5,6)P5. This observation led
to the suggestion that a separate Ins(l,3,4,5,6)P5/TnsP6 signalling pathway
may exist, although a role for the putative messenger - Ins(3,4,5,6)P4 has
not been identified.
Ins(l,3,4,5)P4 and its enantiomer Ins(l,4,5,6)P4 will bind with high affinity
to a protein purified from rat brain (Kanematsu et al., 1992). It should be
noted that Ins(l,4,5,6)P4 is also a cellular constituent which may be
formed in vitro by the action of a 3-phosphatase on Ins(l,3,4,5,6)P5
(Nogimori et al., 1991), and that accumulation of this isomer may
increase following either cell transformation with the src oncogene
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(Mattingly et al., 1991) or treatment with PIC-linked agonists (Barker et al.,
1992).
A high affinity InsP6 binding protein can be found in the nervous system
which contains identical amino acid sequences to, and is recognised by
antibodies raised against the a subunit of the the clathrin assembly
protein AP-2 (Timerman et al., 1992; Volgmaier et al., 1992). In addition
Beck and Keen (1991) have shown that InsP6 inhibits clathrin assembly.
These data suggest that InsP6 may play a regulatory role in
endocytosis/exocytosis cycles involving clathrin coated vesicles.
Further roles for Ins(l,3,4,5,6)P5 and InsP6 may be in the formation of
inositol pyrophosphates. InsPsP and InsP6P (i.e. compounds containing a
diphosphate on the inositol ring) are formed by ATP-dependent
phosphorylation of Ins(l,3,4,5,6)P5 and InsP6 and are rapidly turned over
in AR4-2J cells (Menniti et al., 1993). The standard free energy of
hydrolysis of the inositol pyrophosphates isolated from Dictyostelium
discoideum are 6.5-6.6 kcal mol"1 (Stephens et al., 1992), values similar to
the pyrophopshate bonds of ATP. It is likely therefore that these
compounds represent novel cellular stores of high energy phosphate
bonds.
Hence, in addition to governing the pattern of Ins(l,4,5)P3 formation,
regulation of the Ins(l,4,5)P3 5-phosphatase and 3-kinase enzymes may
serve to regulate the formation of a host of other functional molecules.
Understanding of the factors which could determine the routing of
Ins(l,4,5)P3 through these two pathways in ASM could give valuable
insight into Ca2+ signalling in this tissue and its resultant contractile
effect.
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1.6. RELAXATION OF AIRWAYS SMOOTH MUSCLE
As with the maintenance of ASM contraction, the mechanisms
governing ASM relaxation are not clear. From our current
understanding of the role of cross-bridges in the regulation of ASM tone,
it would appear that when the rate of force generation is less than the rate
of cross-bridge detachment the muscle will relax. Myosin
phosphorylation is the rate-limiting factor for force generation (see
section 1.2.2) but the mechanisms controlling the rate and extent cross-
bridge detachment are not clear. If smooth muscle is relaxed by the
removal of a spasmogenic stimulus a close correlation between myosin
dephosphorylation and relaxation is observed (de Lanerolle and Stull,
1980; Gerthoffer and Murphy, 1983), however little myosin
dephosphorylation accompanies relaxation induced by agents which
decrease [Ca2+]j (Gerthoffer, 1986; Tansey et al., 1990).
It has been appreciated for some time that (3-adrenoceptor agonists (e.g.
isoprenaline) can induce ASM relaxation and these agents represent the
major class of clinical drugs used in the treatment of bronchospasm. (3-
adrenoceptors couple via Gs to activation of adenylyl cyclase with the
resultant formation of the second messenger cAMP which can in turn
activate protein kinse A (PKA). The effects of (3-adrenoceptor agonists on
ASM tone have generally been attributed to their ability to stimulate
PKA. PKA in turn has been thought to effect relaxation by
phosphorylating a number of functionally relevant substrates resulting in
increases in Ca2+-ATPase and Na+/K+-ATPase activity, activation of BKca
channels, inhibition of PIC and modulation of the contractile machinery
(see sections 1.6.1-4 below). In accordance with this theory it has been
observed that cAMP analogues can relax ASM (Francis et al., 1988; Heaslip
et al., 1987; Torphy et al., 1985) and that the bronchorelaxant action of (3-
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adrenoceptor agonists can be mimicked and potentiated by cyclic
nucleotide phosphodiesterase inhibitors (Bryson and Rodger, 1987; Harris
et al., 1989; Poison et al., 1982; Shahid et al., 1991; Small et al., 1989; Torphy
et al., 1988).
Recent evidence however has challenged the dogma that cAMP-mediated
activation of PKA is the sole mechanism underlying the relaxant effects
of (3-adrenoceptor agonists (see Torphy, 1994). For example, cGMP-
dependent protein kinase (PKG) from canine tracheal smooth muscle
shows little selectivity for cGMP over cAMP in vitro (Torphy et al., 1982)
and the increase in cAMP levels following isoprenaline treatment of
bovine coronary arteries results in simultaneous activation of both PKG
and PKA (Jiang et al., 1992). Similarly, preliminary evidence indicates
that treatment of canine trachealis with forskolin (a direct activator of
adenylyl cyclase) also produces activation of PKC and PKG (see Torphy
and Hall, 1994). These data suggest that cAMP may exert some of its
second messenger action through PKG. Moreover, Francis et al. (1988)
showed that the ability of a range of cyclic nucleotide analogues to relax
guinea-pig trachealis correlated with their ability to activate PKG and not
PKA. In support for a role of PKG in relaxation of ASM it has been
observed that increases in the concentration of cGMP, or the application
of non-hydrolysable analogues of cGMP, induce relaxation of pre¬
contracted tracheal smooth muscle preparations (e.g. Heaslip et al., 1987;
Szaduykis-Szadurski and Berti, 1972; Szaduykis-Szadurski et al., 1972).
The demonstration that a greater increase in cAMP content is required to
produce a similar degree of relaxation in canine trachealis treated with
forskolin as compared with isoprenaline also suggests that additional (J-
adrenoceptor-mediated, cAMP-independent mechanisms may contribute
to the relaxant response. Some of the possible mechanisms by which |3-
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adrenoceptor agonists may exert their bronchorelaxant effect are discussed
below.
1.6.1 Regulation of membrane potential
(3-adrenoceptor stimulation of trachealis is accompanied by
hyperpolarisation of the plasma membrane (Allen et al., 1985; Fujiwara et
al., 1988; Honda et al., 1986), an effect which is antagonised by
charybdotoxin, a selective inhibitor of the Ca2+-activated potassium
channel (BKca) (Jones et al., 1990; Murray et al., 1991a) which is densely
distributed in ASM membranes (McCann and Welsh, 1986).
Charybdotoxin treatment also attenuates the relaxant effect of
isoprenaline on ASM (Huang et al., 1993; Jones et al., 1990; Miura et al.,
1992). The observation that the open-state probability of BKca is
increased in rabbit tracheal myocytes following application of either
isoprenaline or exogenous PKA (Kume et al., 1989) led to the suggestion
that this effect might underlie P-adrenoceptor-mediated relaxation of
ASM. In addition it would appear that PKG is also able to regulate BKca
channel activity: Hamaguchi et al. (1992) reported that charybdotoxin
inhibits the relaxation of bovine trachealis in response to agents which
activate guanylyl cyclase and increase the tissue PKG content.
Furthermore, BKca is phosphorylated by PKG in canine coronary smooth
muscle cells (Taniguchi et al., 1993) and rabbit basilar arteries (Robertson
et al., 1993). Hence activation of the BKca channel activity may
contribute to the relaxant effect of P-adrenoceptors on ASM, however part
of the relaxant response is charybclotoxin-insensitive indicating that other
relaxant mechanisms must also exist in this tissue (Huang et al., 1993;
Jones et al., 1990; Miura et al., 1992). In addition to the BKca channel, p-
adrenoceptor agonists can stimulate the plasma membrane Na+/K+-
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ATPase (Gunst and Stropp, 1988) which can also result in membrane
hyperpolarisation and may lower [Ca2+]i by a consequent increase in
Na+/Ca2+ exchange.
1.6.2 Regulation of intracellular calcium concentration
cAMP and cGMP elevating agents, when added immediately prior to or
after the addition of agonist, can attenuate the spasmogen-induced Ca2+
response in ASM (e.g. Felbel et al., 1988; Takuwa et al., 1987; Taylor et al.,
1989). This effect may reflect the ability of cAMP to promote both Ca2+
extrusion and uptake into intracellular stores in smooth muscle
preparations (Itoh et al., 1982; Mueller and Van Breemen, 1979; Schied
and Fay, 1984). Furthermore, the hyperpolarisation induced by (3-
adrenoceptor agonists could reduce Ca2+ entry through the classical
dihydropyridine-sensitive voltage operated Ca2+ channels present in
ASM (Worley and Kotlikoff, 1991). While a continued decrease in Ca2 +
entry may eventually deplete intracellular Ca2+ stores (and hence the
amount of Ca2+ available for the initial spasmogen-induced Ca2 +
transient), such a decrease in Ca2+ entry would be first expected to result
in inhibition of the tonic [Ca2+]j response. The plateau phase of the Hist-
induced Ca2+ response, at least in cultured human airway myocytes
however, is insensitive to organic Ca2+ channel blockers (Murray and
Kotlikoff, 1991). Ca2+ entry in these cultured cells appears to proceed via a
receptor-operated Ca2+ channel rather than a voltage-operated
mechanism which explains the latter result (Murray et al., 1992). It is not
clear whether there are major differences between the Ca2+ entry
pathways of cultured cells and intact human ASM tissue; nonetheless
organic voltage-operated Ca2+ channel blockers have minimal efficacy as
clinical bronchodilators.
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1.6.3 Regulation of phosphoinositide hydrolysis
In ASM, cAMP elevating agents have been shown to inhibit agonist-
stimulated [3H]InsP formation (Hall and Hill, 1988; Hall et ah, 1989;
Madison and Brown, 1988; Offer et al., 1991). The InsP response
stimulated by the non-specific G-protein activator sodium fluoride is also
inhibited by increases in cAMP suggesting a post-receptor mechanism is
involved in this effect (Hall et ah, 1990a). However (3-adrenoceptor
stimulation does not seem to affect the initial Ins(l,4,5)P3 response since
the transient increase in the concentration of this second messenger is
unaffected by isoprenaline pre-treatment in BTSM strips (Challiss and
Boyle, 1994). A differential ability of ^-adrenoceptor agonists to cause
ASM relaxation has been observed, depending on the nature and
concentration of the contractile agonist (Jenne et ah, 1987; Russel, 1984;
van Amsterdam et ah, 1989). The differential relaxant responses are
mirrored by a differential ability of ^-adrenoceptor agonists to inhibit
spasmogen-induced phosphoinositide hydrolysis. Muscarinic
cholinoceptor-stimulated contraction seems particularly resistant to (3-
adrenoceptor-mediated relaxation and InsP responses elicited by
maximally effective concentrations of full muscarinic agonists are
unaffected by (3-adrenoceptor pre-stimulation (Hall and Hill, 1988;
Madison and Brown, 1988; Offer et ah, 1991). However, when tissue
cAMP levels are increased using cyclic nucleotide phosphodiesterase
inhibitors, an attenuation of the [3H]InsP response to low concentrations
of the muscarinic agonist CCh can be observed (Hall et ah, 1990b; Offer et
ah, 1991).
One possible explanation for the relative resistance of muscarinic
receptor-stimulated phosphoinositide hydrolysis to inhibition by (3-
adrenoceptors is the large M3 muscarinic receptor reserve present in
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tracheal smooth muscle (Gunst et al., 1989; van Amsterdam et al., 1989).
This hypothesis however, has been challenged by the observation that
some, but not all, partial muscarinic agonist-stimulated [3H]InsP
responses are susceptible to p-adrenoceptor-mediated inhibition (Offer et
al., 1991). It is possible that a differential stimulation of M2 receptors
(rather than M3 receptors) by these partial agonists may determine their
susceptibility to ^-adrenoceptor inhibition. As detailed earlier, ASM
expresses a large proportion of M2 muscarinic receptors which are
coupled via Gj to the inhibition of adenylyl cyclase. Indeed both basal and
relaxant agonist-stimulated PKA activity in tracheal smooth muscle
preparations are decreased by muscarinic agonists (Langlands and Rodger,
1992; Torphy et al., 1985), and pre-treatment of canine tracheal smooth
muscle with pertussis toxin renders muscarinic agonist-contracted tissue
more sensitive to P-adrenoceptor-mediated relaxation (Mitchell et al.,
1993). In addition, it has been suggested recently that muscarinic
cholinoceptor stimulation may inhibit adenylyl cyclase activity not only
by stimulation of Gj, but also via a functional inactivation of Gs (Pyne et
al., 1992).
1.6.4 Regulation of contractile machinery
As detailed above, PKA can phosphorylate MLCK resulting in a reduction
in its affinity for Ca2+/calmodulin and hence a decreased catalytic activity.
PKA-mediated phosphorylation of MLCK would therefore be expected to
result in a decrease in force generation. In support of such a mechanism
being involved in P-adrenoceptor-mediated relaxation of ASM, de
Lanerolle et al. (1984) reported that forskolin treatment of canine tracheal
smooth muscle increased both cAMP accumulation and phosphorylated
MLCK. It is now clear that isoprenaline-induced relaxation of BTSM
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occurs without a change in the affinity of Ca2+/calmodulin for MLCK
(Miller et al., 1983; Tang et at., 1992) and hence the effects of |3-
adrenoceptor stimulation on the contractile machinery may be secondary
to Ca2+-regulated events.
1.7 AIMS OF THE THESIS
The past decade has witnessed clear advances in our understanding of the
involvement of phosphoinositide metabolism in ASM contraction.
However no detailed studies have examined inositol polyphosphate
metabolism in ASM, and there has been no investigation into the
potential mechanisms involved in regulating Ins(l,4,5)P3 accumulation,
especially at early time-points. The aim of this study was to set up a
model system (bovine tracheal smooth muscle) in which the inositol
polyphosphate isomers formed following receptor stimulation could be
identified and quantified. The protocol facilitates an assessment of the
relative contributions of the 3-kinase and 5-phosphatase pathways to
Ins(l,4,5)P3 metabolism and so permits a study of the differential routing
of Ins(l,4,5)P3 under various conditions - looking at different time-points
following agonist stimulation, the response to different contractile
agonists, and the response observed when phosphoinositide hydrolysis is
modulated by the pre-treatment of BTSM with activators of both PKC and
(^-adrenoceptors. An important finding obtained during the course of
these studies was the agonist-stimulated accumulation of a novel InsP2
isomer, namely Ins(4,5)P2- Experiments were therefore undertaken to
characterise the kinetics of its accumulation and the possible routes for its
formation and metabolism. In addition kinetic studies were undertaken
to address the relative affinities of the 3-kinase and 5-phosphatase
58






Fresh bovine tissue samples (tracheas or adrenal glands) were obtained
from the local abattoir. All radiochemicals were purchased from NEN
(Du Pont) (Stevenage, Herts., U.K.). Dowex anion exchange resins were
from Bio-Rad (Watford, Herts., U.K.) and H.P.L.C. anion exchange
columns and pre-columns from Whatman (Maidstone, Kent, U.K.).
Scintillation cocktails were supplied by Packard (Pangbourne, Berks.,
U.K.), D-inositol 1,4,5-trisphosphate by Reasearch Biochemicals
International (St Albans, Herts., U.K.), calpain inhibitors by Calbiochem
(Nottingham, U.K.) and the BCA protein assay kit by Pierce (Chester,
Cheshire, U.K.). Salmeterol was a kind gift from Glaxo (Ware, Herts.,
U.K.). All other reagents were purchased from either Sigma Chemical
Company Limited (Poole, Dorset, U.K.) or BDH (Lutterworth, Leics.,
U.K.).
2.2 PREPARATION OF BOVINE TRACHEAL SMOOTH MUSCLE SLICES
BTSM slices were prepared according to the method described by Chilvers
et al. (1989a). Fresh bovine tracheas were obtained from the local
abbattoir and the trachealis muscle isolated and transported at 4 °C in pre-
oxygenated (95% O2/5% CO2) modified Krebs-Henseleit buffer (KHB) (118
mM NaCl, 4.7 mM KC1, 1.25 mM CaCl2, 1.2 mM MgS04, 25 mM NaHC03,
and 11.7 mM glucose). Prostaglandins, formed by the action of cyclo-
oxygenase on arachidonic acid (a metabolite of DAG) have been proposed
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to act in an autocrine/paracrine fashion in a variety of cell types
including uterine smooth muscle (Goureau et al., 1990; Okawa et al., 1993)
to affect, either directly or indirectly via adenylyl cyclase, the formation of
inositol polyphosphates. In order to ensure that no such modulation of
receptor-mediated InsPP production occurred in my system the potent
cyclo-oxygenase inhibitor flurbiprofen (1 pM) was included in the buffer
(KHB) for all BTSM preparations. The muscle was dissected free of any
overlying epithelium or connective tissue and chopped into 300 x 300 |im
slices on a wooden block with a McIlwain tissue chopper. The tissue
slices were then washed three times in 200 ml KHB and pre-incubated, in
bulk, in 500 ml oxygenated KHB for 60 min at 37 °C in a shaking water
bath. Buffer was replaced and re-equilibrated every 15 min over this pre¬
incubation period.
2.3 LABELLING OF BOVINE TRACHEAL SMOOTH MUSCLE SLICES
WITHMYO-[3H]INOSITOL
Myo-[3H]inositol (specific activity 17-25 Ci/mmole) was used to label
BTSM slices since incorporation of this molecule facilitates labelling of
both the membrane-bound phosphoinositides and the water soluble
inositol phosphates subsequently formed by the hydrolysis of these lipids.
In addition, inositol is not readily metabolised by any other pathways
than those involved in the inositol polyphosphate metabolism under
study. Two different protocols were utilised to achieve steady-state
radiolabelling of the phosphoinositide pool: agonist-stimulated labelling
requires only a short (one hour) labelling period (Chilvers et al., 1989a),
whereas overnight labelling has the advantages of using much less
radioactivity, thereby being more economical, and of producing far more
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labelled slices from each BTSM preparation, so enabling a larger scale
experiment to be carried out.
2.3.1 Agonist-stimulated labelling
Following pre-incubation (2.2) BTSM slices were allowed to settle and 3
ml of gravity packed slices were transferred to a 25 ml Erlenmeyer flask in
a total volume of 12 ml oxygenated KHB containing 1 pM CCh and 30 pCi
(or 150 pCi for experiments involving H.P.L.C.) cleaned rayo-pHjinositol1
(i.e. 0.5 or 2.5 pCi [3H]inositol/50 pi BTSM slices respectively). The slices
were then incubated at 37 °C for 60 min in a shaking water bath, re-
oxygenating the labelling medium (95% 02/5% CO2) every 15 min. This
labelling period was followed by extensive washing of the slices with
fresh KHB over 30 min to remove any agonist and unincorporated label.
Subsequent stimulations were carried out in 6 ml flat bottomed vials.
Aliquots (50 pi) of gravity packed slices were incubated in the presence of
an identical concentration of myo-[3H]inositol to that described above, in
a final volume of 300 pi oxygenated KHB at 37 °C in a shaking water bath.
Unless otherwise stated LiCl was added 10 min prior to agonists, each
being added in a 10 pi volume. In most experiments CCh and histamine
were used at their maximally effective concentrations (100 pM and 1 mM
respectively, as shown in figure 2.3.1.1). Figure 2.3.1.2 shows the
radioactivity associated with [3H]InsPs and [3H]inositol phospholipids
over a 30 min time-course following stimulation with 100 pM CCh. In
agreement with Chilvers (1991), with the above labelling protocol there is
little change in the labelling of the lipids and an approximately linear
accumulation of the [3H]InsPs, suggesting that steady-state labelling of the
agonist-sensitive phosphoinositide pool has indeed been achieved.
Uhe Myo-[3H]inositol label was previously cleaned of polar contaminants by passing
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Figure 2.3.1.1a & b Concentration-response relationship for carbachol- and
histamine -stimulated total [3H]inositol phosphate accumulation
BTSM slices were pre-labelled for 24 hours with 0.5 pCi [3H]inositol/50 pi
slices (2.3.2) prior to stimulation with the indicated concentration of
agonist for 30 min in the presence of 10 mM LiCl. [3H]InsPs in
neutralised TCA extracts (2.4.2) were were quantified using Dowex anion















































Figure 2.3.1.2a & b Time course of carbachol-stimulated [3H]inositol
incorporation into inositol phosphates and inositol phospholipids
Aliquots (50 pi) of BTSM slices were pre-labelled (short-term) with
[3H]inositol in the presence of 1 pM CCh (2.3.1). After extensive washing,
slices were stimulated in the presence of 5 mM LiCl with 100 pM CCh or
vehicle for the times indicated, in a final volume of 300 pi. Reactions
were terminated with 0.94 ml chloroform/methanol (1:2 v/v) and total
pH]InsPs and pH]PtdIns(P)s separated and quantified as detailed (2.4.1,
2.5). Data represent mean ± SEM of four separate experiments.
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However, when total [3H]InsPPs were assessed over a more detailed,
shorter time-course following CCh stimulation (figure 2.3.1.3), an
attenuation of [3H]InsPP accumulation was seen after 30 seconds. This
may represent a slight decrease in the specific radioactivity of the
phosphoinositides or a small degree of receptor desensitisation, but is
more likely due to an inevitable retardation of the extremely rapid initial
hydrolysis of [3H]PtdIns(4,5)P2. Such rapid metabolism of this lipid
cannot be maintained since its resynthesis by the sequential
phosphorylation of [3H]PtdIns and [3H]PtdIns4P proceeds at a slower rate
(Chilvers et. at. 1991a).
2.3.2 Overnight labelling
BTSM slices (2.2) were washed twice in 20 ml M199 medium containing
50 units/ml of each of penicillin and streptomycin. Aliquots (50 pi) of
gravity packed slices were then transferred to 24 well tissue culture plates
containing M199 medium and 0.92-3.00 pCi/ml myo-[3H]inositol and
incubated at 37 °C for 24 hours in a humidified atmosphere of 5%
C02/95% air. Subsequent stimulations were carried out with the plate
standing on a dry block at 37 °C (returning slices to the incubator when
possible) in a final volume of 1 ml. Unless otherwise stated LiCl was
added to the wells 10 min prior to agonists, each being added in a 10 pi
volume.
65
Figure 2.3.1.3 Detailed early time-course of carbachol-stimulated
[3H]inositol phosphate accumulation
Aliquots (50 pi) of BTSM slices were pre-labelled with [3H]inositol in the
presence of 1 pM CCh (2.3.1). After extensive washing slices, were
stimulated in the presence of 0.5 mM LiCl with 100 pM CCh or vehicle
for the times indicated. [3H]InsPs were separated from neutralised
neutralised TCA extracts (2.4.2) using H.P.L.C. (2.6.3), and the radioactivity
in each fraction quantified by liquid scintillation counting. Results are
presented as radioactivity associated with total [3H]InsPPs against time.
Data represent mean ± SEM of three separate experiments.
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2.4 EXTRACTION OF [3H]INOSITOL PHOSPHATES
2.4.1 Neutral chloroform/methanol extraction
For experiments where both [3H]inositol phospholipids and [3H]InsPs
were to be measured a chloroform/methanol extraction was employed.
Neutral extracts were prepared as described by Bligh and Dyer (1959) with
incubations (300 pi) terminated by the addition of 0.94 ml
chloroform/methanol (1:2, v/v). Following the addition of a further 0.31
ml of each of chloroform and dH20, samples were left to extract at room
temperature for 10 min before partitioning of the resulting aqueous and
organic phases by centrifugation (3,000 g, 20 min, 25 °C). Aliquots (0.75
ml) of the upper aqueous phase were diluted with 2.25 ml dH20 and
stored at 4 °C for subsequent separation and quantification of [3H]InsPs
(see section 2.6).
2.4.2 Trichloroacetic acid extraction
For experiments where [3H]InsPs only, or [3H]InsPs and
[3H]polyphosphoinositides were to be measured, a trichloroacetic acid
extraction (as developed by Sharps and McCarl, 1982) was employed. This
acid extraction protocol has the advantage of faithfully recovering the
higher InsPPs (especially InsP3 and above) which are not so readily
isolated with a neutral chloroform/methanol extraction, and of
facilitating a further acidic chloroform/methanol extraction on the tissue
pellet as is necessary for recovery of the polyphosphoinositides (see
section 2.5). Reactions were terminated with an equal volume of ice-cold
1 M trichloroacetic acid (TCA) (except for those experiments performed in
24 well tissue culture plates, in which 1 ml incubations were terminated
with 300 pi ice-cold 3 M TCA). Samples were left to extract on ice for 10-
20 min and, if necessary, transferred to 6 ml flat bottomed vials. After
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vortex mixing and centrifugation (3000 g, 20 min, 25 °C) the TCA was
removed from the extracts using l,l/2-trichloro-l/2/2-trifluoroethane
(freon)/tri-n-octylamine according to the method described by Downes
and Wusteman (1983). Portions of the supernatants were transferred to
1.5 ml Eppendorf tubes containing an equal volume of freon/octylamine
(1:1, v/v, made fresh) and a quarter volume of 10 mM EDTA (pH 7);
samples were vortexed vigorously, microfuged (10,000 g, 5 min, 25 °C)
and aliquots of the upper aqueous layer neutralised with a 1/5 volume 60
mM NaHCC>3. Neutralised TCA extracts were stored at 4 °C for
subsequent separation and quantification of [3H]InsPs (2.6). Since
neutralisation is achieved by the removal of acid rather than the addition
of alkali there is no increase in the amount of salt in the final samples.
The extracts are also free of any insoluble protein or solvents and
therefore this protocol produces samples ideally suited for subsequent
H.P.L.C. analysis.
2.5 EXTRACTION AND QUANTIFICATION OF pH]PHOSPHO-
INOSITIDES
[3Pl]PtdIns may be isolated by neutral chloroform/methanol extraction as
detailed in section 2.4.1: following centrifugation, aliquots of the lower
organic phase are mixed with Emulsifier-Safe scintillation fluid and
radioactivity in the samples determined by liquid scintillation counting.
The polyphosphoinositides however are highly negatively charged and
tend to associate with protein, possibly via interactions with Ca2+ or Mg2+
ions, and therefore do not readily enter the organic phase followiirg
neutral chloroform/methanol extraction. Accurate quantification of
these polyphosphoinositides requires acidic conditions to supress their
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negative charge and prevent the formation of salt-bridges, thereby
facilitating their partitioning into the organic phase with the other
phospholipids (see Hawthorne and White, 1975).
2.5.1 Acidic chloroform/methanol extraction
TCA precipitated tissue pellets (2.4.2) were washed according to the
method of Creba et al. (1983), with 1 ml 5% (w/v) TCA in 1 mM EDTA,
followed by 1 ml dH20. pHjPolyphosphoinositides were extracted from
this pellet as detailed by Downes and Wusteman (1983): 0.94 ml
chloroform/methanol (2:1, v/v)/100 mM HC1 was added to the pellet and
samples left on ice to extract for 10-15 minutes. A further 0.31 ml
chloroform and 0.56 ml 0.1 M HC1 were added to the samples prior to
vortexing and centrifugalion (3,000 g, 20 min, 4 °C). The upper aqueous
layer was gently aspirated and discarded. Aliquots of the lower organic
phase were evaporated to dryness under nitrogen. The radioactivity in
these samples was determined by redissolving in Emulsifier-Safe
scintillation fluid and liquid scintillation counting, or alternatively the
dried lipids could be stored under nitrogen at -20 °C overnight for
subsequent deglyceration (see section 2.5.2).
2.5.2 Alkaline hydrolysis of [3H]phosphoinositides
Base hydrolysis (deglyceration) of pH]polyphosphoinositides, according to
a method modified from Grado and Ballou (1961), was used to produce a
series of [3H]InsPP standards for characterisation of the H.P.L.C. separation
system. Pooled triplicates of acidic chloroform/methanol extracts (2.5.1)
(previously dried under nitrogen) were redissolved in 0.25 ml 1 M KOH,
and placed in a boiling water bath for 30 min. Samples were then cooled
on ice for five minutes prior to centrifugation (3,000 g, 20 min, 4 °C).
Excess alkali was removed by passing the supernatant through a 0.5 ml
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acidified formate Dowex AG 1-X8, 200-400 mesh column. After washing
the column with 2.25 ml dHbO the combined eluates were extracted, as
described by Clark and Dawson (1981), with 3 ml butan-l-ol/petroleum
ether (5:1 v/v) followed by a further 1.875 ml butan-l-ol/petroleum ether
to remove any contaminating fatty acids and other lipids. Aliquots (2 ml)
of the lower phase were sampled with a long-reach pipette, dried down
under nitrogen and stored at -20 °C for subsequent H.P.L.C. analysis
(2.6.3).
2.6 SEPARATION AND QUANTIFICATION OF [3H]INOSITOL
PHOSPHATES
2.6.1 Separation of total [3H]inositol phosphates
The total [3H]InsP fraction extracted from BTSM slices was separated
using formate Dowex AG 1-X8 (200-400 mesh) anion exchange
chromatography according to a method modified from Rooney and
Nahorski (1986). Open glass columns (5 mm internal diameter, ASA
Derby U.K.) were plugged with glass wool and loaded under water with a
1 ml volume of dH70 pre-washed anion exchange resin (50% w/v slurry).
Neutralised TCA extracts (2.4.2) or the aqueous phase from neutral
chloroform/methanol extracts (2.4.1) were applied to the column and
unbound [3H]inositol removed by washing with 20 ml dH20.
[3H]GroPIns was eluted from the column using 4 ml 0.025 M NH4COOH,
and the remaining [3H]InsPs collected by elution with 10 ml 1 M
NH4COOH/O.I M HCOOH. This latter buffer is of sufficiently high
concentration to remove [3H]InsPi-4. More extensive washing with 0.025
M ammonium formate resulted in early elution of [3H]InsPs present in




Figure 2.6.1 Purity of the [3H]GroPIns fraction from Dowex anion
exchange chromatograpy
(a) Neutralised TCA extracts (2.4.2) from [3H]inositol labelled BTSM slices
(2.3.1) stimulated with CCh (30 min) were applied to formate Dowex AG
1-X8 columns and eluted with 10 x 2 ml dEbO, 5 x 2 ml 0.025 M
NH4COOH (1) and 5x2 ml 1 M NH4COOH/O.I M HCOOH (2).
(b) Samples 12-16 were combined, diluted ten-fold and re-eluted exactly as
described above. Radioactivity in the eluate was determined by liquid
scintillation counting.
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washing there is a significant contamination of the [3H]GroPIns fraction
with [3H]InsPs. Higher [3H]InsPs (i.e. [3H]InsPs and [3H]InsP6> can be
removed from the column with 10 ml 2 M NH4COOH/O.I M HCOOH,
however no such compounds could be detected in neutralised tissue
extracts obtained from tissue labelled under short-term (60 min) agonist-
stimulated conditions (2.3.1) (results not shown). Radioactivity
associated with the separated [3H]InsPs was quantified by liquid
scintillation counting of 2 ml samples of eluant mixed with 18 ml
Emulsifier-Safe.
2.6.2 Separation of [3H]inositol mono-, bis-, tris- and tetrakisphosphates
[3H]Inositol polyphosphate fractions were separated using Dowex anion
exchange chromatography and ammonium formate/formic acid buffers
as detailed by Batty et al. (1985). Neutralised TCA extracts (2.4.2) were
applied to 1 ml formate Dowex AG 1-X8 columns as described above.
Typically [3H]Ins, [3H]GroPIns, [3H]InsP!, [3H]InsP2, [3H]InsP3and [3H]InsP4
were eluted in a sequential manner with 20 ml dH20, 4 ml 0.025 M
NH4COOH, 14 ml 0.2 M NH4COOH, 14 ml 0.5 M NH4COOH/O.I M
HCOOH, 14 ml 0.75 M NH4COOH/O.I M HCOOH and 10 ml 1 M
NH4COOPI/O.I M HCOOH respectively. Due to significant batch-batch
variation in the Dowex anion exchange resin purchased, the exact
concentration and quantity required of each buffer was reassessed for each
new batch resin acquired and varied accordingly. Figure 2.6.2 shows the
separation of [3H]InslP, [3H]Ins(l,4)P2 and [3H]Ins(l,4,5)P3 standards
achieved by this technique. For the 3-kinase and 5-phosphatase
experiments in which, by design, there was little or no degradation of




Figure 2.6.2 Separation of [3H]inositol phosphate standards by Dowex
anion exchange chromatography
10,000 DPM each of [3H]InslP, [3H]Ins(l,4)P2 and [3H]Ins(l,4,5)P3 were
added to BTSM tissue extract (2.4.2) and applied to a formate Dowex AG 1-
X8 column. The column was then washed with with the following
buffers: 10x2 ml dH20 (1), 2 x 2ml 0.025 M NH4COOH (2), 7 x 2 ml 0.2 M
NH4COOH (3), 7 x 2 ml 0.5 M NH4COOH/O.I M HCOOH (4) and 7 x 2 ml
0.75 M NH4COOH/O.I M HCOOH (5). The radioactivity associated with
each 2 ml sample of eluant was quantified by liquid scintillation
counting.
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2.6.3. Separation of individual [3H]inositol polyphosphate isomers
Individual [3H]inositol polyphosphate isomers were separated using
H.P.L.C. according to a method modified from Batty et al. (1989).
Neutralised TCA extracts (2.4.2) were spiked with 50 pM each of
adenosine-, and guanosine- mono, di, tri, and tetraphosphates and
adjusted to a final volume of 2.5 ml with dH20. Aliquots (2 ml) were
then injected onto a Partisphere 5 SAX anion exchange column equipped
with a cartridge pre-column containing anion exchange resin.
Nucleotides were added to provide internal standards for each H.P.L.C.
run. Following sample injection the column was washed for 20 min
with dH20, and the [3H]InsPPs and nucleotides eluted with five
consecutive gradients (i-v) of dH20 (A) and 1.4 M NH4H2PO4 adjusted to
pH 3.7 with H3PO4 (B) buffers, at a flow rate of 1 ml/min: (i) linear
gradient 0-5% B over 30 min, (ii) isocratic elution at 14% B for 15 min, (iii)
linear gradient 14-21% B over 15 min, (iv) isocratic elution at 35% B for 35
min and (v) isocratic elution at 100% B for 5 min (see figure 2.6.3.1).
Nucleotides were detected by continuous U.V. monitoring of the column
eluate at 254 nm - a typical trace from the on line uvicord (Pharmacia) is
shown in figure 2.6.3.1. The eluate was collected in 0.5 ml fractions and
each mixed with 4.5 ml Flo-Scint IV for quantification of radioactivity by
liquid scintillation counting. Identification of [3H]InsPPs was based on co-
elution with standards, both commercial and those generated by the mild
alkaline hydrolysis of [3H]Ins lipids (2.5.2) (see figure 2.6.3.2), or by




Figure 2.6.3.1 H.P.L.C. separation of adenosine and guanosine nucleotides
A distilled water sample (2 ml) was spiked with 20 pM of each nucleotide
(1-9) and loaded onto a Partisphere 5 SAX H.P.L.C. column equipped with
a Whatman cartridge anion exchange pre-column. The column was
washed for 20 min with dH20 before eluting the nucleotides with five
consecutive gradients of dH20 (A) and 1.4 M NH4H2PO4 adjusted to pH
3.7 with H3PO4 (B) buffers, as detailed in section 2.6.3 and shown on the %
buffer B trace. Nucleotides were monitored using an on line U.V.
spectrophotometer and are identified as cAMP (1), AMP (2), GMP (3), ADP



























































































































Figure2.6.3.2dTypicalH.P.L.C.el tionrofil s:TETRAKISPHOSPHATEF ACTION Seelegendtofi ure2.6.3.2a.
2.7 DETERMINATION OF INOSITOL 1,4,5-TRISPHOSPHATE MASS
D-Ins(l/4/5)P3 mass was quantified using a specific radioreceptor assay
according to the method of Challiss et al. (1988, 1990). The assay uses a
bovine adrenal cortex preparation which contains a well characterised,
single high affinity [3H]Ins(l,4,5)P3 binding site and is capable of
distinguishing fmolar concentrations of [3H]Ins(l,4,5)P3.
2.7.1 Preparation of samples for inositol 1,4,5-trisphosphate mass
determination
BTSM slices (300 x 300 pm) were prepared and pre-incubated in
oxygenated KPIB for 60 min as described in section 2.2. Aliquots (50 pi) of
gravity packed slices were transferred to 6 ml flat bottomed vials
containing 230 or 240 pi of either (a) oxygenated KHB for same-day
stimulations or (b) RPMI medium containing 50 units/ml each of
penicillin and streptotomycin for next-day stimulations.
(a) Samples were capped and incubated at 37 °C in a shaking water bath
for 10 min prior to addition of agonists in a 10 pi volume. Reactions
were terminated at the appropriate times with 300 pi ice-cold 1 M TCA
and neutralised extracts (2.4.2) stored at 4 °C.
(b) Samples were incubated for 24 hours at 37 °C in a humidified
atmosphere of 5% CC>2/95% air. Subsequent stimulations were carried
out exactly as described above (a).
The amount of protein in the TCA extracted tissue pellets was
determined following solubilisation overnight in 2 M NaOH using the
BCA protein assay.
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2.7.2 Preparation of inositol 1,4,5-trisphosphate binding protein
Fresh bovine adrenal glands were demedullated and decapsulated to
obtain 60-80 g of adrenal cortex. Tissue was homogenised (Polytron) in 8
volumes ice-cold 20 mM NaHCC^, 1 mM dithiothreitol (DTT), pH 8.0 and
centrifuged at low speed for 15 min (5,000 g, 4 °C). The supernatant was
removed and the pellet rehomogenised in a further 4 volumes of buffer
for re-centrifugation as above. The pooled supernatant fraction was spun
at 38,000 g (20 min, 4 °C) and the resulting pellet washed in 20 mM
NaHCC>3, 1 mM DTT, pH 8.0. The final pellet was resuspended in the
above buffer at a protein concentration of 15-20 mg/ml, as determined
using the BCA protein assay and stored in aliquots at -20 °C.
2.7.3 Inositol 1,4,5-trisphosphate mass assay
Assays were performed in LP3 tubes at 4 °C in a final volume of 120 pi.
Aliquots (30 pi) of neutralised TCA extract (2.4.2) or dH^O containing
standard amounts of D-Ins(l,4,5)P3 (0.036-36000 nmoles, i.e. 0.3-300 nM
final concentration), or 1.2 nmoles (10 pM final concentration) D-
Ins(l,4,5)P3 (to define non-specific binding), were added to 30 pi 100 mM
Tris-HCl, 4 mM EDTA buffer (pH 8.0) and 30 pi water containing 8-10,000
DPM [3H]Ins(l,4,5)P3- Finally 30 pi of adrenal cortex binding protein was
added to the tubes which were vortexed and left to incubate on ice for 30-
60 min. Bound and free [3H]Ins(l,4,5)P3 were separated by rapid filtration
through Whatman GF/B glass fibre filters with 2x3 ml washes of ice-cold
25 mM Tris-HCl, 5 mM NaHC03, 1 mM EDTA (pH 8.0). Emulsifier-Safe
(4 ml) was added to the filter discs and the radioactivity associated with
bound [3H]Ins(l,4,5)P3 determined, after a 1? hour extraction period, by
liquid scintillation counting. Unknown Ins(l,4,5)P3 concentrations were


















Figure 2.7.3 Inositol 1,4,5-trisphosphate mass assay: standard curve
Ins(l/4/5)P3 was incubated, at the concentrations indicated, with
Ins(l,4,5)P3 binding protein (2.6.2) and 8-10,000 DPM [3H]Ins(l,4,5)P3 as
described in section 2.6.3. Bound and free [3H]Ins(l,4,5)P3 were separated
by filtration and the bound [3H]Ins(l,4,5)P3 quantified by liquid
scintillation counting. Values represent means of duplicate samples.
Standard errors (< 5.4% of the mean) lie within the data points. Non¬
specific binding = 1.4%, total [3H]Ins(l,4,5)P3 bound in absence of added
unlabelled Ins(l,4,5)P3 = 40.7%.
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radioimmunoassay programme and corrected for protein content for each
50 (il aliquot of BTSM slices (2.7.1). This method gave consistent standard
curves for the binding of D-Ins(l/4,5)P3 to the bovine adrenal cortex
binding protein: EC50 = 14.21 ± 0.83 nM, non-specific binding = 1.33 ±
0.07%, D-[3H]Ins(l,4,5)P3 bound in absence of competing unlabelled D-
Ins(l,4,5)P3 = 40.27 ± 1.84% (Data represent mean ± SEM of 12 separate
experiments).
2.8 METABOLISM OF [3H]INOSITOL POLYHOSPHATES BY BOVINE
TRACHEAL SMOOTH MUSCLE CELL FREE EXTRACTS
2.8.1 Preparation of bovine tracheal smooth muscle cytosol extract
BTSM strips were dissected free of overlying epithelium and surrounding
connective tissue. Portions (9 g) of tissue were minced with scissors, and
both washed in (5x15 ml), and homogenised in (36 ml), ice-cold isotonic
buffer (10 mM Tris-maleate, 150 mM sucrose buffer, adjusted to pH 7.5
with NaOTI). After centrifugation at low speed for 10 min (5,000 g, 4 °C),
the upper fatty layer was aspirated and discarded and the supernatants
respun at high speed (48,400 g, 90 min, 4 °C). Aliquots of the final
supernatant were stored at -80 °C.
2.8.2 Preparation of bovine tracheal smooth muscle homogenates
BTSM was homogenised and spun at low speed as described above (2.8.1).
Following centrifugation, the upper fatty layer was discarded and the
remaining supernatant and pellet rehomogenised. Aliquots of
homogenate were stored at -80 °C.
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2.8.3 Assay conditions for cell free incubations
Reactions were performed in 1.5 ml Eppendorf tubes in an intracellular-
like 100 mM KC1, 20 mM NaCl, 2 mM MgC^1 and 25 mM HEPES buffer,
adjusted to pH 7.4 using KOH. Standard [3H]Ins(x)PP label (10-60,000
DPM) was diluted in the above buffer and incubated with 20 pi cell free
extract in a final volume 100 pi at 37 °C in a shaking water bath.
Reactions were terminated by the addition of 100 pi ice-cold 1 M TCA
and neutralised extracts prepared as detailed in section 2.4.2 stored at 4 °C
for subsequent separation of [3H]InsPPs using AG 1-X8 Dowex open-
column chromatography (2.6.2) or EI.P.L.C. (2.6.3).
2.9 INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE INCUBATIONS
An Ins(l,4,5)P3 3-kinase enzyme purified from rat brain has been shown
to be susceptible to degradation by the calcium dependent neutral cysteine
protease calpain (Lee et al., 1990), and a cDNA clone of the 3-kinase from
this tissue reveals the presence of six TEST' regions, i.e sequences
common to proteins susceptible to calpain (Choi et al., 1990). In order to
prevent such a degradation of the BTSM Ins(l,4,5)P3 3-kinase in my
studies calpain inhibitors were included in the buffers at all stages of both
preparation and assay of the enzyme. These compounds potently inhibit
the calpains (Kj = 0.12-0.23 nM) but were used at high (pM) concentrations
since the inhibtion exhibited by these agents is reversible.
1 MgCl2 was included in the incubation buffer since the 5-phosphatase has an absolute
requirement for Mg3+. A concentration of 2 niM MgCl2 was chosen as this value lies within
the range of Mg-+ concentrations (1-3 mM) generally required for optimal activity of
Ins(1,4,5)P3 5-phosphatase (e.g. Connolly et al., 1985; Kennedy et al., 1990; Sasaguri et
al., 1985; Scyfred et al., 1984).
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2.9.1 Preparation of bovine tracheal smooth muscle cell free extract for the
assay of inositol 1,4,5-trisphosphate 3-kinase enzyme activity
BTSM was dissected free of overlying epithelium and surrounding
connective tissue. Portions (9 g) of tissue were minced with scissors, and
both washed in (5 x 15 ml), and homogenised in (36 ml), ice-cold (10 mM
Tris-maleate, 150 mM sucrose buffer (pH 7.5, NaOH) containing the
following agents to prevent proteolytic digestion: 100 nM 2,2'-azino-di-(3-
ethyl-benzthiazoline-6-sulphonic acid) (AEBSF), 0.1% (v/v) 2-
mercaptoethanol, 17 pg/ml (i.e. 46 pM) calpain inhibitor I and 7 pg/ml
(i.e. 18 pM) calpain inhibitor II. After centrifugation at low speed for 10
min (5,000 g, 4 °C), the upper fatty layer was discarded and the
supernatants respun at high speed (48,400 g, 90 min, 4 °C). Aliquots of the
final supernatant (8.23 ± 0.23 mg protein/ml1) were stored at -80 °C.
2.9.2 Assay conditions for 3-kinase incubations
In order to optimise the conditions for study of the BTSM Ins(l,4,5)P3 3-
kinase, a buffer was chosen which would facilitate this enzyme activity,
but inhibit dephosphorylation of both its substrate and product. Assays of
3-kinase activity have been performed in a variety of other tissues
including rat brain (Irvine et al., 1986) in which it has been identified that
the 3-kinase is both ATP- and Mg2+-dependent, and therefore these agents
were included in the incubation buffer. In addition, ATP (Hansen et al.,
1987; Shears et al.,1987b) and Mg2+ ions, when present in high enough
concentrations (Connolly et al., 1985; Hansen et al., 1987; Kennedy et al.,
1990; Seyfred et al., 1984), have an inhibitory action on the 5-phosphatase.
This enzyme is also potently inhibted by 2,3-diphosphoglycerate (2,3-DPG)
1 Protein concentration determined using the bicinchoninic acid (BCA) protein assay
(Smith et al., Anal. Biochem. 150: 76-85, 1985) and bovine serum albumin as a standard.
Results represent mean ± SEM of three separate BTSM 3-kinase preparations.
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(Dowries et al., 1982; Hansen et al., 1987; Kennedy et al., 1990; Shears et al.,
1987b).
Ins(l,4,5)P3 3-kinase activity was assayed according to a method modified
from Batty (1987). Reactions were performed in 1.5 ml Eppendorf tubes in
50 mM Tris-maleate, 20 mM MgCH, 10 mM ATP, 5 mM 2,3-
diphosphoglyceric acid, 5 mM EGTA and appropriate concentrations of
CaCh1, pH 7.5 containing 17 pg/ml calpain inhibitor I, and 7 pg/ml
calpain inhibitor II. [3H]Ins(l,4,5)P3 label was diluted in the above buffer
and incubated with 40 pi of the cytosol extract prepared for assay of 3-
kinase activity (2.9.1) (diluted appropriately in the reaction buffer) in a
final volume of 200 pi at 37 °C in a shaking water bath. Reactions were
terminated by the addition of 200 pi ice-cold 1 M TCA, and 20 pi 5% (w/v)
bovine serum albumin added to the samples to aid precipitation of the
protein pellet. Neutralised TCA extracts (2.4.2) were stored at -80 °C for
subsequent separation of pHjlnsPPs.
2.10 INOSITOL 1,4,5-TRIS PHOSPHATE 5-PHOSPHATASE
INCUBATIONS
2.10.1 Preparation of bovine tracheal smooth muscle cell free extracts for
assay of inositol 1,4,5-trisphosphate 5-phosphatase enzyme activity
BTSM was dissected free of overlying epithelium and surrounding
connective tissue. Portions (9 g) of tissue were minced with scissors, and
both washed in (5 x 15 ml), and homogenised in (36 ml), ice-cold 10 mM
Tris-maleate, 150 mM sucrose buffer, adjusted to pH 7.5 with NaOH,
containing 1 mM phenylmethylsulphonyl fluoride (PMSE)2 and 0.1%
hCa2+|frcc was calculated with the use of software based on the work of Pcrrin and Sayce
(1967).
2A high concentration of PMSF was used since it has a short half-life in aqueous solutions.
86
(v/v) 2-mercaptoethanol. After centrifugation at low speed for 10 min
(5,000 g, 4 °C), the upper fatty layer was discarded and the supernatants
respun at high speed (48,400 g, 90 min, 4 °C). Aliquots of the final
supernatant (containing the soluble 5-phosphatase enzyme activity, 8.37 ±
0.87 mg protein/ml1) were stored at -80 °C. The pellet was solubilised in 5
ml of the above buffer containing 1% Nonidet (NP40) (v/v) at 4 °C for
two hours and re-centrifuged to remove any remaining insoluble
material (48,000 g, 90 min, 4 °C). Aliquots of the final supernatant
(containing solubilised particulate 5-phosphatase enzyme activity, 5.84 ±
0.28 mg protein/ml2) were stored at -80 °C.
2.10.2 Assay conditions for 5-phosphatase incubations
Reactions were performed in 1.5 ml Eppendorf tubes in 100 mM KCL, 20
mM NaCl, 2 mM MgCb and 25 mM HEPES buffer, adjusted to pH 7.4.
using KOEI. pH]Ins(l,4,5)P3 (10-12,000 DPM) was diluted in the above
buffer and incubated with 40 pi of the cytosol extract prepared for assay of
5-phosphatase activity (2.10.2) (diluted appropriately in the reaction
buffer) in a final volume of 200 pi at 37 °C in a shaking water bath.
Reactions were terminated by the addition of 200 pi ice-cold 1 M TCA,
and 20 pi 5% (w/v) bovine serum albumin added to the samples to aid
precipitation of the protein pellet. Neutralised TCA extracts (2.4.2) were
stored at -80 °C for subsequent separation of pHjlnsPPs. For experiments
undertaken at determined [Ca2 + ]freC/ ImM EGTA and appropriate
concentrations of CaCb were added to the reaction buffer3.
1 Protein concentration determined using BCA protein assay and bovine scrum albumin as a
standard. Results represent mean ± SEM of three separate BTSM soluble 5-phosphatase
preparations.
2 Protein concentration determined using BCA protein assay and bovine serum albumin as a
standard. Results represent mean ± SEM of three separate BTSM solubilised particulate 5-
phospha tase preparations.






POLYPHOSPHATES IN BOVINE TRACHEAL
SMOOTH MUSCLE
3.1 INTRODUCTION
In BTSM, stimulation with the muscarinic cholinoceptor agonist
carbachol (CCh) results in a rapid increase in Ins(l/4/5)P3 (Chilvers et al.,
1990a) prior to Ca2+ release (Takuwa et al., 1987). This in turn precedes
myosin light chain phosphorylation and the development of tone
(Kamm and Stull, 1985). Although CCh stimulation results in only a
transient increase in Ins(l,4,5)P3 accumulation in BTSM, PtdIns(4,5)P2
hydrolysis is persistent in the continued presence of agonist (Chilvers et.
al., 1991a), suggesting that Ins(l,4,5)P3 is rapidly removed from the system
by its metabolising enzymes and is under stringent regulatory control.
Studies in other tissues (for reviews see Shears, 1991, 1992) have shown
that two major pathways exist for the metabolism of Ins(l,4,5)P3 - namely
the 3-kinase and 5-phosphatase pathways. The latter is initiated by the
removal of a phosphate group from the 5-position of the inositol ring to
produce Ins(l,4)P2, whereas the 3-kinase pathway proceeds by
phosphorylating the inositol ring on the 3-position to form Ins(l,3,4,5)P4.
Both metabolites are subject to further sequential dephosphorylation to
free inositol which may be recycled into the phosphatidylinositol pool.
The production and degradation of these Ins(l,4,5)P3 metabolites has been
studied extensively in other tissues, however characterisation of the
individual inositol polyphosphate isomers formed following receptor
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stimulation, and the relative importance of the 3-kinase and 5-
phosphatase pathways to Ins(l,4,5)P3 metabolism is lacking in BTSM.
Chilvers et al. (1990a) have demonstrated a rapid and transient CCh-
stimulated increase in [3H]Ins(l,4,5)P3 accumulation in BTSM which is
followed by a more delayed increase in [3H]InsP2 and [3H]InsPi. In
addition, H.P.L.C. and enzymic analyses of the [3H]InsP3 isomers showed
a progressive and sustained accumulation of [3H]Ins(l,3,4)P3 in BTSM
slices stimulated with 100 pM CCh. This compound represented the
predominant (> 80 %) [3H]InsP3 isomer present at all time-points greater
than 1 min following CCh stimulation, suggesting that the 3-kinase
pathway operates in BTSM and may contribute substantially to
Ins(l,4,5)P3 metabolism.
I have sought to separate, identify and quantify the individual inositol
polyphosphate isomers produced in BTSM in order to determine the
routes of Ins(l,4,5)P3 metabolism employed in this tissue and the flux of
the inositol headgroup through these pathways. Four major pre¬
requisites for such experiments are:-
(1) that there are no agonist-stimulated changes in [3H]phosphoinositide
(and hence [3H]InsP) specific radioactivity;
(2) that the individual inositol polyphosphates formed can be readily
separated and quantified;
(3) that the enzyme pathways responsible for the metabolism of
Ins(l,4,5)P3 yield mutually exclusive products; and
(4) that there is no major contribution to inositol polyphosphate
accumulation from either PLC-mediated breakdown of Ptdlns or
PtdIns4P, or from PLD action on the inositol-containing phospholipids.
The first two considerations are in part resolved by steady-state labelling
of the phosphoinositides with [3H]inositol as detailed in section 2.3.1 and
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including lithium ions during the agonist-incubation period. Lithium is
an uncompetitive inhibitor of the inositol monophosphatase enzyme
responsible for the degradation of inositol monophosphates to free
inositol (Gee et al., 1988; Hallcher and Sherman, 1980). Inclusion of
lithium ions in the experimental system therefore prevents the total
degradation of [3H]inositol phosphates, so trapping them within the
cytosolic fraction of the cell. The efficient trapping of [3H]InsPis by Li+
using this protocol is partially validated by the linear accumulation of
total [3H]InsPs following CCh stimulation (0-30 min) of BTSM slices (see
figure 2.3.1a). [3H]InsPPs may be extracted with TCA and separated using
H.P.L.C.. Very clear separations (at least five fractions between each
[3H]InsPP isomer) were achieved using the complex H.P.L.C. gradient
system detailed in section 2.6.3, and the radioactivity in each fraction was
quantified by liquid scintillation counting.
The experiments detailed in this chapter were designed to assess whether
or not the requirements (3) and (4) above are satisfied in BTSM, to
determine the flux of [3H]Ins(l,4,5)P3 through it's metabolic pathways and
to evaluate the relative importance of these pathways during a 0-30 min
agonist-stimulated response.
3.2 DETERMINATION OF THE ROUTES OF [3H]INOSITOL 1,4,5-
TRISPHOSPHATE METABOLISM IN BOVINE TRACHEAL SMOOTH
MUSCLE
As detailed previously, two major pathways exist for the metabolism of
[3H]Ins(l,4,5)P3. Chilvers et al. (1990a) have identified [3H]Ins(l,3,4,5)P4
and [3H]Ins(l,3,4)P3 accumulation in [3H]inositol labelled BTSM slices
stimulated with 100 (iM CCh, indicating the presence of a 3-kinase
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pathway in this tissue. In all other cell types studied the 3-kinase pathway
has led to the production of Ins(l,3,4,5)P4, Ins(l/3/4)P3/ Ins(l,3)P2/
Ins(3,4)P2, InslP and Ins3P isomers, whereas in most tissues the sole
products of the 5-phosphatase pathway are Ins(l,4)P2 and Ins4P. Hence
the two pathways give rise to mutually exclusive metabolic products. In
order to determine whether the same pathways of InsPP metabolism also
occur in BTSM, exogenous [3H]InsPPs were incubated with BTSM cell free
extracts (both cytosol extracts and homogenates), under conditions which
prevent further phosphorylation, and the resulting [3H]InsPP degradation
products separated and quantified.
3.2.1 Degradation of [3H]inositol 1,4,5-trisphosphate by bovine tracheal
smooth muscle cytosol extract
To determine optimal conditions for subsequent H.P.L.C. separations the
degradation of [3H]Ins(l,4,5)P3 by BTSM cytosol extract was assessed over a
30 min time-course and the resulting [3H]InsPs separated and quantified
using Dowex AG 1-X8 anion exchange chromatography. Reactions were
performed in an 'intracellular-like' buffer containing 2 mM MgCl2 (to
support 5-phosphatase activity, see section 2.8.3), in the absence of added
ATP to prevent further phosphorylation of the [3H]Ins(l,4,5)P3 substrate.
Figure 3.2.1.1 shows that under these conditions there is a rapid
degradation of [3H]InsP3 (ti/2 = 2.4 min) followed by a transient
accumulation of [3H]InsP2, (maximal after 2 min incubation with cytosol
extract), and secondary increases in [3H]InsPi and [3H]inositol. In control
reactions in which the cytosol extract had been previously heat-
inactivated (100 °C, 30 min) no such degradation of [3H]InsP3 was
observed. These results suggest that in BTSM, [3H]Ins(l,4,5)P3 maY be
metabolised by a sequential dephosphorylation reaction via [3H]InsP2 and
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Figure 3.2.1.1 Metabolism of [3H]inositol 1,4,5-trisphosphate by bovine
tracheal smooth muscle cytosol extract
[3H]Ins(l/4/5)P3 (10,000 DPM) was incubated with 20 pi BTSM cytosol
extract (2.8.1) in a final volume of 100 pi as described in section 2.8.3.
Reactions were terminated with 100 pi TCA at the time-points indicated
and the [3H]InsP fractions separated by Dowex AG 1-X8 anion exchange
chromatography (2.6.2). Results represent the mean ± SEM of three
separate experiments, each performed in duplicate, using three separate
cytosol extract preparations.
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[3H]InsPi to free [3H]inositol. However, these data do not give any
information as to the individual [3H]InsPP isomers formed during the
reaction. In order to determine the isomeric composition of the
[3H]InsPPs generated similar experiments were carried out in which the
incubations were terminated after 10 min (the time at which the
accumulation of [3H]InsPi is maximal), and the individual [3H]InsPP
isomers separated and quantified by H.P.L.C.. Figure 3.2.1.2 shows a
typical H.P.L.C. trace from one of these experiments and the relative
accumulations of each of the [3H]InsPPs is summarised in table 3.2.1.
[3H]Ins(l,4,5)P3 was not degraded by dephosphorylation to less polar
[3H]InsPPs following incubation with the heat-inactivated cytosol extract.
It is unlikely that any further phosphorylation could have taken place
with either the heat-inactivated or active cytosol extracts since there was
no added ATP in the system and any endogenous ATP was substantially
diluted during the cytosol extract preparation. The trace amounts of
[3H]Ins(2,4,5)P3 and [3H]InsP4 detected in the samples represent minor
impurities in the [3H]Ins(l,4,5)P3 standard used. When [3H]Ins(l,4,5)P3
was incubated with active cytosol extract it was degraded solely to
[3H]Ins(l,4)P2 and [3H]Ins4P, as is consistent with sequential actions of the
Ins(l,4,5)P3 5-phosphatase and inositol polyphosphate 1-phosphatase on
[3H]Ins(l,4,5)P3 and [3H]Ins(l,4)P2 respectively.
3.2.2 Degradation of [3H]inositol 1,3,4,5-tetrakisphosphate by bovine
tracheal smooth muscle cytosol extract
The degradation of [3H]Ins(l,3,4,5)P3 by BTSM cytosol extract was
monitored in an identical fashion to that of [3H]Tns(l,4,5)P3. Reactions
were performed in an 'intracellular-like' buffer and [3H]InsPs formed
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% Total Radioactivity
[3H]Ins(x)PP Inactive cytosol extract Active cytosol extract
(n=2) (n=4)
1/3 0.12 ±0.12 0.21 ± 0.04
4 0.06 ± 0.06 81.35 ±4.42
1/3 0.09 ± 0.09 0.08 ±0.01
1,4 0.22 + 0.10 5.81 ±2.13
3,4 0.09 ± 0.03 0.18 ±0.06
4,5 0.23 ± 0.06 0.08 ± 0.03
1,3,4 0.07 ±0.07 0.14 ±0.07
1,4,5 92.99 ± 1.42 8.77 ±3.13
2,4,5 1.97 ±0.40 0.96 ±0.14
1,3,4,5 3.71 ±1.66 2.23 ± 2.07
Table 3.2.1 [3H]Inositol 1,4,5-trisphosphate dephosphorylation metabolites
[3H]Ins(l,4/5)P3 (10-15,000 DPM) was incubated with 20 pi BTSM cytosol
extract (2.8.1) in a final volume of 100 pi as detailed in section 2.8.3.
Reactions were terminated after 10 min with 100 pi 1 M TCA and the
individual [3H]InsPP isomers in neutralised extracts separated, using
H.P.L.C. (2.6.3), and quantified by liquid scintillation counting. Results
are expressed as the percentage of the total retrieved radioactivity
associated with the [3H]InsPs (12,431 ± 1,321 DPM, n=6) and represent the
mean ± SEM of n separate experiments, using two or three separate
cytosol extract preparations.
Dowex AG 1-X8 chromatography (see figure 3.2.2.1). As expected,
incubation of [3H]Ins(l,3,4,5)P4 with cytosol extract resulted in a rapid
decline in the levels of [3H]InsP4 {t\/2 = 1-25 min), accompanied by a
transient accumulation of [3H]InsP3 (maximal at 5 min), a secondary
increase in the level of [3H]InsP2 and delayed accumulations of [3H]InsPi
and [3H]inositol. These results suggest that [3H]Ins(l,3,4,5)P4 is degraded
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Figure 3.2.2.1 Metabolism of [3H]inositol 1,3,4,5-tetrakisphosphate by
bovine tracheal smooth muscle cytosol extract
[3H]Ins(l,3,4,5)P4 (10,000 DPM) was incubated with 20 pi cytosol extract
(2.8.1) in a final volume of 100 pi as described in section 2.8.3. Reactions
were terminated with 100 pi 1 M TCA and the [3H]InsP fractions separated
by Dowex AG 1-X8 anion exchange chromatography (2.6.2). Results
represent the mean + SEM of three or four experiments, each performed
in duplicate, using three separate cytosol extract preparations.
96
to free [3H]inositol by BTSM cytosol extract via a series of sequential
dephosphorylation reactions.
H.P.L.C. separation of the [3H]InsPP isomers formed following incubation
with BTSM cytosol extract for 30 min (the time at which the greatest
accumulation of [3H]InsPi was observed and which therefore affords
optimal conditions for identification of the isomeric composition of
[3H]InsPi) indicates the presence of the 3-kinase pathway metabolites
[3H]Ins(l,3,4)P3, [3H]Ins(3/4)P2, and [3H]Insl/3P (see figure 3.2.2.2 and table
3.2.2). However the other common 3-kinase pathway metabolite
[3H]Ins(l/3)P2 could not be detected. The activity of the InsPP 1-
phosphatase which hydrolyses Ins(l/3/4)P3 to Ins(3,4)P2 exhibits a
sigmoidal dependence on Mg2+ ions with half maximal stimulation
occurring at 0.3 mM [Mg2+] (Inhorn and Majerus, 1987). Since the
incubation buffer utilised in these experiments contains 2 mM MgCl2 it is
likely to favour the 1-phosphatase route of Ins(l,3,4)P3 metabolism. In
addition the 1-phosphatase from calf brain has a slightly higher affinity
for Ins(l/3/4)P3 (Km ~ 20 pM, Inhorn and Majerus, 1987) than the InsPP 4-
phosphatase responsible for the formation of Ins(l,3)P2 (Km = 40 pM,
Bansal et ah, 1990).
Under the conditions outlined, [3H]Ins(l,3,4,5)P4 metabolism results in a
significant accumulation of [3H]Ins(l,4)P2 and [3H]Ins4P, compounds
which cannot be accounted for by metabolism via any of the recognised
'3-kinase pathway' enzymes. Similar data were consistently observed in a
series of five experiments utilising two separate BTSM cytosol extract
preparations, suggesting the presence of an active 3-phosphatase in the
cytosol extract which, under the conditions specified, may attack either
[3H]Ins(l,3,4,5)P4 or [3H]Ins(l,3,4)P3. It is tempting to suggest that the latter
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% Total Radioactivity
[3H]Ins(x)PP Inactive cytosol extract Active cytosol extract
n=2 n=5
1/3 0.00 ± 0.00 30.63 ± 7.79
4 0.00 ± 0.00 1.35 + 0.35
1,3 0.00 ± 0.00 0.00 + 0.00
1,4 0.00 ± 0.00 13.28 ±1.16
3,4 0.00 + 0.00 40.47 ± 4.43
4,5 0.00 ± 0.00 0.23 ± 0.02
1,3,4 0.73 ± 0.62 10.80 ±1.89
1,4,5 0.34 ±0.12 0.20 ± 0.03
2,4,5 0.00 ± 0.00 0.17 ±0.06
1,3,4,5 97.12 ± 0.42 0.60 ± 0.09
Table 3.2.2 [3H]Ins(l/3,4/5)P4 dephosphorylation metabolites
[3H]Ins(l,3,4,5)P3 (40-60,000 DPM) was incubated with 20 pi BTSM cytosol
extract (2.8.1) in a final volume of 100 pi as detailed in section 2.8.3.
Reactions were terminated after 30 min with 100 pi 1 M TCA and the
individual [3H]InsPP isomers in neutralised extracts separated using
H.P.L.C. (2.6.3), and quantified by liquid scintillation counting. Results
are expressed as the percentage of the total radioactivity retrieved (29,462
± 1,738, n=5) and represent the mean ± SEM of n separate experiments,
using two or three separate cytosol extract preparations.
[3H]Ins(l,4,5)P3 could be detected in the samples, however such a reaction
has not been described in any other cell type. The incubation buffer used
also supports 5-phosphatase activity and hence a more likely conclusion
is that any [3H]Ins(l,4,5)P3 formed is rapidly dephosphorylated to
[3H]Ins(l,4)P2 as described in section 3.2.1.
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3.2.3 Degradation of [3H]inositol 1,4,5-trisphosphate and [3H]inositol
1,3,4,5-tetrakisphosphate by bovine tracheal smooth muscle homogenate
The above in vitro experiments indicate that a 5-phosphatase pathway
operates in BTSM which may facilitate the sequential dephosphorylation
of Ins(l,4,5)P3 to free inositol via Ins(l,4)P2 and Ins4P. Ins(l,3,4,5)P4 may
be metabolised by a 3-kinase to Ins(l,3,4)P3, but may also be acted on by a
3-phosphatase enzyme. A similar 3-phosphatase activity has been
identified previously in a variety of cell types including rat liver
(Hodgson and Shears, 1990) and parotid gland (Hughes and Shears, 1990),
in which the total activity in cytosolic and membrane preparations is
greater than in that associated with the parent homogenate. It is possible
that this enzyme may be less active in vivo as a result of being bound or
sequestered within a subcellular compartment. Indeed, in liver, the 3-
phosphatase has been shown to be compartmentalised within the
endoplasmic reticulum (Ali et ai, 1993) and is evenly distributed between
the 'rough' and 'smooth' subfractions (Craxton et al., 1995). The
Ins(l,3,4,5)P4 3-phosphatase from turkey erythrocytes however, is
localised to the inner face of the plasma membrane (Estrada-Garcia et al.,
1991). Craxton et al. (1995) have shown that these two activities are
structurally distinct since the latter enzyme is not recognised by a
polyclonal antibody directed against the hepatic enzyme. It is also
possible that in vivo the 3-phosphatase may be subject to regulation by
agents that are separated from it or diluted in the preparation of cell free
extracts. In view of this uncertainty and the fact that these possible
alterations of regulation could equally well affect any of the enzymes
under study, further experiments were conducted to ascertain the pattern
of metabolism of both [3H]Ins(l,4,5)P3 and [3H]Ins(l,3,4,5)P4 by BTSM
homogenates.
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Table 3.2.3.1 summarises the data obtained when 60,000 DPM of either
[3H]Ins(l,4,5)P3 or [3H]Ins(l,3,4,5)P4 were incubated for 10 or 30 minutes
respectively with BTSM homogenates and the resulting [3H]InsP products
separated and quantified by Dowex anion exchange chromatography.
Neither [3H]Ins(l,4,5)P3 nor [3H]Ins(l,3,4,5)P4 were hydrolysed by the heat-
inactivated homogenate preparation. The active homogenate resulted in
the degradation of [3H]Ins(l,4,5)P3 to [3H]InsP2, [3H]InsPi and [3H]inositol,
with the majority of the radioactivity (81 %) residing in the [3H]InsPi
fraction. H.P.L.C. analysis of samples obtained from identical incubations
showed this monophosphate fraction to be comprised of [3H]Ins4P alone
(see figure 3.2.3.1). [3H]Ins(l,3,4,5)P4 was degraded by treatment with the
BTSM homogenate preparation to [3H]InsP2, [3H]InsPi, and [3H]inositol
(see table 3.2.3.1). Any [3H]InsP3 that may have been formed must itself
have been hydrolysed after a 30 min incubation period. H.P.L.C. analysis
of identical samples showed that the [3H]InsPs formed under the specified
conditions were comprised of [3H]Ins(l,3,4)P3, [3H]Ins(l,3)P2, [3H]Ins(3,4)P2
and [3H]Insl/3P alone (see figure 3.2.3.2 and table 3.2.3.2). X and Y
represent impurities in the [3H]Ins(l,3,4,5)P4 standard. Hence BTSM
homogenates contain enzymes capable of metabolising [3H]Ins(l,3,4,5)P4
to all of its well characterised dephosphorylation products, but unlike
BTSM cytosol extracts do not contain any detectable 3-phosphatase
activity. This latter result is entirely consistent with previous
observations of Ins(l,3,4,5)P4 3-phosphatase activity in other tissues. Such
enzyme activity has only been detected in permeabilised cell (Oberdisse et
al., 1990), broken cell (e.g. Foster et al., 1994; Hoer and Oberdisse, 1991;
Hughes and Shears, 1990; Nogimori et al., 1991) or electroporated cell
(Cullen et al., 1989) preparations and, as mentioned above, the total

































































Figure 3.2.3.1 Typical H.P.L.C. profile (monophosphate fraction) following
incubation of [3H]inositol 1,4,5-trisphosphate with active bovine tracheal
smooth muscle homogenate
[3H]Ins(l,4,5)P3 (40,000 DPM) was incubated with 20 pi active BTSM
homogenate (2.8.2) in a final volume of 100 pi as detailed in section 2.8.3.
The reaction was terminated after 10 min by addition of 100 pi 1 M TCA.
The individual [3H]InsPi isomers were separated and quantified by
H.P.L.C. as described in section 2.6.3, except that the following gradient
was used: After sample injection the column was washed for 10 min
with dH20, and the [3H]InsPi isomers eluted with a linear gradient 0 - 0.07
M NH4H2PO4 (adjusted to pH 3.7 with H3PO4). Radioactivity in the
column eluate was monitored by liquid scintillation counting.
103
025507100255 Fractionnumber

























































































Table3.2.3.2[3H]Inositolpolyphosphateisomersfor dnhydroly sif[ H]ino itol1,3,4,5-tetrakispho phatwit bovinetrachealsmoothmusclehomogenat [3H]Ins(l,3,4,5)P4(60,000DPMwasincubatedi h2piBTSMhomogenate2.8.2)fi lvolumf1asdetail insection2.8.3.Reactionsweret rminat df er30byhadd tionof100pMTCA.indivi ual[ H]I sP isomersnneutralisedTCAext cts(2.4.2)ws paratbyH.P.L C.6 3andq antifiedliqcintil on counting.Resultsrepresentthduplicateatfr ms glex erim .T lt iev drad oactivity=41,462±558
glands was found to be greater than that of the parent homogenate,
indicating that the enzyme may be intimately regulated or even non¬
functional in vivo.
Since the first description of the Ins(l,3,4,5)P4 3-phosphatase it has become
apparent that Ins(l,3,4,5,6)P5 and InsP6 (phytic acid) act as extremely
potent inhibitors of this enzyme (Hoer and Oberdisse, 1991; Hughes and
Shears, 1990; Nogimori et al.r 1991). The latter authors have
demonstrated that these highly phosphorylated InsPs can inhibit the
purified 3-phosphatase from rat liver with Kj values of 25 and 0.5 nM
respectively (similar values were also obtained in pig brain, Hoer and
Oberdisse, 1991), which closely resemble their Km values when used as
substrates for the enzyme. The affinity of InsP6 for the 3-phosphatase is
the highest yet defined for any enzyme involved in inositol phosphate
metabolism. In addition, the 3-phosphatase inhibitory activity of liver co-
elutes with standard InsP6 on Cellufine GCL-90 size exclusion gel
filtration and is depleted by treatment with phytase (Ali et al., 1993).
These data suggest that InsP6, and possibly Ins(l,3,4,5,6)P5 are the true
substrates for the 3-phosphatase in vivo, and given the high intracellular
concentration of these compounds in mammalian cells (see Berridge and
Irvine, 1989; Shears, 1992) dephosphorylation of Ins(l,3,4,5)P4 by this
enzyme in vivo is likely to be negligible. Large amounts of InsP6 have
been found associated with rat cerebellar membranes in the presence of
trace amounts of trivalent cations (Poyner et al., 1993). A similar metal
ion-dependent association of InsP6 with cell membranes may explain the
presence of Ins(l,3,4,5)P4 3-phosphatase activity detected in BTSM cytosol
extracts but not homogenates in the current study.
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Although the cell free experiments described above were not designed to
examine whether or not a 3-kinase activity exists in BTSM, they do
indicate that all of the other enzymes required for formation of exclusive
3-kinase and 5-phosphatase pathway metabolites from Ins(l,4,5)P3 are
present. Chilvers et al. (1990a) have identified Ins(l,3,4,5)P4 and
Ins(l,3,4)P3 in CCh-stimulated BTSM slices indicating that a 3-kinase
enzyme is present in this tissue. Hence it is likely that both the 3-kinase
and 5-phosphatase are important for the regulation of Ins(l,4,5)P3 levels
in BTSM. The data obtained using cell free BTSM extracts imply that in
the absence of 3-phosphatase activity (as would be expected in the intact
cell model), the two pathways do indeed yield mutually exclusive
products.
3.3 ASSESSMENT OF THE ROLE OF PHOSPHATIDYLINOSITOL AND
PHOSPHATIDYLINOSITOL 4-PHOSPHATE HYDROLYSIS IN INOSITOL
POLYPHOSPHATE ACCUMULATION IN BOVINE TRACHEAL
SMOOTH MUSCLE
It has been shown that a number of different isozymes of PIC exist in
tissues which can be distinguished by their biochemical properties,
immunological analysis and their primary protein structure (for reviews
see Crooke and Bennett, 1989; Meldrum et al., 1991; Rhee et al., 1989,
1991). Each of these isozymes are capable of hydrolysing all three of the
major phosphoinositides (i.e. Ptdlns, PtdIns4P and PtdIns(4,5)P2) in vitro
(e.g. Hiramatsu et al., 1992; Wilson et al., 1984), however the substrate
specificity of each of these enzymes in the intact cell is unclear. From
studies carried out in vitro it seems that in general, PIC will hydrolyse the
polyphosphoinositides at low Ca2+ concentrations whereas hydrolysis of
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Ptdlns requires a higher Ca2+ concentration (e.g. Griendling et al., 1991).
Hence it has been suggested that at later time-points of the agonist-
stimulated response, PIC may utilise Ptdlns and PtdIns4P as substrates in
addition to PtdIns(4,5)P2- An increase in [Ca2+]j may also activate PIC
directly since elevation of [Ca2+]frcc from 2.7 nM to 617 nM has been
reported to enhance basal InsP accumulation (1.6-fold) in digitonin-
permeabilised canine tracheal smooth muscle cells (Yang et al., 1993). It
has been widely reported that agents which increase [Ca2+]j/ such as
calcium ionophores and membrane depolarising concentrations of K+
ions, result both in an accumulation of [3H]InsPs in [3H]Ins prelabelled
neuronal and synaptosomal preparations (Baird and Nahorski, 1989, 1990;
Brammer and Weaver; 1989; del Rio et al., 1994; Fisher et al., 1989) and an
increase in Ins(l,4,5)P3 and Ins(l,3,4,5)P4 mass in rat cerebral cortex slices
(Challiss and Nahorski, 1991). These studies noted a preferential
accumulation of [3H]InsP2 over that of [3H]InsP3 following application of
depolarising agents and calcium ionophores even in the presence of the
5-phosphatase inhibitor 2,3-DPG (Fisher et al., 1988), suggesting that in
contrast to agonist activation of PIC, PtdlnsP rather than PtdInsP2 may be
the predominant substrate for such agonist-independent PIC activation.
The majority of these studies have been conducted in excitable tissue, in
particular neuronal cells; however phosphoinositide hydrolysis in
response to calcium ionophores and depolarising agents has also been
observed in guinea-pig visceral smooth muscle preparations (Best and
Bolton, 1986; Jafferji and Michell, 1976; Sasaguri and Watson, 1988;
Watson and Downes, 1983) and guinea-pig trachea (Kardasz et al., 1987).
Some of the responses in these smooth muscle preparations have
subsequently been shown to be neuronal in origin (Watson et al., 1990),
or secondary to endogenous neurotransmitter release from neuronal
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tissue contained within the preparation (Akhtar and Abdel-Latif, 1984;
Watson and Downes, 1983). If PIC is able to hydrolyse the lower
phosphoinositides in significant quantities in BTSM, the resulting
formation of InslP and Ins(l,4)P2 isomers (indistinguishable from those
formed by Ins(l/4/5)P3 metabolism) would preclude the assessment of
Ins(l/4,5)P3 3-kinase and 5-phosphatase metabolites. To address whether
or not a Ca2+-mediated activation of PIC occurred in BTSM slices,
pHjInsPs accumulating over a 30 min period in the presence of lithium
were quantified following incubation with depolarising concentrations of
KC1 or the calcium ionophore ionomycin, and compared with basal and
CCh-stimulated values.
Receptor-stimulated activation of phospholipase D (PLD) is common to a
large number of agonists which also activate PIC, and may occur
secondary to PKC activation (see Billah, 1993). In guinea-pig tracheal
smooth muscle cells PLD can be activated following stimulation with
either bradykinin or the protein kinase C activator phorbol myristate
acetate (PMA) (Pyne and Pyne, 1993). This PLD response is inhibited both
by the PKC inhibitor staurosporine or by prior down regulation of PKC.
Phosphatidylcholine appears to be the preferred substrate for PLD,
however in some systems PLD may also hydrolyse
phosphatidylethanolamine (Kiss, 1992) or Ptdlns (Huang et al., 1992).
Hence a PKC-stimulated PLD activity directed against the
phosphoinositides could occur in BTSM following muscarinic
cholinoceptor stimulation, resulting in a non-direct receptor mediated
accumulation of inositol phosphates. In order to ascertain whether or
not such an activation of PLD contributes significantly to the CCh-
stimulated accumulation of [3H]InsPs in BTSM additional incubations
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were carried out in the presence of the PKC-stimulating phorbol ester
phorbol dibutyrate (PDBu).
3.3.1 Effect of potassium ions, ionomycin and phorbol dibutyrate on
[3H]inositol phosphate accumulation in bovine tracheal smooth muscle
[3H]Inositol pre-labelled BTSM slices were incubated for 30 min with 100
(iM CCh, 80 mM KC1, 5 |iM ionomycin, 100 nM PDBu or vehicle and the
resulting [3H]InsPs separated from neutralised TCA extracts using Dowex
AG 1-X8 resin (see figure 3.3.1). Although not statistically significant,
there was a trend for KC1 to inhibit both basal and CCh-stimulated
[3H]InsP accumulation (17 % and 23 % respectively). This is in agreement
with further KC1 experiments carried out in collaboration with E.R.
Chilvers, R.A.J. Challiss and G.J. Offer (see Chilvers et al., 1994b).
Moreover, these authors report that application of 80 mM KC1 results in a
decrease in both basal and CCh-stimulated Ins(l,4,5)P3 mass after a five
second incubation (the time at which Ins(l,4,5)P3 mass is maximal).
Biden et al. (1993) demonstrated that CCh-stimulated InslP accumulation
is directly proportional to the calculated membrane potential in rat
pancreatic islets, an effect which is not mediated by voltage-gated Ca2+
channels. A similar regulation of phosphoinositide hydrolysis by
membrane-potential in BTSM could account for the decrease in [3H]InsP
accumulation observed in the presence of a high K+ concentration.
Alternatively this effect may result from a Ca2+-mediated inhibition of
Ptdlns synthesis as described in rabbit vas deferens (Egawa, et al., 1981)
and insect salivary glands (Berridge and Fain, 1979). In most mammalian
systems however, Ptdlns synthesis is enhanced by hormonal stimulation.
The concentration of K+ ions in these experiments was chosen specifically
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BTSM, associated with both membrane depolarisation and an elevation
in [Ca2+]j secondary to Ca2+ influx - an effect that can be greatly inhibited
by the Ca2+ channel antagonist nimodipine (Takuwa et al., 1987). No
reduction in the concentration of Na+ ions was performed in the
experiments involving high K+ concentrations since in guinea-pig
visceral smooth muscle cell types this manoeuvre alone can induce
[3H]InsP formation (Best and Bolton, 1986; Sasaguri and Watson, 1988),
possibly via stimulation of a Na+/Ca2+ exchange mechanism. However
Chilvers et al. (1994b) describe control experiments in which addition of
80 mM NaCl fails to reduce Ins(l,4,5)P3 mass (as observed with 80 mM
KC1 addition), indicating that the results observed in their experiments
are not simply due to an osmotic effect of the high KC1 solutions.
By contrast, incubation of [3H]inositol pre-labelled BTSM slices for 30 min
with 5 pM ionomycin (see figure 3.3.1) did result in a significant
accumulation of [3PI]InsPs (27 ± 2 % of that seen with 100 pM CCh). It
would seem therefore that depolarisation of the plasma membrane with
80 mM KC1, which results in an influx of extracellular Ca2+ is unable to
stimulate PIC activity in this tissue, but that increasing [Ca2+]j with 5 pM
ionomycin does enhance the activity of this enzyme. Application of a
calcium ionophore would be expected to result in a much greater increase
in [Ca2+]j than would be achieved by K+ depolarisation since it facilitates
free flow of Ca2+ across the plasma membrane (and also possibly
intracellular membranes), unlike a high KC1 concentration which is
likely to produce a more physiological increase in Ca2+ via the opening
of voltage-operated Ca2+ channels. In order to restrict the rise in [Ca2+]j
with ionomycin to physiologically relevant levels, further incubations
were performed in which 2 mM or 4 mM EGTA was added to the system
(resulting in the reduction of [Ca2+]frcc in the medium from 1.8 mM to 6
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jiM or 0.8 pM respectively1) 30 sec prior to ionomycin addition. Under
such conditions the ionomycin response was completely ablated. Hence
it is possible to augment [Ca2+]j artificially to levels that can sustain
agonist-independent hydrolysis of the [3H]phosphoinositides, but this can
only be achieved at unphysiologically high [Ca2+]j since when [Ca2+]free is
reduced to 6 pM or 0.8 pM no significant accumulation of [3H]InsPs can be
detected.
The effect of the PKC-activating phorbol ester PDBu on [3H]InsP
accumulation was also monitored in order to ascertain whether or not a
PLD-mediated breakdown of the phosphoinositides secondary to PKC
activation occurs in this tissue. PDBu (100 nM) had no significant effect
on the basal accumulation of [3H]InsPs and failed to augment the
ionomycin effect. It is unlikely therefore that PKC-mediated PLD activity
could contribute significantly to the accumulation of [3H]InsPs in BTSM
since no detectable increase in [3H]InsP levels was observed after a 30 min
incubation in the presence of PDBu.
These data indicate that there is no significant contribution to [3H]InsP
accumulation in BTSM slices from either PLD-mediated phosphoinositde
hydrolysis, or breakdown of PtdIns(4,5)P2 or the lower phosphoinositides
by PIC secondary to physiologically relevant increases in [Ca2+]j.
hThc Ca2+lfrcc under identical conditions had been determined in the study by Chilvers et
al., (1994) using a Ca2+-sensitivc electrode according to the method of Wojcikiewicz et al.
(1990).
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3.4 MUSCARINIC CHOLINOCEPTOR-STIMULATED ACCUMULATION
OF [3H]INOSITOL POLYPHOSPHATE ISOMERS IN BOVINE TRACHEAL
SMOOTH MUSCLE
It is well established that lithium ions inhibit inositol monophosphatase
in an uncompetitive manner (see Nahorski et al., 1991), thus in the
presence of an ample concentration of its substrate (InsPi) lithium ions
potently inhibit this enzyme, and provide an effective block of InsPi
hydrolysis. BTSM exhibits a low level of basal inositol phospholipid
hydrolysis (see table 3.4.1), and therefore by introducing lithium ions into
the system 10 min prior to agonist/vehicle addition, a sufficiently high
concentration of InsPi can be attained to facilitate inhibition of the
inositol monophosphatase enzyme, thereby trapping any [3H]InsPs
formed within the cytosolic fraction of the cell. The effective trapping of
[3H]InsPs in the cytoplasm is demonstrated by their linear CCh-stimulated
accumulation in this system (figure 2.3.1.2a). The use of this protocol
should thus enable accurate quantification of the [3H]InsPPs formed in
these experiments. Since the 3-kinase and 5-phosphatase pathways yield
mutually exclusive products in this tissue (see section 3.2), and there
would appear to be no significant contribution to [3H]InsPP accumulation
from PIC action on the lower [3H]phosphoinositides or PLD-mediated
breakdown of the [3H]inositol phosphates (see section 3.3) it can be
concluded that an appropriate experimental system has been devised for
the study of the flux of [3H]Ins(l,4,5)P3 metabolism through the 3-kinase
and 5-phosphatase enzymes.
The only additional requirement of these studies is that agonist
stimulation of BTSM should result only in accumulation of [3H]InsPP
isomers that can be accounted for by the 3-kinase and 5-phosphatase
pathways. As detailed in section 3.4.1 below, this pre-requisite was also
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fulfilled except for the quantitatively very minor accumulations of
[3H]Ins(4/5)P2 and [3H]Ins(2,4,5)P3 (see table 3.4.1) which would have no
significant bearing on the calculations of flux of [3H]Ins(l,4,5)P3 through
the 3-kinase and 5-phosphatase pathways. The use of a short-term
[3H]inositol labelling strategy was a deliberate ploy to ensure that the
results were not complicated by the labelling of additional InsPPs.
3.4.1 Accumulation of [3H]inositol polyphosphates following 30 minute
carbachol stimulation of BTSM slices
[3H]Inositol pre-labelled BTSM slices were incubated with 100 pM CCh or
vehicle in the presence or absence of 5 mM LiCl for 30 min and the
resulting individual [3H]InsPP isomers separated and quantified using
H.P.L.C.. The results of these experiments are summarised in table 3.4.1.
An accumulation of [3H]InsPs was observed over the 30 min incubation,
even under basal conditions in the absence of lithium ions. When
lithium was added into the system a 3.3-fold increase in basal [3H]InsP
accumulation could be detected. CCh caused a dramatic (33-fold) increase
in [3H]InsP accumulation which was also markedly enhanced (6.7-fold) by
the inclusion of lithium ions. Several [3H]InsPP isomers were isolated
from the BTSM slices and were identified on the basis of co-elution with
commercial and generated standards, and by comparison with other
inositol polyphosphate H.P.L.C. separation studies (e.g. Batty et al., 1989;
Wong et al., 1992) as illustrated in the materials and methods section
(2.6.3).
Two dominant peaks of radioactivity were detected in the [3H]InsPi
fraction under all conditions specified which co-eluted exactly with
[3H]Insl/3P and [3H]Ins4P standards. [3H]InslP and [3H]Ins3P are
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employed here. [3H]Insl/3P represented the dominant [3H]InsPi isomer
present under basal conditions. The accumulation of both
monophosphates was enhanced following prolonged CCh stimulation
with [3H]Ins4P constituting the major [3H]InsPi under these conditions
(64 ± 3 % and 73 ± 1 % of the [3H]InsPi pool in the absence and presence of
lithium respectively). In addition, a further very minor [3H]InsPi peak
could be detected in some of the basal samples which has been tentatively
identified as [3H]Ins2P since it co-eluted with a generated standard for this
compound (see section 2.6.3), however it is also possible that it represents
[3H]Ins5P, low concentrations of which have been detected in brain
(Ackermann et al., 1987). The accumulation of this isomer was negligible
(if detectable at all) under all conditions assayed.
Four peaks of radioactivity were detected in the [3H]InsP2 fraction, two co-
eluting with standard or generated [3H]Ins(l,4)P2 and [3H]Ins(4,5)P2 (see
section 2.6.3), the other two being identified as [3H]Ins(l,3)P2 and
[3H]Ins(3,4)P2 by comparison with a similar study by Batty et al. (1989) in
rat cerebral cortex slices. [3H]Ins(l,4)P2 was the major bisphosphate in all
samples assayed.
Three [3H]InsP3 peaks were observed - two of which co-eluted with
standard and generated [3H]Ins(l,4,5)P3 and [3H]Ins(2,4,5)P3 (see section
2.6.3), the third identified as [3H]Ins(l,3,4)P3 since it is the only known
trisphosphate isomer to elute prior to Ins(l,4,5)P3 (Batty et al., 1989; Wong
et al., 1992). [3H]Ins(l,4,5)P3 was the major [3H]InsP3 present in basal
samples whereas [3H]Ins(l,3,4)P3 was by far the main constituent under
CCh-stimulated conditions. Accumulation of [3H]Ins(2,4,5)P3 was
negligible under all conditions assayed. This isomer may represent an
acid-hydrolysis product of trace amounts of [3H]Ins(l:2c,4,5)P3, which has
been reported to accumulate in a variety of tissues including thrombin-
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stimulated platelets (Ishii et al., 1986) and vasopressin-stimulated WRK1
rat mammary tumour cells (Wong et al., 1988).
Although the H.P.L.C. gradient used in these studies does not allow good
separation of [3H]InsP4 isomers, it is probable from previous data on CCh-
stimulated increases in Ins(l,3,4,5)P4 in this model (Chilvers et al., 1991b)
that the agonist-stimulated increase in [3H]InsP4 accumulation represents
an increase in the [3H]Ins(l,3,4,5)P4 isomer. In addition no late-running
[3H]InsP4 peak or shoulder to the [3H]InsP4 peak was observed suggesting
that there is no significant accumulation of [3H]Ins(l,3,4,6)P4 under the
described conditions.
The presence of 5 mM LiCl in the control incubations resulted in a minor
increase in the accumulation of both [3H]Insl/3P and [3H]Ins4P. Under
CCh-stimulated conditions the presence of lithium resulted in a 9-fold
and 13-fold increase in [3H]Insl/3P and [3H]Ins4P accumulation
respectively, and a 2.6-fold increase in [3H]Ins(l,4)P2- Lithium had a more
minor effect on [3H]Ins(l,3)P2, [3H]Ins(3,4)P2 and [3H]Ins(l,3,4)P3
accumulation. These results are in keeping with the known effects of
lithium as a potent uncompetitive inhibitor of the inositol
monophosphatase responsible for converting each of the inositol
monophosphate isoforms into free inositol, and a weaker inhibitor of the
inositol polyphosphate 1-phosphatase which converts Ins(l,4)P2 and
Ins(l,3,4)P3 into Ins4P and Ins(3,4)P2 respectively. Lithium ions therefore
result in a marked accumulation of the immediate substrates of these
enzymes, and a lesser accumulation of their upstream precursors. In
addition, lithium resulted in a 10-fold increase in [3H]Ins(4,5)P2 in CCh-
stimulated BTSM slices, suggesting the presence of at least one further
lithium-sensitive metabolising enzyme. The lithium-sensitive, agonist-
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stimulated accumulation of this novel bisphosphate isomer is discussed
in further detail in chapter six.
It is possible therefore to calculate the relative proportions of
[3H]Ins(l/4/5)P3 that had been metabolised by the 3-kinase and 5-
phosphatase pathways in these experiments by totalling the radioactivity
associated with each of the respective pathway metabolites (i.e. the 5-
phosphatase pathway metabolites are quantified by totalling the
radioactivity in the [3H]Ins(l/4)P2 and [3H]Ins4P fractions, whereas the 3-
kinase pathway is represented by the total radioactivity associated with
[3H]Ins(l,3,4,5)P4, [3H]Ins(l,3,4)P3/ [3H]Ins(l,3)P2, [3H]Ins(3,4)P2/ and
[3H]Insl/3P). The only [3H]inositol polyphosphate isomers excluded from
these calculations were [3H]Ins2P, [3H]Ins(2,4,5)P3 and [3H]Ins(4,5)P2, as the
source of these isomers is uncertain, and their accumulation following
CCh stimulation was very minor (accumulation of the two former
isomers was negligible under all conditions assayed, while [3H]Ins(4,5)P2
represented only 1 % of the total inositol polyphosphate pool after 30 min
in the presence of Li+). Using this approach, the relative contributions of
these two enzyme pathways to [3H]Ins(l,4,5)P3 metabolism has been
assessed for each of the experimental incubations described above.
When lithium ions were included in the system the contribution to
[3H]Ins(l,4,5)P3 metabolism by the 5-phosphatase pathway increased from
38 % to 50 % in basal samples, and from 68 % to 75 % in 30 min CCh-
stimulated samples. The inclusion of lithium ions probably gives a more
accurate portrayal of the activity of these two enzyme pathways since the
hydrolysis of [3H]InsPi isomers to [3H]Ins, and therefore their omission
from the calculations, would be negligible under these conditions. In the
presence of lithium ions, [3H]Ins(l,4,5)P3 formed under basal,
unstimulated conditions would appear to be metabolised in equal
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proportions by the 3-kinase and 5-phosphatase over the 30 min
incubation period. Because of the small accumulation of [3H]InsPP
isomers under basal conditions however, the calculation is much less
certain. In the presence of a maximally effective concentration of CCh
(100 pM) the 5-phosphatase enzyme clearly dominates, accounting for 75
% of the total [3H]Ins(l,4,5)P3metabolism.
In other tissues it has been shown that Insl/3P and Ins4P share a
common enzyme for their degradation to free inositol and that this
enzyme has a similar affinity (Km = 0.1-0.2 mM) for Insl/3P and Ins4P
(Gee et al., 1988; Hallcher and Sherman, 1980). If a similar
monophosphatase is responsible for the degradation of these isomers in
BTSM then steady-state [3H]InsPP accumulation should still reflect the
metabolism of [3H]Ins(l,4,5)P3 through the 3-kinase and 5-phosphatase
pathways in the absence of lithium.
3.4.2 Accumulation of [3H]inositol polyphosphates over a 30 minute
time-course of carbachol stimulation
The accumulation of [3H]InsPP isomers in [3H]inositol pre-labelled BTSM
slices in response to CCh stimulation in the presence of 5 mM LiCl was
assessed over a 30 min time-course. Table 3.4.2 summarises the results
obtained from these experiments, and the accumulation of [3H]InsPPs
over the first 5 min following agonist stimulation is illustrated in figure
3.4.2.1. Agonist stimulation resulted in a rapid (< 5 sec) rise in the
accumulation of [3H]Ins(l,4,5)P3 (figure 3.4.2.lc), consistent with it being
the primary product of muscarinic receptor-stimulated [3H]PtdIns(4,5)P2
hydrolysis. In the continued presence of agonist the accumulation of this
isomer returned to basal levels within 1 min with only a minor increase







































































































































Figure 3.4.2.1 Pattern of pHlinostiol polyphosphate accumulation over five minutes
following carbachol-stimulation of bovine tracheal smooth muscle slices
[3H]Inositol pre-labelled BTSM slices (2.3.1) were incubated with 100 pM CCh in the
presence of 5 mM LiCl in a final volume of 300 pi. Reactions were terminated at the
times indicated by addition of 300 pi 1 M TCA. Individual [3H]InsPPs were separated
from poled triplicate neutralised extracts (2.4.2) by H.P.L.C. (2.6.3) and the radioactivity
associated with each isomer quantified by liquid scitntillation counting. Results represent
the mean + SEM of three separate experiments.
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possible that this delayed and quantitatively very minor increase in the
'[3H]Ins(l,4,5)P3 peak' was due to the accumulation of non-resolving
[3H]InsP3 isomers such as [3H]Ins(l,4,6)P3 which has previously been
identified in avian erythrocytes (Stephens and Downes, 1990; Stephens et
al., 1989) and its enantiomer [3H]Ins(3,4,6)P3 identified in the slime mould
Dictyostelium discoideum (Stephens and Irvine, 1990). Indeed Wong et
al. (1992) identified an additional minor component in their 'Ins(l,4,5)P3
peak' which increased following stimulation with vasopressin. They
provide evidence to indicate that this compound was Ins(l,4,6)P3.
A rapid elevation in the levels of [3H]Ins(l,4)P2, the product of Ins(l,4,5)P3
5-phosphatase, was seen upon CCh stimulation (see figure 3.4.2.1a),
which plateaued after 1 min (the time at which [3H]Ins(l,4,5)P3
radioactivity had returned to basal values). [3H]Ins(l,4)P2 was the major
[3H]inositol bisphosphate present in all samples assayed. The other 5-
phosphatase pathway metabolite [3H]Ins4P showed a linear accumulation
in response to CCh, and was the dominant [3H]InsPi isomer at all time-
points measured.
[3H]Inositol tetrakisphosphate accumulated only to a minor degree over
the agonist stimulation period (figure 3.4.2.1 d), and in agreement with
Chilvers et al. (1990a) only increased to significant levels after 5 min. It
would seem that at early time-points any [3H]Ins(l,3,4,5)P4 formed is
rapidly dephosphorylated to [3H]Ins(l,3,4)P3 since large increases in this
isomer can be detected within 30 sec following agonist addition (figure
3.4.2.1c). The rate of increase in this [3H]inositol trisphosphate slows after
1 min. In agreement with Chilvers et al. (1990a), [3H]Ins(l,3,4)P3 was the
major trisphosphate isomer in BTSM slices stimulated for 30 sec or more
with 100 (iM CCh, accounting for > 80 % of the trisphosphate fraction
after 1 min of stimulation with this agonist. The other major 3-kinase
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pathway metabolites ([3H]Ins(l,3)P2, [3H]Ins(3,4)P2 and [3H]Insl/3P)
exhibited a delayed accumulation in response to CCh, only increasing to
significant levels after 1 and 5 min for the bisphosphates and
monophosphates respectively (figures 3.4.2.1a and b).
[3H]Ins(2/4,5)P3 and [3H]Ins2P levels were negligible under all conditions
assayed and hence are not illustrated in figure 3.4.2.1. Interestingly,
[3H]Ins(4,5)P2 showed a very delayed accumulation in response to CCh
stimulation (figure 3.4.2.Id) suggesting an indirect formation of this
bisphosphate isomer. Further studies designed to address the possible
routes of formation and metabolism of this isomer are detailed in chapter
six.
The flux of the inositol headgroup through the Ins(l,4,5)P3 3-kinase and
5-phosphatase regulated pathways following CCh stimulation was
determined in an identical fashion to that described in section 3.4.1 and is
shown in table 3.4.2. Although the initial contribution from the two
pathways (at 0 sec) appears to vary slightly from that documented for
basal conditions over 30 min (see section 3.4.1), the difference between
these values is not statistically significant. The 5-phosphatase was the
dominant Ins(l,4,5)P3 metabolising pathway at all time-points following
CCh stimulation, however it would seem that the 3-kinase becomes
increasingly important after 1-5 min. A detailed picture of the flux of the
inositol headgroup through these two enzymes was obtained when the 3-
kinase and 5-phosphatase metabolites were quantified over time-
intervals (as opposed to the cumulative response). The result of this
analysis is summarised in figure 3.4.2.2. The 5-phosphatase pathway was
the dominant route for [3H]Ins(l,4,5)P3 metabolism at all time-intervals
measured, accounting for over 85 % of its metabolism over the first 5 sec
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Figure 3.4.2.2 Flux of [3H]inositol 1,4,5-trisphosphate through the 3-kinase
and 5-phosphatase pathways following carbachol-stimulation
[3H]Inositol pre-labelled BTSM slices (2.3.1) were incubated with 100 pM
CCh in the presence of 5 mM LiCl in a final volume of 300 pi. Reactions
were terminated after 0 sec, 5 sec, 30 sec, 1 min, 5 min and 30 min by the
addition of 300 pi 1M TCA and the individual [3H]InsPP isomers present
in pooled triplicate neutralised extracts (2.4.2) separated and quantified by
H.P.L.C. (2.6.3). The individual [3H]InsPPs accumulating over the time-
intervals shown were calculated, and the radioactivity associated with the
[3H]Ins(l,4,5)P3 3-kinase and 5-phosphatase metabolites over these time-
intervals determined. Data represents the mean ± SEM of three separate
experiments.
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response however, the contribution from the 3-kinase pathway became
increasingly important.
3.5 DISCUSSION
The experiments described in this chapter were designed to characterise,
in detail, the accumulation of [3H]inositol polyphosphates following
agonist stimulation of BTSM and to assess the routes of metabolism of
Ins(l,4,5)P3. While the dominant route of metabolism, both at early and
late time-points after agonist addition, appears to be via the 5-
phosphatase pathway, the 3-kinase pathway plays an increasing role at
later time-points following agonist addition. A second bifurcation point
in inositol polyphosphate metabolism is seen with the breakdown of
Ins(l,3,4)P3 since this compound can be converted either to Ins(l,3)P2 or
to Ins(3,4)P2- Following prolonged CCh stimulation (30 min), a greater
accumulation of [3H]Ins(l,3)P2 over [3H]Ins(3,4)P2 was detected (see table
3.4.1) both in the absence and presence of lithium (2.5- and 4-fold
respectively). This is in agreement with Batty et al. (1989) who detected
an accumulation of [3H]Ins(l,3)P2 to levels three times that of
[3H]Ins(3,4)P2 following CCh stimulation (30 min) of rat cerebral cortex
slices and with Wreggett and Irvine (1993) who found Ins(l,3)P2 to be the
predominant Ins(l,3,4)P3 metabolite in thrombin- and histamine-
stimulated human umbilical vein endothelial cells. The latter two
studies were carried out in the presence of lithium ions which inhibit the
Ins(l,4)P2/Ins(l,3,4)P3 1-phosphatase and would therefore favour
metabolism of Ins(l,3,4)P3 via the 4-phosphalase. It is also possible that
the greater proportion of [3H]Ins(l,3)P2 produced following CCh
stimulation in the absence of lithium ions in the present study results
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from [3H]Ins(l/3/4)P3 competing with the much larger concentration of
[3H]Ins(l/4)P2 for the Ins(l,3,4)P3/Ins(l,4)P2 1-phosphatase (Inhorn and
Majerus, 1987, 1988). Indeed, under basal conditions, when the 3-kinase
pathway contributes substantially to Ins(l,4,5)P3 metabolism,
proportionally more [3H]Ins(3,4)P2 is produced compared to [3H]Ins(l,3)P2
(see table 3.4.1).
Despite its continued formation [3H]Ins(l,4,5)P3 accumulates only
transiently following CCh stimulation (Chilvers et al., 1991a). The
underlying reason for this apparent tight metabolic control of Ins(l,4,5)P3
accumulation in BTSM remains uncertain, and contrasts to the situation
pertaining in a number of other tissues including rat cerebral cortex slices
where Ins(l,4,5)P3 mass remains elevated for a prolonged period
following agonist stimulation (Challiss et al., 1988). It is possible that
some of the more recently described functions of Ins(l,4,5)P3, such as its
effect on tyrosine phosphatase activity (Stader and Hofer, 1992) underlie a
need for differential regulation of Ins(l,4,5)P3 metabolism between
tissues. Hence it may be more important to rapidly curtail the Ins(l,4,5)P3
response in BTSM, a process which would require stringent regulation of
the enzymes responsible for the metabolism of this second messenger.
The demonstration that the 5-phosphatase and 3-kinase pathways yield
mutually exclusive products was verified in part by examining
[3H]Ins(l,4,5)P3 and [3H]Ins(l,3,4,5)P4 metabolism in BTSM homogenates.
Given evidence suggesting little, if any, hydrolysis of the Ptdlns and
PtdIns4P, or PLD-stimulated phosphoinositide hydrolysis in the
production of InsPs in this tissue, it would seem that the individual
InsPP isomers detected in these experiments are derived predominantly
from the sequential dephosphorylation of Ins(l,4,5)P3 and its primary
metabolite Ins(l,3,4,5)P4. The short-term labelling protocol employed in
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these studies has been extensively validated and provides steady-state
phosphoinositide labelling and prevents agonist-stimulated changes in
the specific radioactivity of [3H]PtdIns(4,5)P2 (Chilvers et al., 1989a). This
approach results in very little, if any, labelling of higher inositol
phosphates (i.e. Ins(l,3,4,5,6)P5 and InsP6) and hence avoids many of the
problems inherent in attempting to follow Ins(l,4,5)P3 metabolism in
tissues labelled to isotopic equilibrium over many days. This BTSM
model therefore provides a good preparation for the study of Ins(l,4,5)P3
metabolism, facilitating the analysis of the relative contributions of the 3-
kinase and 5-phosphatase pathways.
Although the 3-kinase enzyme contributes significantly to Ins(l,4,5)P3
breakdown under the conditions specified, the 5-phosphatase pathway
appears to dominate especially at early time-points after agonist
stimulation when the accumulation of Ins(l,4,5)P3 is still elevated over
control values. Of interest was the finding that the 3-kinase pathway
becomes an increasingly important route for Ins(l,4,5)P3 metabolism at
later time-points following agonist stimulation. This could relate to a
Ca2+/calmodulin-mediated activation of this enzyme as suggested in
insulin secreting RINm5F cells (Biden and Wollheim, 1986) and later
substantiated in a variety of tissues including rabbit tracheal smooth
muscle (Rosenberg et al., 1991), pig aortic smooth muscle (Yamaguchi et
al., 1987), rat aortic smooth muscle (Rossier et al., 1987) and rat heart
(Renard and Poggioli, 1987). Increases in the concentration of this ion
following CCh stimulation occur as a result of both its release from
intracellular stores and an increase in Ca2+ influx (Takuwa et al., 1987). In
most cases studied the 5-phosphatase is unaffected by physiological
increases in [Ca2+]j (e.g. Biden et al., 1986), however notable exceptions are
the 5-phosphatases present in porcine coronary artery smooth muscle,
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which is enhanced by 0.1-1 (iM free Ca2+ concentrations (Sasaguri et al.,
1985), and that found in bovine iris sphincter smooth muscle which is
inhibited by [Ca2+]frcc concentrations greater than 1 pM (Wang et al.,
1994).
There are also reports that PKC may regulate the 3-kinase and 5-
phosphatase enzymes: PKC-mediated phosphorylation results in a 3-fold
stimulation of the Type la 5-phosphatase enzyme from human platelets
(Connolly et al., 1986). This effect is substantiated by data in thrombin-
stimulated platelets where inhibition of PKC with staurosporine results
in a decrease in 5-phosphatase activity (King and Rittenhouse, 1989). To
date however, PKC-regulation of 5-phosphatase activity has not been
described in any other cell type, although indirect evidence for such
regulation was obtained in C62B glioma cells in which pre-treatment
with the PKC-inhibitor sphingosine resulted in an enhanced ACh-
stimulated I11SP3 accumulation, accompanied by a concurrent decrease in
InsP2 accumulation (Brooks et al., 1987). By contrast, the conversion of
Ins(l,4,5)P3 to Ins(l,4)P2 in RINm5F cells decreased slightly in the
presence of the PKC activating phorbol ester phorbol myristate acetate
(PMA) (Biden et al, 1988b).
The activity of the Ins(l,4,5)P3 3-kinases from rat brain (Sim et al., 1990)
and human platelets (Lin et al., 1990) are inhibited by PKC-dependent
serine phosphorylation, an effect mediated by a dramatic reduction in the
Vmax of the enzyme (Sim et al., 1990). In contrast with this data Imboden
and Pattison (1987) reported a PKC-mediated activation of the 3-kinase
from a clonal T cell line and Biden et al., (1988a and b) noted a slight
enhancement of 3-kinase activity in the presence of PMA in both insulin-
secreting RINm5F cells and rat hepatocytes. Furthermore the Vmax of the
3-kinase in saponin-permeabilised platelets was increased 1.8-fold in the
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presence of PDBu (King and Rittenhouse, 1989). The 3-kinases cloned
from rat brain (Takazawa et al., 1990b) and human hippocampus
(Takazawa et al., 1991a) contain putative PKC-dependent serine and
threonine phosphorylation sites.
The Km values of the Ins(l,4,5)P3 5-phosphatase and 3-kinase enzymes
have been calculated in rabbit ASM as 95 pM and 5 pM respectively
(Rosenberg et al., 1991). Indeed, in all tissues studied so far the 3-kinase
has a greater affinity for Ins(l,4,5)P3 than the 5-phosphatase. It would
therefore be anticipated that at low concentrations of Ins(l,4,5)P3 this
second messenger would be metabolised preferentially by the 3-kinase
enzyme. It is important to note however that Ins(l,4,5)P3 may be
compartmentalised within the cell (Horstman et al., 1988; Challiss et al.,
1990) or produced preferentially at a specific cellular locus, and therefore
may be present locally in concentrations above that expected from our
data. This consideration may be of particular relevance in BTSM where
mass measurements suggest a relatively high resting Ins(l,4,5)P3
concentration of 3-4 pM (Challiss et al., 1990), as compared with the
'normal' range of 0.1-0.2 pM (see Shears, 1991).
Studies now performed in a variety of other tissues suggest that the flux
of Ins(l,4,5)P3 via the 3-kinase and 5-phosphatase pathways may vary
considerably, not only with regard to the differential routing during the
lifetime of the agonist-stimulated response but also with respect to the
tissue, agonist and species under study: Batty and colleagues (1992) have
shown in rat cerebral cortex stimulated with a maximally effective
concentration of CCh that Ins(l,4,5)P3 is metabolised by the 3-kinase and
5-phosphatase enzymes in roughly equal proportions; Wreggett and
Irvine (1993) have demonstrated that the 3-kinase pathway is more active
in human umbilical vein endothelial cells stimulated with histamine
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than with thrombin at concentrations which give a comparable level of
total InsPs; Pirotton et al. (1991) have shown that ATP stimulation of
vascular endothelial cells results in a rapid and transient routing of
Ins(l,4,5)P3 metabolism almost exclusively through the 5-phosphatase
pathway at early time-points of stimulation followed by a small, but
sustained increase in 3-kinase routing. In light of these studies it is very
possible that the metabolic fate of Ins(l,4,5)P3 accumulation in response to
other PIC-coupled agonists, or even sub-maximal concentrations of CCh,
may differ to that described in this study. Such possibilities are examined
in chapter five.
It is now clear that at least three different isoforms of both the Ins(l,4,5)P3
5-phosphatase and 3-kinase exist, with the possibility of further active
forms of the latter enzyme being produced by limited proteolysis (see
section 1.5.1). If these 3-kinase and 5-phosphatase isoforms vary in their
kinetics of Ins(l,4,5)P3 metabolism their differential distribution or
activation may account for the variations in Ins(l,4,5)P3 accumulation
seen in many tissues. Indeed the Type lb (Hodgkin et al., 1994; Mitchell et
al., 1989) and Type II (Erneux et al., 1989; Hansbro et al., 1994; Hansen et
al., 1991) 5-phosphatases generally exhibit a lower affinity for Ins(l,4,5)P3
than their Type la counterparts. In addition, a differential ability of PKC
to phosphorylate these 5-phosphatase isoforms has been detected in
platelets where PKC phosphorylates the Type la (Conolly et al., 1986) but
not the Type lb (Mitchell et al., 1989) enzyme. Consistent with these
observations, several putative PKC phosphorylation sites have been
identified on the Type la receptors cloned from dog thyroid (Verjans et
al., 1994) and human placenta (Laxminarayan et al., 1994) but not on the
type lb enzymes cloned from human erythroleukaemic and
megakaryocytic cells (Ross et al., 1991).
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PIC-linked receptor agonists may also activate a host of different
signalling pathways secondary to Ptdlns(4/5)P2 hydrolysis which may
interact with the phosphoinositide cycle, regulating both the formation
and metabolism of Ins(l,4,5)P3. For example, PKA (stimulated following
activation of adenylyl cyclase and formation of cAMP) may be an
important regulator of 3-kinase activity since cloning of the rat brain 3-
kinase has revealed a consensus sequence for PKA phosphorylation on
serine (Takazawa et al., 1990b), and reconstitution experiments conducted
by Sim et al. (1990) demonstrate a near doubling of the Vmax following
cAMP-dependent serine phosphorylation of this enzyme.
Further studies aimed at identification and characterisation of the
possible modes of regulation of the 3-kinase and 5-phosphatase enzymes
which could thereby dictate the flux of Ins(l,4,5)P3 through these two
metabolic pathways are detailed in chapters four and five.
The regulation of Ins(l,4,5)P3 metabolism is clearly an important control
point with respect to Ins(l,4,5)P3-mediated Ca2+ release, but may also play
a crucial role in cell functioning by determining the cytosolic
concentrations of other inositol polyphosphates, in particular
Ins(l,3,4,5)P4. The 5-phosphatase pathway is generally thought of as being
merely an inactivating pathway with Ins(l,4)P2 having no Ca2 +
mobilising activity. The 3-kinase pathway on the other hand may,
through the generation of Ins(l,3,4,5)P4 and a host of other InsPPs with




CHARACTERISATION OF THE INOSITOL 1,4,5-
TRISPHOSPHATE 3-KINASE AND 5-PHOSPHATASE
ENZYMES
4.1 INTRODUCTION
As detailed in chapter three, Ins(l,4,5)P3 is metabolised via two major
enzyme pathways, a 5-phosphatase route to Ins(l,4,)P2 and a 3-kinase
route to Ins(l,3,4,5)P4. The activity of these two enzymes therefore plays a
critical role in determining the levels and patterns of Ins(l,4,5)P3
accumulation following receptor stimulation. While the Ins(l,4,5)P3 3-
kinase and 5-phosphatase enzymes have been studied in a variety of
tissues, very little data exists regarding the activity of these enzymes in
ASM. Large variations in the Km and Vmax values of these enzymes have
been observed in different tissue types (see Shears, 1991) which, although
in part may reflect the differing assay conditions employed in these
studies, more likely reflects a differential regulation of these enzymes (e.g.
by Ca2+, PKC or PKA) or the presence of more than one isozyme.
Characterisation of the Ins(l,4,5)P3 3-kinase and 5-phosphatase in BTSM
is therefore an essential component in our understanding of the factors
influencing of Ins(l,4,5)P3 metabolism.
Only two previous studies have examined the kinetics of these
Ins(l,4,5)P3 metabolising enzymes in ASM. Chilvers (1991) determined
Ins(l,4,5)P3 3-kinase Km (1.9 pM) and Vmax (385 pmol min-1 mg protein'1)
values in soluble BTSM extracts. These values differ slightly from those
obtained in soluble extracts of rabbit tracheal smooth muscle (Rosenberg
et al., 1991) where apparent Km and Vmax values of 5 pM and 137.8 pmol
min-1 mg protein-1 respectively were calculated. In common with most
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other determinations of 3-kinase activity, both of these studies were
performed in the absence of calpain inhibitors. This consideration is
likely to be of importance since Lee and co-workers (1990) have now
shown that the rat brain Ins(l,4,5)P3 3-kinase may, in common with a
number of other calmodulin-binding proteins, be a substrate for calpain, a
Ca2+-activated neutral cysteine-proteinase. The presence of six putative
calpain cleavage sites ('PEST' regions) in the amino acid sequence
predicted from a rat brain 3-kinase cDNA clone (Choi et ah, 1990) support
this observation. It is therefore highly likely that the 3-kinase may be a
substrate for calpain both in vivo and in vitro and that this proteinase
may regulate the activity of the 3-kinase during an agonist-stimulated
response. Of interest is the accumulating evidence to suggest that
excessive activation of calpain could play a key role in the pathology of a
variety of disorders (see Wang and Yuen, 1994).
Studies performed in the absence of calpain inhibitors have provided
strong evidence to support a role for Ca2+ ions in stimulating 3-kinase
activity. This effect is mediated by the close association of the 3-kinase
with calmodulin (Daniel et al., 1988; Johanson et ah, 1988; Kimura et ah,
1987; Takazawa et ah, 1989; Yamaguchi, et ah, 1987) and results in an
increase in the Vmax of the enzyme (Biden and Wollheim, 1986; Renard
and Poggioli, 1987; Rosenberg et ah, 1991; Takazawa et ah, 1989). To date
however, the effect of Ca2+ ions on a 3-kinase activity prepared in the
presence of calpain inhibitors has not been addressed.
The effect of Ca2+ ions on Ins(l,4,5)P3 5-phosphatase activity is far more
controversial. Most studies have indicated that this enzyme is unaffected
by physiological changes in the concentration of Ca2 f ions (e.g. Biden and
Wollheim, 1986; Kennedy et ah, 1990; Mitchell et ah, 1989; Shears et ah,
1987a and b). Other studies however, including those conducted on
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smooth muscle preparations, suggest that this enzyme may be either
inhibited (Wang et al., 1994, bovine iris smooth muscle) or stimulated
(Sasaguri et al., 1985, porcine coronary artery) by Ca2+ ions. In view of the
evidence indicating a major, early activation of the enzymes responsible
for Ins(l,4,5)P3 breakdown in agonist-stimulated BTSM, the potential for
Ca2+ to exert a direct effect on 3-kinase or 5-phosphatase is of considerable
interest. The characterisation of the 5-phosphatase and 3-kinase activities
is particularly important in BTSM since this tissue appears to have an
extremely high (1-4 pM) basal Ins(l,4,5)P3 mass concentration (Challiss et
al., 1990; Chilvers et al., 1989b) implying that a 3-kinase enzyme with a
typical affinity for Ins(l,4,5)P3 (Km = 0.2-2 pM) may be fully active even
under resting conditions.
It is apparent therefore that the enzyme kinetics of both the 3-kinase and
5-phosphatase warrant further study and experiments were undertaken
to characterise the two enzymes in BTSM and, in particular, to assess the
effect of Ca2+ ions on their activities.
4.2 CHARACTERISATION OF THE SOLUBLE INOSITOL 1,4,5-
TRISPHOSPHATE 3-KINASE ACTIVITY IN BOVINE TRACHEAL
SMOOTH MUSCLE
Previous studies on the Ins(l,4,5)P3 3-kinase from a variety of tissues e.g.
RINm5F cells (Biden and Wollheim, 1986), turkey erythrocytes (Morris et
al., 1987), rat brain (Johanson et al., 1988; Moon et al., 1989), guinea-pig
peritoneal macrophages (Kimura et al., 1987), Rat-1 fibroblast cells
(Johnson et al., 1989) and pig aortic smooth muscle (Yamaguchi et al.,
1988) indicate that this enzyme is predominantly cytosolic. The latter
study showed that 94 % of the total cellular 3-kinase activity could be
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located in the cytosolic fraction of the cell. BTSM cytosol was therefore
utilised as a source of 3-kinase activity in the following 3-kinase enzyme
studies. Calpain inhibitors were included throughout both the enzyme
preparation procedures and the enzyme activity assays.
4.2.1 Determination of the optimal conditions for the study of inositol
1,4,5-trisphosphate 3-kinase activity
Preliminary experiments were designed to establish conditions suitable
for defining the basic kinetic properties of the 3-kinase enzyme (i.e. a
linear rate of conversion of [3H]Ins(l,4,5)P3 to [3H]Ins(l,3,4,5)P4 with
minimal hydrolysis of substrate or product) and were conducted in the
absence of competing unlabelled Ins(l,4,5)P3. BTSM cytosol extracts (see
section 2.9.1) were incubated at various dilutions with [3H]Ins(l,4,5)P3 for
0-20 min in the presence of 1 pM Ca2+ under conditions which inhibit 5-
phosphatase activity (see section 2.9.2). The conversion of [3H]Ins(l/4/5)P3
was assessed by monitoring the production of [3H]InsP4, using AG 1-X8
Dowex columns to separate total [3H]InsP3 from [3H]InsP4. Of the various
dilutions of cytosol extract chosen (25, 100 and 250-fold dilutions), the 25-
fold dilution (final protein concentration = 0.329 ± 0.009 mg/ml) gave the
most appropriate results (see figure 4.2.1.). Under these conditions a
linear conversion of [3H]Ins(l,4,5)P3 was observed over 10 min. Since a
large proportion (54 %) of the [3H]Ins(l,4,5)P3 had been metabolised by 10
min a 5 min incubation period was chosen for all subsequent
experiments.
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Figure 4.2.1 Metabolism of [3H]Ins(l,4,5)P3 with bovine tracheal smooth
muscle cytosol extract
[3H]Ins(l/4/5)P3 (12,000 DPM) was incubated with a 25-fold dilution of
BTSM cytosol extract (2.9.1) at 37 °C in a final volume of 200 ju.1 (2.9.2).
Reactions were terminated at the times indicated with 200 |il 1 M TCA and
[3H]InsP fractions separated from neutralised TCA extracts (2.4.2) by Dowex
AG 1-X8 anion-exchange chromatography (2.6.2). The increase in
radioactive label associated with the [3H]InsP4 fraction was used as an
index of [3H]Ins(l,4,5)P3 metabolism by the Ins(l,4,5)P3 3-kinase and is
expressed as a percentage of the total retrieved radioactivity. Data is from a
single experiment.
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4.2.2 Effect of calcium ions on the cytosolic bovine tracheal smooth
muscle inositol 1,4,5-trisphosphate 3-kinase
In order to assess the effect of Ca2+ ions on the metabolism of Ins(l,4,5)P3
by the soluble BTSM 3-kinase, incubations were carried out as described
in section 4.2.1 in the presence of 'zero', 1 pM and 1 mM [Ca2+]free. All
cytosol extract preparations (diluted 25-fold) exhibited linear metabolism
of [3H]Ins(l,4,5)P3 over 5 min with the three [Ca2+]free concentrations
tested (see figure 4.2.2.1). Data obtained in the presence of 1 pM Ca2+ was
not greatly different from that obtained in the absence of Ca2+ (22.6 %
metabolism and 18.33 % metabolism after 5 min respectively), however
addition of 1 mM Ca2+ resulted in a stimulation of enzyme activity (43.09
% metabolism after 5 min). The isomeric composition of the
[3H]Ins(l,4,5)P3 metabolites formed during the reaction was determined
using H.P.L.C.; the results are shown in figure 4.2.2.2 and table 4.2.2.
Of some interest in these studies was the finding that even in the
presence of 5 mM 2,3-DPG, 10 mM ATP and 20 mM MgCl2 (all inhibitors
of the Ins(l,4,5)P3 5-phosphatase) a small proportion (~ 5-6 %) of the
[3H]Ins(l,4,5)P3 substrate was broken down to [3H]Ins(l,4)P2- Despite this,
negligible amounts of the [3H]InsP4 formed were metabolised
([3H]Ins(l,3,4)P3 and its downstream dephosphorylation metabolites
accounted for less than 2 % of the total retrieved radioactivity even in the
presence of 1 mM Ca2+ when [3H]InsP4 accumulation is maximal).
Accurate determinations of 3-kinase activity could still be calculated
therefore if the formation of [3H]InsP4 was used as a measure of enzyme
activity rather than removal of [3H]InsP3-
The data obtained in the previous two sections (4.2.1 and 4.2.2) indicate















Figure 4.2.2.1 Effect of calcium ions on inositol (1,4,5)P3 3-kinase activity
[3H]Ins(l,4,5)P3 (12,000 DPM) was incubated for the times indicated with a
25-fold dilution of BTSM cytosol extract (2.9.1) at 37 °C in the presence of
'zero', 1 |iM and 1 mM [Ca2+]free (2.9.2). Reactions were terminated with
1 M TCA after 5 min and the [3H]InsP fractions in neutralised extracts
(2.4.2) separated using Dowex AG 1-X8 anion-exchange chromatography
(2.6.2). The increase in radioactive label associated with the [3H]InsP4
fraction was used as an index of metabolism by the Ins(l,4,5)P3 3-kinase
and is expressed as a percentage of the total retrieved radioactivity. Data
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Ca2+ ions and in the presence of either 1 pM or 1 mM [Ca2+]free for up to 5
min. Under these conditions there is minimal breakdown of
[3H]Ins(l,3/4/5)P4. Hence a 5 min incubation with a 25-fold dilution of
cytosol extract provides appropriate conditions for the kinetic analysis of
the soluble BTSM Ins(l,4,5)P3 3-kinase.
4.2.3 Determination of kinetic parameters of soluble inositol 1,4,5-
trisphosphate 3-kinase
[3H]Ins(l,4,5)P3 was incubated at 37 °C with a 25-fold dilution of cytosol
extract in the presence of 0.1-5 pM competing unlabelled Ins(l,4,5)P3 for 5
min, in the presence of 'zero', 1 pM and 1 mM Ca2+. The initial reaction
velocity (Vo) was calculated for each substrate concentration ([S]) and is
illustrated on an Eadie-Hofstee (Vo vs Vo/[S]) plot in figure 4.2.3. A
computer-generated line of best fit was drawn through the data points for
each Ca2+ concentration to facilitate accurate calculation of the Km and
Vmax values of the enzyme (y axis intercept = Vmax; gradient = -Km) and
these parameters are listed in table 4.2.3. Although the data indicate a
trend towards an increase in the Vmax of the 3-kinase when the [Ca2+]free
is raised from 0 to 1 mM this effect is not statistically significant (two-
tailed, unpaired student's t-test). There was no statistically significant
difference in either the Km or Vmax values of the soluble BTSM 3-kinase
obtained in the absence of Ca2+ as compared to those obtained in the
presence of either 1 pM or 1 mM [Ca2+]frcc.
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Figure 4.2.3 Eadie-Hofstee analysis of BTSM Ins(l,4,5)P3 3-kinase activity
[3H]Ins(l,4/5)P3 (12,000 DPM) was incubated at 37 °C with a 25-fold
dilution of BTSM cytosol extract (2.9.1) in the presence of varying
concentrations (0.1-5 pM) of competing unlabelled Ins(l,4,5)P3 (2.9.2).
Reactions were terminated after 5 min with 200 pi 1 M TCA and [3H]InsP
fractions separated from neutralised extracts (2.4.2) using Dowex AG 1-X8
anion-exchamge chromatography (2.6.2). The increase in radioactive
label associated with [3H]InsP4 was used as an index of metabolism by the
Ins(l,4,5)P3 3-kinase and the reaction velocity calculated for each substrate
concentration. Results represent the mean ± SEM of three or four
separate experiments, each performed in duplicate, using three separate
BTSM cytosol extract preparations.
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[Ca2+]free Km (pM) Vmax
(pmol min"* mg protein"*)
0 2.49 ± 0.45 361.921 55.52
1 |iM 2.07 ± 0.24 322.831 41.53
1 mM 1.6010.04 488.531 16.89
Table 4.2.3 Effect of calcium ions on the Km and Vmax values of the
soluble bovine tracheal smooth muscle inositol 1,4,5-trisphosphate 3-
kinase activity
[3H]Ins(l/4/5)P3 (12,000 DPM) and unlabelled Ins(l,4,5)P3 (0.1-5 (iM) were
incubated with BTSM cytosol extract (2.9.1) (diluted 25-fold) at 37 °C for 5
min in a final volume of 200 (il (see section 2.9.2). Reactions were
terminated with 200 pi 1 M TCA and [3H]InsP fractions were separated
from neutralised TCA extracts (2.4.2) using Dowex AG 1-X8 anion-
exchange chromatography (2.6.2). The increase in radioactive label
associated with the [3H]InsP4 fraction was used as an index of
[3H]Ins(l/4,5)P3 3-kinase activity. Km and Vmax values were determined
using Eadie-Hofstee plots. Results represent the mean ± SEM for three or
four separate experiments, each performed in duplicate, using three
different BTSM cytosol extract preparations.
4.3 CHARACTERISATION OF THE SOLUBLE AND PARTICULATE
INOSITOL 1,4,5-TRISPHOSPHATE 5-PHOSPHATASE IN BOVINE
TRACHEAL SMOOTH MUSCLE
In the majority of tissues studied to date 5-phosphatase enzyme activity
has been found to be predominantly associated with particulate fractions
of cells, e.g. in bovine brain (Erneux et al., 1989), rat brain (Hansen et al.,
1987; Moon et al., 1989), rat liver (Joseph et al, 1985; Seyfred et al., 1984;
Shears et al., 1987a, 1988; Takimoto et al., 1989), turkey and human
erythrocytes (Morris et al., 1987; Shears et al., 1987b) and guinea-pig
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macrophages (Kukita et al., 1986). There are however, some notable
exceptions: the 5-phosphatases from human platelets (Connolly et al.,
1985), rabbit peritoneal neutrophils (Kennedy et al., 1990) and porcine
skeletal muscle (Hansbro et al., 1994) are all predominantly soluble while
the activity in porcine coronary artery (Sasaguri et al., 1985) and bovine
iris smooth muscle (Wang et al., 1994) appear to be fairly evenly
distributed between the soluble and particulate fractions of the cell.
Given this diversity of 5-phosphatase enzyme distribution, the BTSM
Ins(l,4,5)P3 5-phosphatase activity was studied in both a cytosolic and a
detergent-solubilised membrane fraction. Nonidet P40 was the detergent
chosen to solubilise the membrane-associated BTSM 5-phosphatase since
it has been utilised successfully in the solubilisation of 5-phosphatases
from bovine testes (Hodgkin et al., 1991) and rat liver microsomes
(Takimoto et al., 1989).
4.3.1 Determination of optimal conditions for the study of inositol 1,4,5-
trisphosphate 5-phosphatase activity
Preliminary experiments were conducted using both cytosolic and
solubilised membrane preparations in order to determine conditions in
which linear metabolism of Ins(l,4,5)P3 could be achieved. BTSM cell
extracts were incubated at various dilutions with [3H]Ins(l,4,5)P3 for 0-20
min in the absence of added ATP to prevent phosphorylation (see section
2.10.2) and the conversion of [3H]Ins(l,4,5)P3 to [3H]Ins(l,4)P2 was
monitored by measuring the increase in label into [3H]Ins and [3H]InsPi-2
(separated by Dowex AG 1-X8 anion-exchange chromatography). A 50-
fold dilution of the cytosol extract preparation (final protein
concentration = 0.167 ± 0.017 mg/ml) provided linear metabolism for
approximately 10 min, while a 75-fold dilution of the solubilised
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membrane extract (final protein concentration = 0.078 ± 0.004 mg/ml) was
required for linear metabolism over 5 min (figure 4.3.1). Since a 5 min
incubation of [3H]Ins(l,4,5)P3 with the membrane extract resulted in a
high percentage (63.85 ± 0.85 %) of substrate being metabolised, the
incubation period was reduced to 2 min for subsequent experiments.
4.3.2 Effect of calcium ions on the soluble and membrane-associated
inositol 1,4,5-trisphosphate 5-phosphatase activities
In order to address the effect of Ca2+ ions on the metabolism of
[3H]Ins(l,4,5)P3 by the soluble and membrane-associated BTSM 5-
phosphatases, incubations were carried out as described in section 4.3.1 in
the presence of varying [Ca2+]frcc (0-1 mM). The results are illustrated in
figure 4.3.2. It would appear that Ca2+ ions have very little effect over a
physiologically relevant range, however a statistically significant increase
in both the soluble and membrane-associated 5-phosphatase activity was
observed in the presence of 1 mM [Ca2+]frce.
4.3.3 Determinations of kinetic parameters of soluble and membrane-
associated inositol 1,4,5-trisphosphate 5-phosphatase
[3H]Ins(l,4,5)P3 was incubated at 37 °C with either BTSM cytosol or
membrane extract under conditions which exhibit linear substrate
metabolism (see section 4.3.1), in the presence of competing unlabelled
Ins(l,4,5)P3 and varying [Ca2+]frec ('zero', 1 pM and 1 mM). The results
are illustrated as Eadie-Hofstee plots (figure 4.3.3) and the calculated Km
and Vmax values for the soluble and particulate 5-phosphatase activities
are shown in table 4.3.3. The Km values determined for both the soluble
and particulate enzymes were very similar whereas the Vmax value was
much greater for the particulate enzyme. Increasing [Ca2+]frec from 'zero'
to 1 pM did not affect the KIT1 or Vmax values of either the soluble or
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(b) Solubilised membrane extract o Heat-inactivated
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Figure 4.3.1 [3H]Ins(l,4,5)P3 metabolism by BTSM 5-phosphatase
[3H]Ins(l/4/5)P3 (12,000 DPM) was incubated at 37 °C with a 50-fold or 75-
fold dilution of BTSM cytosol or membrane extract (2.10.1) respectively
(2.10.2). Reactions were terminated at the times indicated and the
[3H]InsP fractions in neutralised extracts (2.4.2) separated by Dowex
chromatography (2.6.2). Data represents the mean ± SEM of a single









































Figure 4.3.2 Effect of Ca2+ ions on the BTSM Ins(l,4,5)P3 5-phosphatase
[3H]Ins(l/4/5)P3 (12,000 DPM) was incubated at 37 °C with a 50- or 75-fold
dilution of BTSM cytosol or membrane extract (2.10.1) respectively
(2.10.2). Reactions were terminated after (a) 10 or (b) 2 min and [3H]InsP
fractions in neutralised TCA extracts (2.4.2) separated by Dowex
chromatography (2.6.2). Data represent the mean ± SEM of (a) three or (b)
two experiments, each performed in triplicate. Two or three separate
solubilised membrane or cytosol extracts were used respectively.
* * Denotes p < 0.01 for comparisons with data obtained in Ca2+-free
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Figure 4.3.3 Eadie-Hofstee analysis of BTSM 5-phosphatase activities
[3H]Ins(l,4,5)P3 (12,000 DPM) was incubated at 37 °C with 50- or 75-fold
dilutions of BTSM cytosol or membrane extract (2.10.1) respectively in the
presence of 1-40 pM competing unlabelled Ins(l,4,5)P3 (2.10.3). Reactions
were terminated after (a) 10 or (b) 2 min and [3H]lnsP fractions in TCA
extracts (2.4.2) separated by Dowex chromatography (2.6.2). Data
represents the mean ± SEM of three separate experiments, each
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particulate 5-phosphatase. However, Eadie-Hofstee analysis
demonstrated a statistically significant decrease in both the Km and Vmax
of the enzymes in the presence of 1 mM Ca2+. It is unclear if this reflects a
real regulation of 5-phosphatase activity by Ca2+ since the Eadie-Hofstee
plot deviates from a straight-line under these conditions (indicating non¬
standard Michaelis-Menten kinetics). These latter results may reflect a
degree of co-operativity exhibited by the 5-phosphatase in the presence of
1 mM Ca2 + or may simply be due to indirect effects of the
unphysiologically high Ca2+ concentration used.
4.4 DISCUSSION
The kinetic parameters of the Ins(l,4,5)P3 3-kinase an 5-phosphatase
enzymes have been determined in detail in cell free extracts of BTSM.
Ca2+ ions exerted very little effect on the 3-kinase and 5-phosphatase
activities over a physiologically relevant concentration range, although
both enzymes appeared to be stimulated in the presence of a much higher
(1 mM) Ca2+ concentration. The enzymes were subsequently
characterised further in order to obtain Km and Vmax values for
Ins(l,4,5)P3 metabolism at 'zero', 1 gM and 1 mM [Ca2 + ]free
concentrations.
The 3-kinase is generally understood to be a Ca2+-regulated enzyme with
increases in [Ca2+] causing an increase in the Vmax of the enzyme via its
interaction with calmodulin. Activation appears to occur across a narrow
range of Ca2+ concentrations (Biden et al., 1988a; Imboden and Pattison,
1987; Morris et al., 1987; Ryu et al., 1987), a property that is a common
feature of calmodulin-stimulated enzymes. However, maximum
stimulation of the 3-kinase by Ca2+ is generally only 2-3 fold, provided
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[Ca2+]frce is at least 1 |iM (Balla et al., 1988; Biden et al., 1988a; Biden and
Wollheim, 1986; Johanson et al., 1988; Kimura et al., 1987; Morris et al.,
1987; Renard and Poggioli, 1987) and hence the physiological significance
of Ca2+-mediated regulation may need to be questioned. The data
obtained from the experiments described in this chapter, performed in
the presence of calpain inhibitors, argue that the intact soluble BTSM 3-
kinase kinetic parameters are unaffected by increases in [Ca2+] over a
physiological range. An increase in Vmax (from 362 to 489 pmol min"1
mg protein*1) was observed in the presence of 1 mM [Ca2+]frcc but found
to be statistically insignificant. Experiments conducted in pig aortic
smooth muscle (Yamaguchi et al., 1987), guinea-pig peritoneal
macrophages (Kimura et al., 1987), human platelets (Daniel et al., 1988),
insulin-secreting RINm5F cells (Biden et al., 1987) and rat brain
(Johanson et al., 1988) indicate that the purified 3-kinase is only regulated
by Ca2+ ions in the presence of added exogenous calmodulin. The
experiments described here however, utilised a crude BTSM cytosol
extract as a source of 3-kinase activity; the enzyme would therefore be
expected to have access to endogenous BTSM calmodulin.
It is possible that calpain acts as a regulator of the 3-kinase in vivo by
selective proteolysis of the enzyme. Even when cell-extracts are prepared
in the presence of a battery of protease inhibitors many contain a number
of differently sized peptides which exhibit 3-kinase activity (Choi et al.,
1990; Lee et al., 1990; Lin et al., 1990; Takazawa et al., 1989, 1991a). Indeed
Lee et al., (1990) identified several calpain proteolysis products of the rat
brain 3-kinase which surprisingly retained catalytic activity; moreover,
the specific activity of the 40 KDa enzyme obtained in this study was
slightly higher than that of the parent 53 KDa enzyme. In summary
therefore, when prepared in the presence of calpain-inhibitors, BTSM
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cytosol extract contains a 3-kinase activity which does not appear to be
modulated by Ca2+. Clearly this does not preclude a regulation of the 3-
kinase by Ca2+ ions in vivo: calpain may be activated during the agonist-
stimulated response and may partially degrade the 3-kinase to form
smaller proteins which retain enzyme activity but have altered regulatory
properties; alternatively Ca2+ may stimulate other enzymes (e.g. PKC)
which could in turn regulate 3-kinase activity.
The Km calculated for the soluble BTSM 3-kinase was 2.49 ± 0.45 pM. This
figure is very comparable to that obtained in the same tissue by Chilvers
(1991). Km values determined for the 3-kinase from other sources are
shown in table 4.4.1. In the majority of tissues a Km value of between 0.2
and 2 pM was observed; the Km for the BTSM 3-kinase hence lies at the
top of this range and therefore this enzyme can be considered to have a
relatively low affinity for Ins(l,4/5)P3. In a few of the tissues studied
however, a higher range of Km values, between 5 and 11 pM, were
determined. It is possible that these variations could represent
alternative isozymes. The high resting concentration of Ins(l,4,5)P3 in
BTSM may explain the relatively low affinity of the BTSM 3-kinase for
Ins(l,4,5)P3, as this may be required in order to prevent its constitutive
activation.
It is not generally possible to compare Vmax values from different studies,
since this parameter is dependent on the specific activity of the enzyme
and therefore the purity of the enzyme preparation. The BTSM cytosol
extract utilised in the present study however, was prepared according to a
similar protocol used by Chilvers (1991), and hence the Vmax value
obtained by this author (385 pmol min-1 mg protein-1) can be readily
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The kinetic parameters of both the soluble and particle-associated BTSM
5-phosphatases were found to be unaffected by physiologically relevant
Ca2+ concentrations, however the Km and Vmax values were both
dramatically decreased in the presence of 1 mM [Ca2+]free. These results
are in accordance with data obtained in human platelets (Mitchell et al.,
1989), rabbit peritoneal neutrophils (Kennedy et al., 1990), human
placenta (Laxminarayan et al., 1993), and rat liver (Takimoto et al., 1989)
where no effect of Ca2+ was seen over a physiological Ca2+ range but
gradual inhibition was observed at higher Ca2+ concentrations. The
stimulation of the BTSM Ins(l,4,5)P3 5-phosphatase activity noted at 1
mM [Ca2+]frcc in the absence of added competing unlabelled Ins(l,4,5)P3
(see section 4.3.2) probably reflects the increased affinity of this enzyme for
Ins(l,4,5)P3 (i.e. the lowered Km), since an extremely low concentration of
substrate (-1-1.5 nM) is available to the enzyme under these conditions
and the Vmax is therefore highly unlikely to be attained.
The Km values obtained for Ins(l,4,5)P3 dephosphorylation by both the
soluble and particle-associated 5-phosphatase enzymes are very similar
suggesting that these two enzyme activities may represent the same
protein. These results are reminiscent of previous data in which the
kinetic and physical properties of the Type la soluble 5-phosphatase and
particulate 5-phosphatase activities were found to be remarkably similar
(Erneux et al., 1989; Takimoto et al., 1989). It is likely therefore that the
BTSM 5-phosphatase activities identified here in BTSM are of a Type la
classification (i.e. hydrolyse both Ins(l,4,5)P3 and Ins(l,3,4,5)P4). It is clear
that an enzyme exists in BTSM capable of converting Ins(l,3,4,5)P4 to
Ins(l,3,4)P3 (see chapter 3); whether this 5-phosphatase activity is the
same as that characterised in the present chapter remains to be
155
determined. It would be interesting to carry out further kinetic
experiments to characterise the Ins(l,3,4,5)P4 5-phosphatase.
The much higher Vmax value of the Ins(l,4,5)P3 5-phosphatase in BTSM
membrane extracts than in cytosol extracts is indicative of a concentration
of the enzyme in the particulate fraction. In agreement, the 5-
phosphatase has been found to be predominantly particulate in most
systems studied to date, and in liver has been localised to the cytoplasmic
face of the plasma membrane (Seyfred et al., 1984; Shears et al., 1987b,
1988; Joseph et al., 1985).
The Km values determined for the 5-phosphatase from various sources
are shown in table 4.4.2; the affinity of the enzyme for Ins(l,4,5)P3 is
highly variable with Km values ranging from 1 to 95 (iM. Although the
Km for Ins(l,4,5)P3 metabolism determined in BTSM (-12-20 (iM) is in
close agreement with those observed in rat liver membranes, human
erythrocyte membranes, human platelet cytosol, rabbit peritoneal
neutrophil cytosol and rat pancreatic islets, it is dramatically lower than
determined in rabbit tracheal smooth muscle and slightly lower than that
of the bovine iris smooth muscle 5-phosphatase. Where Ins(l,4,5)P3 and
Ins(l,3,4,5)P4 metabolism by the 5-phosphatase have been studied in the
same tissue, the affinity of the enzyme for Ins(l,3,4,5)P3 is always much
higher than for Ins(l,4,5)P3 (with the exception of soluble Type II
isozymes, classified as such because they do not readily metabolise
Ins(l,3,4,5)P4); the Vmax values however, are much higher for Ins(l,4,5)P3r
generally 10-15 fold higher, with the notable exception of the soluble type
I enzyme from porcine skeletal muscle which has a 28-fold greater Vmax



















































































































Table4.4.2Kineticparametersof5-ph sphataseactivi ifr variousourc (InsP3andI 4representIns(l,4,5)P3(l,3,4,5) 4s ectiv ly).
The Ins(l,4,5)P3 3-kinase and 5-phosphatase enzymes have been
characterised in BTSM cell free extracts. Although the affinity of the
BTSM 3-kinase for Ins(l/4/5)P3 is relatively low compared to the enzyme
from other tissues, it is still much greater than that of the BTSM 5-
phosphatase; the 3-kinase pathway therefore is likely to be the favoured
route of Ins(l,4,5)P3 metabolism at low concentrations of this second
messenger. The 5-phosphatase however, has a greater capacity to
metabolise Ins(l,4,5)P3 than the 3-kinase (as exemplified by their Vmax
values). These kinetic properties of the Ins(l,4,5)P3 metabolising enzymes
may explain, at least in part, the observed flux of Ins(l,4,5)P3 through the
3-kinase and 5-phosphatase pathways following agonist stimulation. At
early time-points of the agonist-stimulated response the elevated
Ins(l,4,5)P3 concentration would be expected to favour metabolism
through the 5-phosphatase pathway whereas after 30 sec, when the
Ins(l,4,5)P3 concentration has decreased, the 3-kinase enzyme with its
higher affinity for Ins(l,4,5)P3 could be activated. Surprisingly both
enzymes appear to be relatively unaffected by Ca2+ ions over a
physiologically relevant range, however it is possible that Ca2+ may have
an indirect effect on their activity in vivo by modulating the activity of




REGULATION OF INOSITOL POLYPHOSPHATE
METABOLISM IN BOVINE TRACHEAL SMOOTH
MUSCLE
5.1 INTRODUCTION
As discussed in chapters three and four, a host of different regulatory-
factors could influence the routing of Ins(l,4,5)P3 metabolism through the
3-kinase and 5-phosphatase pathways. The experiments described in this
chapter were designed to address some of the potential mechanisms
underlying this regulation. One obvious but important factor which may
influence Ins(l,4,5)P3 metabolism is the concentration of this second
messenger itself. The enzyme kinetic experiments detailed in chapter
four show that the 3-kinase from BTSM has a much greater affinity for
Ins(l,4,5)P3 than does the 5-phosphatase and hence at low concentrations
of Ins(l,4,5)P3 the 3-kinase pathway would be expected to be the preferred
route of removal for this compound. To explore this hypothesis further,
experimental conditions were examined which could (or might be
predicted to) reduce the level of agonist-stimulated inositol phosphates
formed and hence the level of Ins(l,4,5)P3 accumulation. The effects of
stimulation with an alternative PIC-linked agonist aside from CCh,
activation of PKC with phorbol dibutyrate (PDBu), and the addition of p2"
adrenoceptor agonists or glucocorticosteroids on the accumulation of
[3H]InsPs was examined. The rationale behind these experiments is
discussed in more detail in sections 5.2-5. In addition to studying the
effects of a reduced Ins(l,4,5)P3 concentration, the differing assay
conditions also enabled the function of other possible regulatory
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processes to be addressed concurrently. For example, the use of two
different agonists could highlight the potential for receptor-mediated
and/or G-protein-mediated regulation of Ins(l,4,5)P3 metabolism. There
is very little data available regarding the effects of PKC activation on
[3H]InsP accumulation in ASM, and hence the data obtained in the
presence of PDBu is of particular interest, allowing the role of PKC in the
regulation of InsP formation and metabolism in this tissue to be
examined. In addition treatment with salmeterol, a long-acting P2-
adrenoceptor agonist, provides an important opportunity to explore the
relative importance of P2-adrenoceptor-mediated inhibition of InsP
formation to the relaxation of ASM. Furthermore, the use of both P2-
adrenoceptor agonists and the glucocorticosteroid dexamethasone may
provide some insight into the potential interaction of other hormones
and second messenger pathways with the InsP response in BTSM.
5.2 COMPARISON OF CARBACHOL- AND HISTAMINE-STIMULATED
INOSITOL POLYPHOSPHATE ACCUMULATION IN BTSM
Phosphoinositide hydrolysis is a mode of signal transduction utilised by
an extensive range of eukaryotic cell types in response to a wide variety of
stimuli (see Berridge, 1987; Berridge and Irvine, 1989; Rana and Hokin,
1990). The pattern, regulation and localisation of inositol polyphosphate
production is therefore likely to vary considerably in response to different
stimuli to allow this common signalling pathway to generate its vast
array of discrete effector events. In order to address whether Ins(l,4,5)P3
metabolism, or the pattern of InsPP accumulation differs following
stimulation with different PIC-linked agonists the accumulation of
[3H]InsPP in response to a prolonged stimulation with both Hist and CCh
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was assessed. These two compounds stimulate InsPP formation through
Hi-histaminergic (Barnes et al., 1986) and M3-muscarinic (Roffel et al.,
1990) receptors respectively and the different classes of receptors may well
recruit alternative subsets of G-proteins or PIC isozymes which could
influence the pattern of inositol polyphosphate formation.
[3H]Inositol labelled BTSM slices (2.3.1) were incubated with a maximally
effective concentration of either histamine (1 mM) or CCh (100 |iM) for 30
min in the presence of 5 mM LiCl and the accumulating [3H] InsPP
isomers isolated and separated using H.P.L.C. (as detailed in section 2.6.3).
As shown in table 5.2, stimulation of the BTSM slices with Hist resulted
in a reduced accumulation of [3H]InsPs compared to that following CCh
stimulation (31 % of the CCh response). This reduction in [3H]InsP
formation was associated with a statistically significant (p < 0.05, two-
tailed, unpaired student's t-test) change in the routing of Ins(l,4,5)P3
through the 3-kinase pathway (calculated as detailed in chapter three)
from 23.77 ± 1.80 % in the presence of CCh to 33.02 ± 2.38 % in the
presence of Hist. The proportional increase in 3-kinase activity observed
in the presence of Hist (compared to CCh) resulted in an increase in the
relative accumulation of [3H]Ins(l,3,4,5)P4 and hence may have important
implications in calcium signalling (see section 1.5.2). In addition the ratio
of [3H]Ins(l,4)P2 to [3H]Ins4P accumulation was greatly reduced in the
presence of Histamine compared to CCh. This latter result probably
reflects the uncompetitive nature of the inhibition of the InsPP 1-
phosphatase by LiCl, i.e. the smaller amount of [3H]Ins(l,4)P2 formed in
the presence of Hist decreases the effectiveness of Li+ inhibition and
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5.3 PROTEIN KINASE C-MEDIATED REGULATION OF CARBACHOL-
AND HISTAMINE-STIMULATED INOSITOL POLYPHOSPHATE
ACCUMULATION IN BOVINE TRACHEAL SMOOTH MUSCLE.
PKC proteins represent a large family of isoenzymes which appear to
differ markedly in their tissue expression, substrate specificity, and mode
of activation (see Hug and Sarre, 1993). To date ten different PKC
isoenzymes have been identified which can be classified into those
requiring Ca2+ for activation (the Ca2+-dependent or cPKCs) including the
09 Pi/ P2 and y isoforms, the Ca2+-independent or novel PKCs (nPKCs)
including the 5, £, r\ and 9 isoforms, and the atypical (aPKCs) which are
not activated by phorbol ester and include the and A. isoforms.
A wealth of evidence has accumulated to suggest that activation of PKC
may inhibit receptor-stimulated phosphoinositide hydrolysis. For
example activation of cPKC/nPKC with either phorbol esters or stable
analogues of DAG has been shown to inhibit the agonist-stimulated
inositol phosphate response in a range of cell types including Hist-, CCh-
and GTPyS-stimulated astrocytoma cells (Orellana et al., 1985, 1987),
angiotensin Il-stimulated rat aorta smooth muscle cells (Brock et al., 1985;
Pfeilschifter et al., 1989), CCh-stimulated PC12 cells (Vincentini et al.,
1985) Hist- and bradykinin-stimulated adrenal chromaffin cells (Boarder
and Challiss, 1992), epidermal growth factor-, angiotensin II- and
adrenaline-stimulated hepatocytes (Johnson and Garrison, 1987; Lynch et
al., 1985) thrombin-stimulated platelets (Rittenhouse and Sasson, 1985)
and CCh-stimulated intestinal smooth muscle (Prestwich and Bolton,
1995). Moreover, the addition of purified PKC to astrocytoma cell
membrane preparations has been shown to mimic the effects of phorbol
myristate acetate (PMA) in decreasing agonist-stimulated [3H]InsP3
production (Orellana et al., 1987), while inhibition (Boarder and Challiss,
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1992; King and Rittenhouse, 1989) or down-regulation (Pfeilschifter et ah,
1989) of PKC activity have the opposite effect.
A similar phorbol ester-mediated regulation of phosphoinositide
hydrolysis has also been demonstrated in airways smooth muscle where
both muscarinic- and histaminergic-stimulated accumulation of InsP is
markedly attenuated in the presence of phorbol ester (Baba et ah, 1989;
Murray et ah, 1989; Yang et ah, 1994). In order to ascertain whether PKC
activation could influence InsPP metabolism in BTSM and whether or
not such an effect could discriminate between CCh- and Hist-stimulated
responses, [3H]InsPP accumulation was monitored following a 30 min
pre-incubation with 0.1 nM - 10 pM PDBu.
5.3.1 Differential effect of phorbol dibutyrate on carbachol- and histamine-
stimulated [3H]inositol phosphate accumulation
The effect of a 30 min pre-incubation of BTSM slices with various
concentrations of PDBu (0.1 nM - 10 pM) on CCh (100 pM)- and
Histamine (1 mM)-stimulated [3H]InsP generation is illustrated in figure
5.3.1. Both the CCh- and Hist-stimulated [3H]InsP responses were
inhibited by PDBu treatment in a concentration-dependent manner. The
Hist response was decreased by as little as 1 nM PDBu and could be
completely abolished (99.1 ± 0.6 % inhibition) with 10 pM PDBu (IC50 = 5
nM). The CCh-stimulated [3H]InsP response was far more resistant to
inhibition by PDBu pre-treatment with detectable inhibition only being
observed at concentrations greater than 10 nM, and a 'maximal'
inhibition of 75.7 ± 1.6 % (IC50 = 230 nM).
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Figure 5.3.1 Phorbol dibutyrate concentration-response curve for
carbachol- and histamine-stimulated [3H]inositol polyphosphate
accumulation in bovine tracheal smooth muscle.
[3H]Inositol pre-labelled bovine tracheal smooth muscle slices (2.3.1) were
pre-incubated for 30 min with 5 mM LiCl and the indicated concentration
of PDBu prior to a 30 min stimulation with either 100 pM CCh or 1 mM
Hist. Total [3H]InsPs were separated from neutralised TCA extracts (2.4.2)
by Dowex AG 1 X-8 anion-exchange chromatography (2.6.1) and
quantified by liquid scintillation counting. Results are expressed as the
percentage maximal [3H]InsPP response (415434 ± 39930 and 162121 ± 5066
DPM/50 pi BTSM slices for CCh and Hist respectively), and represent the
mean ± SEM of three separate experiments, each performed in duplicate.
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5.3.2 Effect of phorbol dibutyrate on carbachol- and histamine-stimulated
inositol 1,4,5-trisphosphate mass and [3H]inositol 1,4,5-trisphosphate
metabolism
Since pre-treatment of BTSM slices with PDBu can inhibit, albeit it to a
different extent, the CCh- and Hist-stimulated total [3H]InsP responses, it
might be expected that this agent may also decrease the peak
concentration of Ins(l,4,5)P3 accumulation in response to these agonists.
This prediction is based on the assumption that PKC activation results in
receptor-PIC uncoupling (e.g. Murray et al., 1989; Orellana et al., 1987),
unlike the inhibition of agonist-stimulated [3H]InsP accumulation
observed with p?-adrenoceptor stimulation that results in inhibition of
the sustained but not immediate phase of PtdIns(4,5)P2 hydrolysis
(Challiss and Boyle, 1994). Such a proposal is also supported by the
observation that the response to maximally effective (1 mM) Hist
stimulation of BTSM is approximately 30 % of that following maximally
effective (100 pM) CCh stimulation for both total [3H]InsP accumulation
over 30 min (see table 5.2) and Ins(l,4,5)P3 mass at 5 sec (Chilvers et al.,
1989b). In addition, the concentration-response curves for CCh-
stimulated [3H]InsP accumulation (see figure 2.3.1.1; Chilvers et al., 1994b)
and Ins(l,4,5)P3 accumulation (Chilvers et al., 1989b) are near identical.
Indeed data obtained by Chilvers (personal communication, see figure
5.3.2.1) show that the peak Ins(l,4,5)P3 response in CCh-stimulated BTSM
slices is reduced by 36.9 ± 2.5 % following a 30 min pre-incubation with 1
pM PDBu. This data correlates closely with the above [3H]InsP
accumulation data (figure 5.3.1).
As described earlier, small alterations in the concentration of Ins(l,4,5)P3
may in itself have a significant influence on the routing of this second
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Figure 5.3.2.1 Effect of phorbol dibutyrate on carbachol-stimulated inositol
1,4,5-trisphosphate mass in bovine tracheal smooth muscle
BTSM slices (2.2) were pre-incubated for 30 min in oxygenated KHB in the
presence or absence of 1 pM PDBu (2.7.1) prior to further incubation with
either CCh (100 pM) or vehicle. Reactions were terminated at the
indicated time-points with 1 M TCA and the Ins(l,4,5)P3 present in
neutralised extracts (2.4.2) quantified using a radioreceptor assay (2.7.3).
Results represent the mean ± SEM of three separate experiments, each
performed in triplicate.
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assess the effect PDBu could have on the metabolism of Ins(l,4,5)P3 by the
3-kinase and 5-phosphatase enzymes a concentration of PDBu (100 nM)
was chosen that could facilitate a measurable decrease in the CCh-
stimulated [3H]InsP response while still permitting a significant Hist-
stimulated response. The effect of 100 nM PDBu pre-treatment on the
accumulation of the individual [3H]InsPP isomers in response to
prolonged CCh- and Hist stimulation is shown in table 5.2, and the flux of
[3H]Ins(l,4,5)P3 through the 3-kinase and 5-phosphatase pathways
illustrated in figure 5.3.2.2. PDBu (100 nM) pre-treatment results in a
71.05 ± 3.75 % reduction in the total [3H]InsP response to Hist, and a 30.88
± 14.15 % and a 12.53 ± 2.17 % reduction of the [3H]InsP response in
control and CCh-stimulated slices respectively. It is clear from this data
that although there is a trend in all experiments undertaken in the
presence of PDBu for more [3H]Ins(l,4,5)P3 to be metabolised via the 3-
kinase route, this does not reach statistical significance. These results
exclude any major influence of PKC stimulation on Ins(l,4,5)P3 routing
over a 30 min agonist stimulation period.
5.4 P2-ADRENOCEPTOR AGONIST-MEDIATED REGULATION OF
CARBACHOL- AND HISTAMINE-STIMULATED [3H]INOSITOL
PHOSPHATE ACCUMULATION IN BOVINE TRACHEAL SMOOTH
MUSCLE
It is well documented that agents which elevate the tissue cAMP
concentration in ASM including ^-adrenoceptor agonists can inhibit
spasmogen-induced contraction and initiate relaxation in tissue pre¬
contracted with a range of agonists (e.g. Ellis et al., 1995; Francis et al.,



















Figure 5.3.2.2 Effect of phorbol dibutyrate on [3H]inositol 1,4,5-
trisphosphate routing through the 3-kinase and 5-phosphatase pathways
[3H]Inositol pre-labelled BTSM slices (2.3.1) were pre-incubated for 30 min
at 37 °C with 100 nM PDBu prior to histamine- (1 mM) or CCh- (100 pM)
stimulation (30 min) in the presence of 5 mM LiCl. [3H]InsPPs in pooled
triplicate extracts (2.4.2) were separated using a Partisphere 5 SAX H.P.L.C.
column (2.6.3) and quantified by liquid scintillation counting. Results are
expressed as the proportion of [3H]Ins(l,4,5)P3 metabolised by the 3-kinase
and phosphatase pathways (see section 3.4.1) and represent the mean ±
SEM of n separate experiments.
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muscle from a number of tissues expresses both Pi- and p2-adrenoceptors,
predominantly P2, coupled to adenylyl cyclase (Barnes et al., 1983c;
Popovich et al., 1984). The p-adrenoceptor agonists salmeterol and
salbutamol exhibit very high P2- versus pi-selectivity (e.g Dougall et al.,
1991). Salmeterol, (a derivative of salbutamol with a long, flexible,
lipophilic N-substituted side-chain) is a designer P2-adrenoceptor agonist,
specifically formulated to provide long-acting P2-adrenoceptor
stimulation (see Johnson et al., 1993; Jack, 1991 and references therein).
By virtue of its lipophilic side-chain, salmeterol is thought to bind non-
competitively to an exo-site deep within the hydrophobic core of the
receptor protein. This agent does not therefore readily dissociate from the
membrane and is capable of producing both persistent, non-desensitising
relaxation of ASM in vitro (Johnson et al., 1993) and long-lasting (> 12 h)
bronchodilatation in vivo, (see Jack, 1991) Salmeterol (Salm) and
salbutamol (Salb) have been characterised as partial agonists (with respect
to adrenaline and isoprenaline) for P-adrenoceptor stimulation of cAMP
accumulation (Dougall, et al., 1991), although the potency of Salm for
relaxation is similar to that of isoprenaline in guinea-pig trachea and
human bronchus (Ball et al., 1991; Bradshaw et al., 1987). The availability
of highly selective p2-adrenoceptor agonists with very different kinetics
with respect to the duration of relaxation (both in vivo and in vitro)
affords an opportunity to re-assess the likely relative importance of p-
adrenoceptor-mediated inhibition of PtdIns(4,5)P2 hydrolysis to ASM
relaxation.
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5.4.1 Comparison between effects of salmeterol and salbutamol on
agonist-stimulated [3H]inositol phosphate accumulation in bovine
tracheal smooth muscle
To permit a subsequent comparison between the effects of Salm and Salb
on the duration of inhibition of Hist-stimulated [3H]InsP accumulation
initial experiments were performed to investigate the potency of these
two (^-adrenoceptor agonists on agonist-stimulated [3H]InsP
accumulation. BTSM slices were pre-treated for 30 min with either Salm
(0.01-100 nM) or Salb (3 nM - 1 pM) prior to stimulation for 30 min with
Hist (1 mM) or CCh (100 pM). The CCh-stimulated [3H]InsP response was
unaffected by Salm (see figure 5.4.1.1), whereas the Hist-stimulated
[3H]InsP response was significantly attenuated by both Salm and Salb (see
figures 5.4.1.1 and 5.4.1.2). Salm was more potent (IC50 = 0.24 ± 0.9 nM)
than Salb (IC50 = 10.8 ± 2.9 nM) in inhibiting the Hist-stimulated [3H]InsP
response. These potencies correlate well with those obtained in a
comparable system by Ellis and co-workers (1995) where IC50 values of 1.4
nM and 13.8 nM were obtained for Salm- and Salb-mediated inhibition of
Hist-stimulated [3H]InsP accumulation respectively. These authors noted
that the maximal inhibitory effect of the two p-adrenoceptor agonists (~
60 % inhibition) on the [3H]InsP response were not significantly different.
While Salm appeared to be more effective in inhibiting Hist-stimulated
[3H]InsP accumulation than Salb in the present study (maximal
inhibition = 59.8 ± 1.8 % and 49.5 ± 1.8 % for Salm and Salb respectively)
this difference did not reach statistical significance and the results are
therefore in close agreement with Ellis and co-workers. Similarly, the
maximal inhibitory effect of Salb and isoprenaline on Hist-stimulated
[3H]InsP formation were not found to differ (66 % and 68 % respectively)



































Figure 5.4.1.1 Effect of salmeterol on prolonged (30 minute) carbachol-
and histamine-stimulated [3H]inositol phosphate accumulation
[3H]Inositol labelled BTSM slices (2.3.2) were pre-incubated in 24 well
tissue culture plates for 30 min in the presence or absence of 100 nM
salmeterol. The slices were subsequently incubated (30 min) with 100 pM
CCh, 1 mM Hist or buffer in the presence of 10 mM LiCl. Total [3H]InsPs
were separated from neutralised TCA extracts (2.4.2) by Dowex AG 1-X8
anion-exchange chromatography (2.6.1) and quantified by liquid
scintillation counting. Results are exressed as the percentage of the CCh-
stimulated [3H]InsP response in the absence of salmeterol (449,424 ± 90,837
DPM/50 pi slices), and represent the mean ± SEM of five or six separate
experiments, each performed in duplicate. * Denotes p < 0.05 for
comparisons between salmeterol-treated and -unteated slices (two-tailed,
unpaired student's t-test).
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Figure 5.4.1.2 Salmeterol and salbutamol concentration-response curves
for inhibition of histamine-stimulated [3H]inositol phosphate
accumulation
[3H]Inositol labelled BTSM slices (2.3.2) in 24 well tissue culture plates
were pre-incubated for 30 min in the presence of the indicated
concentrations of either salmeterol or salbutamol. The slices were then
further incubated (30 min) with 1 mM Hist in the presence of 10 mM
LiCl. Total [3H]InsPs were separated from neutralised TCA extracts (2.4.2)
by Dowex AG 1-X8 anion-exchange chromatography (2.6.2) and quantified
by liquid scintillation counting. Results are expressed as the percentage
inhibition of the 1 mM Hist-stimulated [3H]InsP response in the absence
of added inhibitor (133,569 ± 26,928 DPM/50 pi slices) and represent the
mean ± SEM of three separate experiments, each performed in duplicate.
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lower potency of Salb for this effect (IC50 = 290 nM) than described here.
This discrepancy may reflect differences in the experimental conditions
since Hist and Salb were added simultaneously in the study by Hall and
Hill.
5.4.2 Time-course for salbutamol- and salmeterol-mediated inhibition of
histamine-stimulated [3H]inositol phosphate accumulation
While p2-adrenoceptor agonists are capable of relaxing ASM pre¬
contracted with a variety of agents, it would appear that the relative
extent of relaxation is dependent on both the contractile agonist (e.g.
Russell, 1984; Torphy et al., 1985) and the initial contractile state of the
tissue (Torphy, 1984). For example, muscarinic cholinoceptor-mediated
contraction is relatively resistant to P2-adrenoceptor-induced relaxation
(Hall et al., 1990; Madison and Brown, 1988; Offer et al., 1991). Salm and
Salb are unable to inhibit the [3H]InsP response to the muscarinic agonist
CCh but significantly attenuate the response to Hist in BTSM (see above).
In addition, these two p-adrenoceptor agonists exhibit a differential
inhibitory effect on both the [3H]InsP response (Figure 5.4.1.2) and the
contractile response (Ellis et al., 1995) stimulated by Hist. It is therefore
possible that the effects of Salm and Salb on [3H]InsP accumulation may
explain, at least in part, their differential relaxant activity.
A close temporal correlation between the Salm- and Salb-mediated
relaxation of methacholine-induced tone and intracellular cAMP
accumulation has been observed in BTSM (Ellis et al., 1995). In this
model Salm resulted in a slowly developing reversal of induced tone
accompanied by a progressive accumulation of cAMP, with both
responses maximal after 30-40 min. By contrast, Salb resulted in rapid
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effects on both induced tone and cAMP which were maximal within 5
min and declined thereafter. Hence the relaxant effects of P2-
adrenoceptor agonists in this model would seem to be secondary to
elevation of cAMP.
The time-course of Salm- and Salb-mediated inhibition of Hist-
stimulated [3H]InsP accumulation was investigated in order to address
whether or not the differential inhibition of phosphoinositide hydrolysis
could account for the long-term relaxant effects of Salm and the shorter-
term relaxant effects of Salb. [3H]Inositol pre-labelled BTSM slices were
incubated with the ^-adrenoceptor agonists or buffer for 0-24 h prior to a
30 min stimulation with Hist, and the resulting accumulation of
[3H]InsPs quantified. Figure 5.4.2 shows that while the [3H]InsP response
was highly sensitive to short-term treatment with both [^-adrenoceptor
agonists, the [3H]InsP response gradually recovered at later time-points
and no inhibition of Hist-stimulated [3H]InsP accumulation was observed
12 h after Salm or Salb addition. At the earliest time-point analysed (1 h)
the inhibition of [3H]InsP accumulation was significantly greater in Salm-
treated BTSM slices than in those treated with Salb. At later time-points
(3, 6, 12 and 24 h) however, no such differential inhibition was evident.
Control values for Hist-stimulated [3H]InsP accumulation remained





Figure 5.4.2 Time-course of salmeterol and salbutamol inhibition of
histamine-stimulated [3H]inositol polyphosphate accumulation
[3H]Inositol labelled BTSM slices (2.3.2) were pre-incubated for the times
indicated with concentrations of Salm or Salb (100 nM and 5 pM
respectively) that gave equivalent (maximal) inhibition of Hist-
stimulated [3H]InsP accumulation after 30 min pre-incubation (see figure
5.4.1.2). The slices were then stimulated with 1 mM Hist for 30 min in
the presence of 10 mM LiCl. Total [3H]InsPs were separated from
neutralised TCA extracts (2.4.2) by Dowex AG 1-X8 anion-exchange
chromatography (2.6.1) and quantified by liquid scintillation counting.
Results are expessed as the percentage of the Plist-stimulated [3H]InsP
response in the absence of inhibitor and represent the mean ± SEM of
three separate experiments, each performed in triplicate. * Denotes p <
0.05 for comparisons between salmeterol and salbutamol treated slices
(two-tailed, paired student's t-test).
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5.4.3 Effect of salmeterol on carbachol- and histamine-stimulated inositol
1,4,5-trisphosphate mass
BTSM slices were incubated with a maximally effective concentration of
Salm for 30 min prior to stimulation with agonist and subsequent
measurement of Ins(l,4,5)P3 mass. In agreement with Chilvers and co¬
workers (1989b), CCh (100 pM) resulted in a transient increase in
Ins(l,4,5)P3 that was maximal at 5 sec and decreased to sub-basal values by
30 sec (data not shown). No difference was observed between Ins(l,4,5)P3
accumulation in control BTSM slices and those pre-treated with 100 nM
Salm (0-300 sec). Further experiments were conducted to establish the
effect of Salm pre-treatment on the peak (5 sec) Ins(l,4,5)P3 accumulation
in response Hist- and CCh. Data from freshly prepared BTSM slices and
tissue incubated overnight in RPMI medium were not significantly
different and were pooled for statistical analysis. Figure 5.4.3 shows that
Hist stimulation results in only a very modest increase in Ins(l,4,5)P3
accumulation at 5 sec, which is significantly inhibited by Salm pre-
treatment. The basal and CCh-stimulated accumulation of Ins(l,4,5)P3
however is unchanged by such treatment.
5.5 EFFECT OF DEXAMETHASONE ON CARBACHOL- AND
HISTAMINE-STIMULATED PHOSPHOINOSITIDE HYDROLYSIS IN
BOVINE TRACHEAL SMOOTH MUSCLE
In addition to inhibition of inflammatory mediator release (Bersenstein
et al., 1987; Fitzke and Dieter, 1991), glucocorticoids have also been shown
to modulate ASM responses to contractile agonists (e.g. Powell et al.,
1993). Furthermore, activation of glucocorticoid receptors with





















Figure 5.4.3 Effect of salmeterol on peak (5 second) histamine- and
carbachol-stimulated Ins(l,4,5)P3 accumulation
BTSM slices (2.2) were incubated in the presence or absence of salmeterol
for 30 min at 37 °C in either oxygenated KHB or RPMI medium (2.7.1).
The slices were then further incubated for 5 sec with Hist (1 mM), CCh
(100 (iM) or buffer. Reactions were terminated with 1 M TCA and the
Ins(l,4,5)P3 present in neutralised TCA extracts (2.4.2) quantified using a
radioreceptor assay (2.7.3). Results are expressed as the percentage
Ins(l,4/5)P3 mass in control slices in the absence of salmeterol (17.0 ± 3.6
pmol/mg protein), and represent the mean ± SEM of 12 separate
experiments, each performed in duplicate or triplicate. * Denotes p < 0.05
for comparisons between salmeterol-treated and -untreated BTSM slices
(unpaired, two -tailed student's t-test).
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macrophages (Fitzke and Dieter, 1991) results in inhibition of agonist-
stimulated phosphoinositide hydrolysis. The latter study showed this
effect to be specific for glucocorticoids since cortisone exhibited a similar
action, but other steroids such as progesterone were without effect. These
authors concluded that the effect of dexamethasone on agonist-
stimulated phosphoinositide hydrolysis was due to an inhibition of the
incorporation of [3H]inositol into the membrane phospholipids rather
than an inhibition of PLC. Fitzke and Dieter (1991) demonstrated that
prolonged (> 6 h) exposure to dexamethasone was necessary for this
steroid to influence zymosan-stimulated phosphoinositide hydrolysis in
macrophages and also noted a similar time-dependent inhibition of
zymosan-stimulated InsP formation in response to protein- and RNA-
synthesis inhibitors. These results strongly suggest an indirect action of
glucocorticosteroids on phosphoinositides involving de novo synthesis
of proteins.
In order to address whether or not such a corticosteroid-mediated
inhibition of agonist-stimulated phosphoinositide hydrolysis could occur
in BTSM, the ability of Dex to influence CCh- and Hist-stimulated
accumulation of [3H]InsPs and incorporation of [3H]inositol into the
inositol phospholipids was assessed.
5.5.1 Effect of dexamethasone on carbachol- and histamine-stimulated
[3H]inositol phosphate accumulation
[3FI]Inositol-labelled BTSM slices were pre-incubated for 24 h with 1 pM
Dex prior to further incubation (30 min) with varying concentrations of
either CCh or Hist. The resulting accumulation of [3H]InsPs was
quantified and is illustrated in figure 5.5.1. Dex (1 (lM) had no effect on
[3H]InsP formation in response to either Hist (10 nM - 1 mM) or CCh (10
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Figure 5.5.1 Effect of dexamethasone on carbachol- and histamine-
stimulated [3H]inositol phosphate accumulation in bovine tracheal
smooth muscle
[3H]Ins labelled BTSM slices (2.3.2) were pre-incubated for 24 h with 1 pM
Dex prior to agonist stimulation (30 min) with 100 pM CCh or 1 mM Hist.
[3H]InsPs were separated from neutralised acidified
chloroform/methanol extracts (2.5.1) by Dowex AG 1-X8 anion-exchange
chromatography (2.6.1) and quantified by liquid scintillation counting.
Results represent the mean ± SEM of two-three separate experiments.
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nM - 100 pM). Addition of Dex 6 or 18 h prior to agonist stimulation was
also without effect on agonist-stimulated [3H]InsP formation (data not
shown).
5.5.2 Effect of dexamethasone on carbachol- and histamine-stimulated
[3H]inositol incorporation into inositol phospholipids in bovine tracheal
smooth muscle slices
BTSM slices were labelled by pre-incubation (24 h) with [3H]inositol (2.3.2)
prior to treatment (24 h) with Dex (1 pM) and further incubation (30 min)
with either CCh (10 nM - 100 pM) or Hist (10 nM - 1 mM). The
incorporation of [3H]inositol into the inositol phospholipids was
quantified (2.5.1) and is illustrated in figure 5.5.2. Despite the [3H]inositol
label being present for 48 hp labelling of the CCh-accessible
[3H]phosphoinositide pool to isotopic equilibrium was not reached.
Hence a definite increase in incorporation of [3H]inositol is observed with
1 pM CCh. 1 pM Dex had no significant effect on the degree of
[3H]inositol incorporation observed under basal or agonist-stimulated
conditions. Addition of Dex 6 or 18 h prior to agonist stimulation was
also without effect on agonist-stimulated [3H]inositol incorporation.
5.6 DISCUSSION
The experiments described in this chapter were designed principally to
modulate the agonist-stimulated InsPP response in order to shed light on
the factors regulating InsPP metabolism in BTSM. While stimulation
with Hist and CCh results in broadly similar patterns of TnsPP generation,
i.e. a transient accumulation of Ins(l,4,5)P3 and dominant metabolism of
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Figure 5.5.2 Effect of dexamethasone on CCh- and Hist-stimulated
[3H]inositol incorporation into membrane phospholipids
[3H]Ins labelled BTSM slices (2.3.2) were incubated for 24 h in the presence
or absence of 1 pM Dex prior to agonist stimulation (30 min) with 100 pM
CCh or 1 mM Hist. [3H]Phosphoinositide incorporation was quantified by
measuring the radioactivity in the lower phase of partitioned acidified
chloroform/methanol extracts (2.5.1). Results represent the mean ± SEM
of two-three separate experiments.
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of these responses clearly do exist. Stimulation of BTSM slices with a
maximally effective concentration of Hist produces an [3H]InsP response
only 35 % of that seen in response to a maximally effective CCh
concentration. This reduction in [3H]InsP accumulation is accompanied
by a 54 % reduction in the peak Ins(l,4,5)P3 mass concentration and a
small but significant increase in the proportion of Ins(l,4,5)P3 metabolised
by the 3-kinase pathway. Hence the decrease in Ins(l,4,5)P3 available for
metabolism results in a relative increase in metabolism through the 3-
kinase pathway. Due to the much higher affinity of the 3-kinase than the
5-phosphatase for Ins(l,4,5)P3 it is likely that this 'shift' reflects a relative
reduction in the amount of Ins(l,4,5)P3 metabolised via the 5-
phosphatase rather than an enhancement of 3-kinase activity. It cannot
be ruled out however, that the metabolism of Ins(l,4,5)P3 may be subject
to direct receptor-mediated regulation. This possibility is supported by
the fact that the 5-phosphatase is located predominantly on the inner
leaflet of the plasma membrane where it may come into contact with the
active receptor/G-protein complex.
The PKC-stimulating phorbol ester PDBu had a major but differential
effect on the Hist- and CCh-stimulated [3H]InsP responses. While
[3H]InsP accumulation following CCh- and Hist addition were clearly
decreased in response to a 30 min pre-incubation with a high
concentration (10 pM) of this phorbol ester, PDBu had both a greater
potency and greater efficacy for inhibition of the Hist-stimulated [3H]InsP
response than that stimulated by CCh. A similar heterogeneity of PKC-
mediated feedback inhibition of agonist-stimulated InsP responses has
also been observed in a number of cell-types. For example, in rat
hepatocytes the Ins(l,4,5)P3 response to angiotensin II stimulation is
attenuated, whereas the response to epidermal growth factor is
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completely blocked following activation of PKC (Johnson and Garrison,
1987). In addition phorbol ester treatment of bovine adrenal chromaffin
cells inhibits the peak Hist- and bradykinin-stimulated Ins(l,4,5)P3
responses by 70 % and 30 % respectively (Boarder and Challiss, 1992). A
more dramatic difference can be observed in Rat-l-fibroblasts (Plevin et
al., 1991) where application of PMA results in an inhibition of the
lysophosphatidic acid stimulated inositol phosphate formation whereas
the response to endothelin-1 is completely unaffected. Furthermore a
differential regulatory activity of PKC can be observed between different
cell-types. For example Ward and Cantrell (1990) have demonstrated
that antigen-stimulated phosphoinositide metabolism is inhibited
following PKC activation in Jurkat cells but not in T lymphoblasts.
The mechanisms underlying the PKC-mediated inhibition of agonist-
stimulated InsP responses and the apparent agonist and/or tissue
specificity of this regulation are currently unclear. Several studies have
demonstrated that the receptor number and affinity for its agonist are
unchanged following addition of phorbol ester (e.g. Brock et al., 1985;
Orellana et al., 1985, 1987; Vincentini et al., 1985). A notable exception
however, is the ai-adrenoceptor from liver: following perfusion of liver
membranes with PMA, a 30-40 % reduction in receptor number was
observed (Lynch et al., 1985). Nonetheless, the large number of different
agonist responses which can be modulated by PKC activation suggest a
common component of the signal transduction mechanism, and not the
receptor, is the site of PKC action. In support of this hypothesis
guanosine nucleotide- (Murray et al., 1989; Orellana et al., 1987) or
fluoroaluminate- (Yang et al., 1994) stimulated inositol phosphate
formation is also inhibited by PKC activation. These results suggest a
post-receptor site of action for PKC, possibly by phosphorylation of the G-
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protein or PIC enzyme. To date there does not appear to be any evidence
for PKC-mediated phosphorylation of Gq, however both Gsa (Pyne et al.,
1992a) and Gja (Bushfield et al., 1991) may be subject to such modulation.
In addition PKC may phosphorylate and thereby inhibit PIC-pi (Ryu et al.,
1990). The differential inhibition of agonist-stimulated InsP responses by
PKC may therefore arise as a result of the expression or activation of
distinct G-protein and PIC isozymes. This differential regulation could
also be mediated in vivo by the activation of alternative PKC isoforms
and therefore it is interesting to note that while rat RBL-2H3 cells contain
several PKC isoforms, only PKCa and PKCe can inhibit antigen-induced
phosphoinositide hydrolysis (Ozawa et al., 1993).
It is also possible that some of the effects observed following PKC
activation could be secondary to adenylyl cyclase activation and cAMP
accumulation since treatment of cultured guinea-pig tracheal smooth
muscle cells with either PMA or bradykinin results in enhanced adenylyl
cyclase activity (Stevens et al., 1994). The bradykinin-stimulated
activation of adenylyl cyclase is mediated through PLD rather than PLC
signallling (Stevens et al., 1994) and does not involve the activation of
PKCa (Pyne et al., 1994).
Whether a PKC-mediated feedback inhibition of the PIC response occurs
in vivo is difficult to judge since the phorbol ester used in this study is
relatively stable and induces highly unphysiological and global activation
of multiple PKC isoforms. Its cellular counterpart - PtdInsP2-derived
DAG - is likely to be subject to rapid metabolism. Since the CCh-
stimulated pHjlnsP response does not readily desensitise in this tissue,
with a linear accumulation of [3H]InsP evident for at least 90 min
(Chilvers et al., 1989a), it would appear most unlikely that PKC activation
has a major curtailing influence on M3-mediated PtdInsP2 hydrolysis.
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The Hist response however does desensitise with time (Hall and Hill,
1988) and exhibits a greater sensitivity to inhibition by PDBu. Therefore
the possibility of a physiological PKC-mediated feedback loop regulating
Hist receptor signalling is far more likely. Clearly, with the advent of
more selective PKC isozyme inhibitors and more detailed knowledge of
the precise PKC isoforms targetted by PtdInsP2-derived DAG it may, in the
future, be possible to dissect these pathways further. It should also be
noted that PLC-mediated phospholipid hydrolysis may not be the only
route of DAG formation in ASM since bradykinin clearly induces
phosphatidylcholine hydrolysis in cultured guinea-pig tracheal smooth
muscle cells (Pyne and Pyne, 1993). There is therefore a strong possibility
of cross-talk between the different signal transduction pathways in this
tissue.
In addition to regulating PLC activity, PKC activation may also modulate
the enzymes responsible for Ins(l,4,5)P3 metabolism (see chapter three).
However any effect of PKC on the these enzymes must be 'balanced' since
there was no significant difference in the routing of Hist- or CCh-
stimulated Ins(l,4,5)P3 metabolism in the presence of PDBu.
A further differential activity on CCh- and Hist-stimulated [3H]InsP
formation is exhibited by the (^-adrenoceptor agonists Salm and Salb.
Salm did not affect the accumulation of [3H]InsP in response to a
maximally effective concentration of CCh, or the peak CCh-stimulated
increase in Ins(l,4,5)P3 mass. The Hist-stimulated [3H]InsP response
however was significantly attenuated by both Salm and Salb. Salm was
the more potent in its inhibition of the [3H]InsP response to Hist, and this
agent also significantly reduced the Hist-stimulated Ins(l,4,5)P3 mass
response. Maximally effective concentrations of Salm and Salb elicited a
similar degree of inhibition of the Hist-stimulated [3H]InsP response (50-
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60 %) which was also comparable to that observed for isoprenaline (68 %,
Hall and Hill, 1988).
The mechanisms underlying the inhibition of Hist-stimulated [3H]InsP
accumulation by P2-adrenoceptor agonists remain to be elucidated but
could be mediated at several levels of the inositol phosphate signal
transduction pathway. A reduction in the available substrate
(PtdIns(4,5)P2) is unlikely since [3H]inositol incorporation into membrane
phospholipids is unaffected by Salb in Hist-stimulated BTSM slices (Hall
and Hill, 1988). Alternatively, ^-adrenoceptor agonists may affect the Hi
receptor, the receptor-G-protein complex, or even directly inhibit PIC.
Since agents which increase intracellular levels of cAMP can inhibit
fluoroaluminate-stimulated [3H]InsP formation, a post-receptor mediated
mechanism has been implicated in the ^-adrenoceptor mediated
inhibition of phosphoinositide hydrolysis (Hall et al., 1990a). Hence
alterations in the G-protein-PIC coupling mechanism may underlie the
effect of p2-adrenoceptor agonists on receptor-stimulated [3H]InsP
accumulation. Indeed the possibility for G-protein regulation by P-
adrenoceptor agonists is exemplified by the phosphorylation in vitro of
Gsa by PKA (Pyne et al., 1992b). It should also be noted that py G-protein
subunits liberated following P-adrenoceptor-mediated stimulation of Gs
can activate P-adrenergic and muscarinic acetylcholine receptor kinases
(Kameyama et al., 1993; Koch et al., 1993). These kinases may
phosphorylate the receptors or G-proteins involved in phosphoinositide
hydrolysis thereby serving to uncouple the receptor from its G-protein.
Hence, as discussed above for PKC activation, the recruitment of distinct
G-protein and PIC isoenzymes may explain the differential susceptibility
of various agonists to p2-adrenoceptor activation.
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It has been suggested that the relative resistance of muscarinic receptor-
mediated contraction to relaxation with [^-adrenoceptor agonists may be
explained, at least in part, by the ability of muscarinic receptor
stimulation to inhibit cAMP accumulation in ASM tissue and cells (Jones
et al., 1987; Sankary et al., 1988; Yang et al., 1991). ASM contains two
subtypes of muscarinic cholinoceptors, M2 and M3 (e.g. Yang et al., 1991;
Mahesh et al., 1992). The latter are coupled to phosphoinositide
hydrolysis while the former (the predominant receptor subtype in most
species thus far studied) appears to be linked via G; to the inhibition of
adenylyl cyclase. Activation of muscarinic cholinoceptors may also serve
to inhibit adenylyl cyclase via a functional inactivation of Gs (Pyne et al.,
1992c). The ability of (3y G-protein subunits to bind to- and inactivate Gsa
could possibly underlie this latter effect (Hildebrandt and Kohnken, 1990).
The relative importance of M2 and M3 muscarinic receptor subtypes in
determining the extent of inhibition of adenylyl cyclase is highly
controversial (see Eglen et al., 1994b and c; Roffel et al., 1994a). Watson
and Eglen (1994) suggested that M2 receptors are primarily responsible for
this inhibition since the selective M2 antagonist methoctramine
augmented the relaxant potency of isoprenaline in guinea-pig trachea at a
concentration associated with minimal M3 receptor occupancy. This data
is supported by the observation in guinea-pig ileum that following
alkylation of M3 receptors, M2 receptor activation inhibits the relaxant
responses to [^-adrenoceptor agonists (Reddy et al., 1994). However, a
similar study in guinea-pig trachea failed to reveal such an effect (Eglen et
al., 1994a). An alternative proposal is that the extent of p-adrenoceptor-
induced relaxation is controlled instead by the level of M3 receptor-
mediated tone (Roffel et al., 1994b). Indeed small alterations in the
contractile tone are associated with large shifts in the potency of
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isoprenaline for relaxation (van Amsterdam et al., 1989). To date the
study of M2/M3 receptor-mediated regulation of ASM contraction has
been severely hampered by the absence of a highly selective M2 receptor
antagonist. The future development of more subtype-specific muscarinic
receptor agonists, antagonists and antisera may lead to greater
understanding of muscarinic receptor functions.
When the Hist-stimulated [3H]InsP response was monitored at different
times following Salm/Salb pre-incubation, a difference between the
effects of the two fb-adrenoceptor agonists was only observed at the
earliest time-point studied (1 h), with no difference in the apparent
duration of inhibition between the two agents. Hence it is unlikely that
the inhibition of Hist-stimulated InsP formation by Salm explains the
prolonged relaxant effects of this agonist observed both in vitro and in
vivo (see Jack, 1991). The spasmolytic effects (relaxation of pre-contracted
tissue) of these agents probably reflect the increased cAMP formation
(Ellis et al., 1995), while the inhibition of Hist-mediated phosphoinositide
hydrolysis may be important in the maintenance of the relaxed state
(anti-spasmogenic effect).
P2-adrenoceptor agonists have proved to be useful tools in the treatment
of asthma and hence the role of these agents in ASM relaxation has been
a topic of much interest in recent years. P2_adrenoceptor agonists may
exert their relaxant effect by regulating the intracellular Ca2 +
concentration. (3-adrenoceptor stimulation of ASM is often accompanied
by membrane hyperpolarisation (Allen et al., 1985; Fujiwara et al., 1988),
which can be induced by both cAMP-dependent (Kume et al., 1989) and
-independent (Kume et al., 1992, 1994) activation of high conductance
Ca2+-activated potassium channels (BKca)- Membrane hyperpolarisation
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would prevent influx of Ca2+ through voltage-dependent Ca2+-channels
and could thereby influence the sustained (tonic) phase of contraction.
When considering the effects of (3-adrenoceptor agonists, it should be
appreciated that cAMP may activate PKG in addition to PKA: cAMP
activates PKG with an EC50 (80 nM) only slightly greater than that for
PKA (30 nM) in canine trachealis (Torphy et al., 1982). Moreover, the
relaxant potencies of cyclic nucleotide analogues against K+-induced
contractions of guinea-pig trachea strongly correlate with their EC50
values for PKG but not PKA (Francis et al., 1988). Further to the effects of
increased levels of cAMP, P-adrenoceptor agonists may also stimulate
direct receptor-mediated effects to induce relaxation of ASM as evidenced
by the cAMP-independent action of isoprenaline on BKca-
In addition to modulating Ca2+ signalling by agonist-stimulated InsP
formation, agents which activate both PKC and PKA may also be able to
regulate intracellular Ca2+ release downstream of Ins(l,4,5)P3 formation
through the phosphorylation of the Ins(l,4,5)P3 receptor. Consensus
sequences for phosphorylation by PKA have been identified on the
InsP3R-l (Furuichi et al., 1989; Mignery et al., 1990) and InsP3R-2 (Sudhof
et al., 1991) receptors. Although these sequences are often conserved
between tissues, phosphorylation of Ins(l,4,5)P3 receptors by PKA appears
to have different effects in different cell types. For example the sensitivity
of the receptor from cerebellar microsomes is decreased by PKA-mediated
phosphorylation (Supattapone et al., 1988) whereas Ca2+ release from
permeabilised hepatocytes is potentiated by pre-treatment of the cells with
the catalytic subunit of PKA (Burgess et al., 1991). The Ins(l,4,5)P3
receptor is also known to be a target for PKC (Ferris et al., 1991) and
phosphorylation by this kinase is associated with accelerated Ca2+ release
(Matter et al., 1993).
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A final attempt to manipulate InsPP formation and metabolism in BTSM
utilised the glucocorticoid dexamethasone. While glucocorticoids have
been shown to inhibit agonist-stimulated InsP formation in a number of
tissues, the data obtained in BTSM show that dexamethasone is without
effect on either InsP formation, or incorporation of inositol into the
membrane lipids. These results are in agreement with Michoud and co¬
workers (1994) who demonstrated that treatment of cultured rat tracheal
smooth muscle cells with 100 nM dexamethasone had no effect on the
subsequent 5-hydroxytyptamine-stimulated PLC activity.
The experiments detailed in this chapter provide further insight into the
factors regulating InsPP metabolism in ASM. It would appear from the
experiments performed in the presence of PDBu that receptor-PIC
coupling can be modulated in an agonist-specific way by PKC-mediated
feedback. The Hist experiments indicate that a reduction in the
concentration of Ins(l,4,5)P3 (compared to CCh-stimulated
concentrations) may facilitate a relative increase in its metabolism
through the 3-kinase pathway. Whether this reflects a direct effect of PKC
in regulating the activity of the 3-kinase and 5-phosphatase enzymes
themselves, or is simply due to the higher affinity of the 3-kinase enzyme
for Ins(l,4,5)P3 is uncertain. The reduced formation of InsPs in response
to both Hist and CCh in the presence of PDBu highlight the possibility for
cross-talk between different signal transduction pathways (e.g. inhibition
of phosphoinositide hydrolysis by the PLD-mediated production of DAG).
The susceptibility of both Hist- and CCh-stimulated InsP responses to
PDBu indicate similar components may be involved in the hydrolysis of
phosphoinositides in response to these two agonists. The differential
sensitivities of the two responses to PDBu suggest however, that the Hist-
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and CCh- receptors themselves (and the G-proteins/PIC
isozymes/phosphoinositide pools they recruit) may be subject to
differential regulation. A similar differential inhibitory effect is exerted
by (32-adrenoceptor agonists, i.e. the Hist-stimulated InsP response can be
inhibited by both Salm and Salb, while the CCh-stimulated response is
unaffected by these agents. The effect of Salm and Salb on Hist-
stimulated InsP accumulation further substantiates a role for cross-talk
between signal transducing pathways in the regulation of InsP formation.
However, the very similar time-course for the inhibition of Hist-
stimulated [3H]InsP accumulation by these agents, despite differing cAMP
accumulation and relaxant effects, suggests that inhibition of
phosphoinositide hydrolysis may not be the primary mechanism
underlying p-adrenoceptor-mediated relaxation of ASM. In contrast to
many other tissues studied, InsP accumulation does not appear to be




INOSITOL 4,5-BISPHOSPHATE IN BOVINE
TRACHEAL SMOOTH MUSCLE
6.1 INTRODUCTION
Muscarinic receptor stimulation of BTSM slices results in a Li+-sensitive
accumulation of a novel inositol bisphosphate isomer, namely
[3H]Ins(4,5)P2 (see section 3.4). This isomer has previously been detected
in only a limited number of mammalian cell types: thyrotropin-releasing
hormone-stimulated GH3 cells (Dean and Moyer, 1987; Hughes and
Drummond, 1987), unstimulated WRK1 rat mammary tumour cells
(Wong et al., 1992) and CCh-stimulated rat cerebral cortex slices (Batty et
al., 1989; Jenkinson et al., 1992). Jenkinson and co-workers (1992) have
carried out the only detailed study of the accumulation of [3H]Ins(4,5)P2 to
date and, in agreement with the data described here and with Hughes and
Drummond (1987), showed that the accumulation of [3H]Ins(4,5)P2 is Li+-
sensitive.
Since the accumulation of Ins(4,5)P2 in BTSM, GH3 cells and in rat
cerebral cortex slices may be agonist-stimulated, it is possible that this
novel InsP2 isomer may play some role in signal transduction. Ins(4,5)P2
has been shown to be as effective as Ins(l,4,5)P3 in mobilising Ca2+ from
non-mitochondrial intracellular stores in permeabilised guinea-pig
hepatocytes (Burgess et al., 1984) and Swiss mouse 3T3 cells (Irvine et al.,
1984) albeit with a much lower potency. Ins(4,5)P2 does not appear to
accumulate to very high concentrations even under agonist-stimulated
conditions as it represents only 2.9 ± 0.1 % and 1.71 ± 0.21 % of the total
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[3H]InsP2 pool following 30 min CCh stimulation in rat cerebral cortex
slices (Batty et al., 1989) and BTSM slices (see section 3.4.1) respectively. It
is possible however, that this isomer may play a significant calcium-
signalling role at later time-points in the agonist-stimulated response,
when the Ins(l,4,5)P3 concentration has returned to basal values, and may
be of particular importance in patients receiving Li+ therapy for manic
depression or other affective disorders. Ins(4,5)P2 has also been shown to
be an effective inhibitor of the Ca2+-ATPase of human erythrocytes in
vitro (Davis et al., 1991). In addition, Ins(4,5)P2 may function as an
extracellular signalling molecule since superfused Ins(4,5)P2 causes a
concentration-dependent increase in luteinising hormone release from
non-permeabilised rat pituitary cells (Przylipiak et al., 1990).
The origins and metabolic fate of Ins(4,5)P2 in the cell is unknown. There
are several possible routes for both the formation and metabolism of this
compound which are summarised in figure 6.1. Ins(4,5)P2 may be formed
by the action of a 1-phosphatase on Ins(l,4,5)P3, or possibly Ins(l,3,4,5)P4
followed by subsequent hydrolysis by a 3-phosphatase. A novel
Ins(l,4,5)P3 1-phosphatase has been described in Dictyostelium
discoideum (Van Lookeren Campagne et al., 1988) but no mammalian
counterpart has been identified to date. The well-characterised
Ins(l,4)P2/Ins(l,3,4)P3 1-phosphatase has no activity against either
Ins(l,4,5)P3 or Ins(l,3,4,5)P4 (Inhorn and Majerus, 1987). Recent interest
in the role of InsPs and InsP6 in cell signalling was sparked by the
observation of an agonist-stimulated conversion of Ins(l,3,4,5,6)P5 to
Ins(3,4,5,6)P4 in rat pancreatoma cells (Menniti et al., 1990). Hence
mammalian cells appear to contain an alternative 1-phosphatase enzyme,
the substrate specificity of which is currently unknown. The













documented (Stephens et al., 1989); however this study indicated that
Ins(l,3/4)P3 was formed by a 6-phosphatase action on Ins(l,3,4,6)P4.
An alternative route of Ins(4,5)P2 formation could be a PLD-mediated
hydrolysis of PtdIns(4,5)P2- While a role for PLD in transmembrane
signalling in ASM, secondary to PKC stimulation, has been suggested
(Pyne and Pyne, 1993), there is little, if any, evidence to date implicating
PLD in the hydrolysis of the phosphoinositides in ASM.
The metabolism of Ins(4,5)P2 is likely to proceed by a dephosphorylation
pathway to form either Ins4P or Ins5P. Ins(4,5)P2 has been shown to be a
substrate (albeit a poor one) for the Ins(l,4,5)P3/Ins(l,3,4,5)P4 5-
phosphatase (Mitchell et al., 1989), whereas the significant accumulation
of Ins5P observed in muscarinic receptor-stimulated rat cerebral cortex
might suggest the involvement of a 4-phosphatase (Ackermann et al.,
1987). In addition, it is possible that Ins(4,5)P2 could be phosphorylated to
Ins(3,4,5)P4 since it can be metabolised slowly by an Ins(l,4,5)P3 3-kinase
purified from rat brain (Morris et al., 1988).
The purpose of this chapter is to assimilate the data obtained in
experiments described earlier with a focus on the accumulation of
Ins(4,5)P2- To expand on these studies further experimental data on the
effect of Li+ and phorbol ester pre-treatment on agonist-stimulated
[3H]Ins(4,5)P2 accumulation are presented which give some insight into
the possible routes of formation and metabolism of this novel inositol
phosphate isomer in BTSM.
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6.2 CARBACHOL- AND HISTAMINE-STIMULATED INOSITOL 4,5-
BISPHOSPHATE ACCUMULATION
Experiments conducted to establish the flux of Ins(l,4,5)P3 through the 3-
kinase and 5-phosphatase pathways (detailed in section 2.4) utilised
H.P.L.C. to separate and quantify individual [3H]InsPP isomers. An
unexpected observation of these experiments was the presence in BTSM
slices of a late running [3H]InsP2 peak which was easily separated from
the common [3H]Ins(l,3)P2, [3H]Ins(l,4)P2 and [3H]Ins(3,4)P2 isomers (see
figure 6.2.1). This novel [3H]InsP2 isomer co-eluted with [3H]Ins(4,5)P2
generated by alkaline hydrolysis of the [3H]phosphoinositides isolated
from BTSM (see section 2.6.3). Alkaline hydrolysis cleaves
phosphoinositides into its glycerol and inositol phosphate moieties, and
hence the major [3H]InsP2 isolated by this process is [3H]Ins(4,5)P2- Since
no labelled alditols would be formed following periodate oxidation of
[2-3H]Ins(4,5)P2, this technique could not be used to positively identify the
isomeric composition of the late running [3H]InsP2- It may be possible to
give a clearer identification of this isomer by examining the products
formed following its dephosphorylation by a purified
Ins(l,4,5)P3/Ins(l,3/4/5)P4 5-phosphatase.
Under basal conditions [3PI]Ins(4,5)P2 was hardly detectable, however its
accumulation increased following muscarinic cholinoceptor stimulation
with CCh and was dramatically enhanced in the presence of 5 mM LiCl
(see figure 6.2.2). Following prolonged (30 min) CCh (100 pM)
stimulation in the presence of 5 mM LiCl, [3H]Ins(4,5)P2 represented 1.27
± 0.06 % of the total retrieved [3H]InsPPs and 8.61 ± 1.18 % of the total
[3H]InsP2 pool. Time-course experiments indicated that the accumulation
of [3H]InsP2 following receptor stimulation was delayed, only
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Figure 6.2.1 Typical H.P.L.C. elution profile obtained following carbachol
stimulation of bovine tracheal smooth muscle slices
[3H]Inositol pre-labelled BTSM slices (2.3.1) were incubated for 30 min at
37 °C in the presence of 5 mM LiCl and 100 pM CCh. [3H]InsP2S were
separated from pooled triplicate TCA extracts (2.4.2) using a Partisphere 5





























Figure 6.2.2 Effect of lithium ions on prolonged carbachol-stimulated
inositol 4,5-bisphosphate accumulation
[3H]Inositol pre-labelled BTSM slices (2.3.1) were incubated for 30 min at
37 °C in the presence or absence of 5 mM LiCl and 100 pM CCh.
[3H]Ins(4,5)P2 was separated from pooled triplicate TCA extracts (2.4.2)
using a Partisphere 5 SAX PI.P.L.C. column (2.6.3) and quantified by liquid
scintillation counting. Results represent the mean ± SEM of n separate











































Figure 6.2.3 Time-course of carbachol-stimulated inositol 4,5-
bisphosphate accumulation
[3H]Inositol pre-labelled BTSM slices (2.3.1) were incubated with 100 pM
CCh or vehicle in the presence of 5 mM LiCl in a final volume of 300 pi.
Reactions were terminated at the times indicated by the addition of 300 pi
1 M TCA. [3H]Ins(4,5)P2 was separated from pooled triplicate neutralised
extracts (2.4.2) by H.P.L.C. (2.6.3) and the radioactivity associated with each
isomer quantified by liquid scintillation counting. Results represent the
mean ± SEM of three separate experiments. * Represent p < 0.05; **
represents p < 0.01 for comparisons with basal values (two-tailed, paired
student's t-test).
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This delayed accumulation of [3H]Ins(4,5)P2 contrasts the very rapid
generation and accumulation of [3H]Ins(l,4,5)P3 and [3H]Ins(l,4)P2 (see
section 3.4.2) and would suggest an indirect route for the formation of
[3H]Ins(4,5)P2 following stimulation with CCh.
In order to gain some insight into the pathways responsible for the
formation of [3H]Ins(4,5)P2 the effects of different agonists on
[3H]Ins(4,5)P2 accumulation were examined. Experiments were
performed comparing the effects of CCh (100 |iM) and Hist (1 mM)
stimulation on [3H]InsPP accumulation in BTSM. Stimulation with
agonists for 30 min in the presence of Li+ resulted in a 1,751-fold increase
in the accumulation of [3H]Ins(4,5)P2 in response to 100 pM CCh and a
106-fold increase in response to 1 mM Hist stimulation. These 'fold'
stimulations may be misleading however, due to the negligible
accumulation of [3H]Ins(4,5)P2 under basal conditions (2 ± 1 DPM/50 pi
BTSM slices). CCh stimulation produces relatively more [3H]Ins(4,5)P2 (as
a percentage of the total [3H]InsPPs) than Hist stimulation (see fig 6.2.4).
Hence it would seem that muscarinic-cholinoceptor stimulation of BTSM
slices is significantly more effective in producing [3H]Ins(4,5)P2 than
stimulation with histaminergic agonists.
6.3 EFFECT OF PHORBOL DIBUTYRATE ON CARBACHOL- AND
HISTAMINE-STIMULATED [3H]INOSITOL 4,5-BISPHOSPHATE
ACCUMULATION
It is possible that [3H]Ins(4,5)P2 may be formed secondary to PKC
stimulation and a subsequent activation of PLD-mediated
[3H]PtdIns(4,5)P2 hydrolysis. Hence it is interesting to consider the effects




Figure 6.2.4 Effect of phorbol dibutyrate on histamine- and carbachol-
stimulated [3H]inositol 4,5-bisphosphate accumulation
[3H]Inositol pre-labelled BTSM slices (2.3.1) were pre-incubated for 30 min
at 37 °C in the presence or absence of 100 nM PDBu prior to Hist (1 mM)-
or CCh (100 pM)-stimulation (30 min) in the presence of 5 mM LiCl.
[3H]Ins(4/5)P2 was separated from pooled triplicate TCA extracts (2.4.2)
using a Partisphere 5 SAX H.P.L.C. column (2.6.3) and quantified by liquid
scintillation counting. Results are expressed as the percentage of total
retrieved radioactivity associated with [3H]Ins(4,5)P2 and represent the
mean ± SEM of three or five experiments for Hist and CCh incubations
respectively. * Represents p < 0.05; * * represents p < 0.01 (two-tailed,
unpaired student's t-test).
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stimulation may alter the pattern of [3H]Ins(4,5)P2 formation. Pre-
treatment of BTSM slices with 100 nM PDBu resulted in a decrease in the
accumulation of [3H]Ins(4,5)P2 in both CCh- and Hist-stimulated BTSM
slices (22.0 ± 15.5 % and 82.9 ± 12.4 %, section 5.3.1). However, these
decreases reflected the observed decreases in total [3H]InsPPs (12.5 ± 2.1
and 71.1 ± 3.8 for CCh- and Hist-stimulated slices respectively) and
therefore the percentage of [3H]InsPPs present as [3H]Ins(4,5)P2 remained
unaltered (two-tailed, unpaired student's t-test) by PDBu treatment (see
figure 6.2.4).
6.4 EFFECT OF LITHIUM IONS ON [3H]INOSITOL 4,5-BISPHOSPHATE
ACCUMULATION
As described above, the CCh-stimulated accumulation of [3H]Ins(4,5)P2 is
highly sensitive to Li+. Jenkinson et al. (1992) demonstrated a bell-shaped
Li+-concentration curve for the CCh-stimulated accumulation of
[3H]Ins(4,5)P2 in rat cerebral cortex slices. If a similar response to Li+
occurs in BTSM it is possible that an even greater accumulation of
[3H]Ins(4,5)P2 may occur at lower, therapeutically relevant concentrations
of Li+. Hence the accumulation of [3H]InsPP isomers in response to
prolonged CCh stimulation over a range of LiCl (0 - 10 mM)
concentrations was studied. The results are shown in table 6.4. At low
concentrations of LiCl (< 10 mM) [3H]Ins(4,5)P2 accumulates in a manner
similar to the Li+-sensitive [3H]InsPis with a progressive increase in
[3H]Ins(4,5)P2 levels, suggesting a Li+-sensitive metabolism of this isomer.
The EC50 for the effect of Li+ on [3H]Ins(4,5)P2 accumulation is 1.06 mM
compared to 1.12 mM and 0.87 mM for [3H]Insl/3P and [3H]Ins4P
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however, demonstrated a marked attenuation of [3H]Ins(4,5)P2
accumulation in the presence of 30 mM LiCl (see table 6.4, figure 6.4.1).
Hence, in accordance with the results of Jenkinson et al. (1992) a bell-
shaped Li+ concentration-response curve for the accumulation of
[3H]Ins(4,5)P2 is observed if LiCl is increased to high (> 10 mM)
concentrations. It is important to note that 30 mM LiCl also caused a
marked decrease in [3H]Ins4P accumulation (table 6.4, figure 6.4.2) and a
parallel increase in [3H]Ins(l,4)P2 accumulation (table 6.4) implying that
this concentration of Li+ can inhibit the 1-phosphatase responsible for the
conversion of Ins(l,4)P2 to Ins4P. The near identical concentration-
dependence of both [3H]Ins4P and [3H]Ins(4,5)P2 on Li+ ions suggest that
similar enzymes might be involved in the formation and metabolism of
these two [3H]InsPs.
6.5 DISCUSSION
The demonstration of an agonist-stimulated accumulation of
[3H]Ins(4,5)P2 in BTSM is of particular interest since the accumulation of
this isomer cannot be accounted for by any conventional routes of
mammalian InsPP metabolism. The agonist-stimulated nature of its
accumulation from very low basal levels suggests that Ins(4,5)P2, or one
of its precursors or metabolites, may play an important role in signalling
in this tissue. Furthermore, the sensitivity of its accumulation in the
presence of Li+ ions suggests that the flux of the inositol headgroup
through Ins(4,5)P2 may be substantial in vivo.
Two alternative routes of formation of Ins(4,5)P2 are PLD action on
PtdIns(4,5)P2 or metabolism of Ins(l,4,5)P3. Muscarinic cholinergic
stimulation of BTSM slices produced a greater proportion of [3H]Ins(4,5)P2
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Figure 6.4.1 Effect of lithium ion concentration on carbachol-stimulated
[3H]inositol 4,5-bisphosphate accumulation
[3H]Inositol pre-labelled BTSM slices (2.3.1) were stimulated with 100 pM
CCh in the presence of the indicated concentration of LiCl for 30 min.
[3H]Ins(4/5)P2 was separated from pooled triplicate TCA extracts (2.4.2)
using a Partisphere 5 SAX H.P.L.C. column (2.6.3) and quantified by liquid
scintillation counting. Results are expressed as the radioactivity
associated with [3H]Ins(4,5)P2 as a percentage of the value obtained in the
absence of LiCl, and represent the mean ± SEM of four separate
experiments.
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Figure 6.4.2 Effect of lithium ion concentration on carbachol-stimulated
[3H]inositol 4-monophosphate accumulation
[3H]Inositol pre-labelled BTSM slices (2.3.1) were stimulated with 100 (iM
CCh in the presence of the indicated concentration of LiCl for 30 min.
[3H]Ins4P was separated from pooled triplicate TCA extracts (2.4.2) using a
Partisphere 5 SAX H.P.L.C. column (2.6.3) and quantified by liquid
scintillation counting. Results are expressed as the radioactivity
associated with [3H]Ins4P as a percentage of the value obtained in the
absence of LiCl, and represent the mean ± SEM of four separate
experiments.
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(in comparison to total [3H]InsPPs) than histaminergic stimulation. It is
possible therefore that CCh stimulation may effect Ins(4,5)P2
accumulation by routes other than Ins(l,4,5)P3 metabolism. However, as
detailed in the previous chapter, Ins(l,4,5)P3 can be channelled
differentially through the 3-kinase and 5-phosphatase pathways in
response to CCh and Hist; equally a putative 1-phosphatase activity could
be subject to such differential regulation.
Studies in a variety of cell types have indicated that receptor-mediated
activation of PLD may occur through several mechanisms including
protein tyrosine kinase activation (e.g. Cook and Wakelam, 1992),
increases in intra- and extracellular Ca2+ (e.g. Lin and Gilfillan, 1992; Wu
et al., 1992) and activation of G-proteins (MacNulty et al., 1992). However
PLD activation is most widely recognised to occur secondary to PKC
activation since in most cells phorbol esters cause persistent activation of
both PKC and PLD (see Shukla and Halenda, 1991). It would seem
unlikely that a PKC-stimulated PtdIns(4,5)P2-specific PLD activity was
responsible for the [3H]Ins(4,5)P2 accumulation in the present study for
the following reasons: (1) CCh-stimulated activation of PLD in BTSM
and bradykinin-stimulated PLD activation in guinea-pig ASM cells is
rapid and transient and therefore could not (alone) account for the
delayed and progressive accumulation of [3H]Ins(4,5)P2 observed in BTSM
(Challiss et al., manuscript in preparation; Pyne and Pyne, 1993); and (2)
treatment of BTSM slices with PDBu fails to induce [3H]Ins(4,5)P2
accumulation or alter the proportion of [3H]Ins(4,5)P2 accumulating in
response to either Hist or CCh. This latter observation is in agreement
with the study by Jenkinson et al. (1992) in rat cerebral cortex in which
neither activation nor inhibition of PKC had any effect on the basal or
CCh-stimulated accumulation of [3H]Ins(4,5)P2-
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Ins(4/5)P2 is more likely produced by the action of a novel 1-phosphatase
on Ins(l,4,5)P3 similar to that described in the slime mould Dictyostelium
discoideum (Van Lookeren Campagne et al., 1988). These authors
demonstrate that the major route of dephosphorylation of Ins(l,4,5)P3 is
via a 1-phosphatase and that the resulting Ins(4,5)P2 is further degraded to
Ins4P. Hence, as suggested by Bominaar et al. (1991), two novel enzymes
catalysing the specific dephosphorylation of Ins(l,4,5)P3 at the 1-position
and of Ins(4,5)P2 at the 5-position may exist in this organism, in addition
to the more familiar Ins(l,4,5)P3/Ins(l,3,4,5)P4 5-phosphatase and the
Ins(l,4)P2/Ins(l,3,4)P3 1-phosphatase. Jenkinson et al (1992) were unable
to demonstrate a dephosphorylation of [3H]Ins(l,4,5)P3 to [3H]Ins(4,5)P2
with crude brain homogenates. However, Hughes and Drummond
(1987) state that in the absence of added ATP, sonicated GH3-cell
preparations can, to small extent, metabolise [3H]Ins(l,4,5)P2 to a
substance with identical chromatographic properties to [3H]Ins(4,5)P2- It is
possible therefore that compartmentalisation or concentration of
Ins(l,4,5)P3 with the putative Ins(l,4,5)P3 1-phosphatase in vivo may
allow such a reaction to proceed.
A dramatic enhancement of [3H]Ins(4,5)P2 accumulation was observed in
the presence of low concentrations of Li+. An EC50 of 1.06 mM was
calculated for this effect, approximately one order of magnitude greater
than that determined in rat cerebral cortex (94 pM, Jenkinson et al., 1992).
These data suggest that metabolism of either Ins(4,5)P2 or possibly its
primary metabolite is inhibited by Li+. In the latter case the metabolism
of Ins(4,5)P2 would be subject to product inhibition. Support for this
hypothesis comes from the study by Jenkinson et al. (1992) in rat cerebral
cortex. After muscarinic receptor blockade with atropine any
accumulated [3IT]Ins(4,5)P2 quickly decays in the absence of Li+, implying
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that metabolism of this isomer occurs rapidly in the intact cell. In the
presence of Li+ however, the metabolism of [3H]Ins(4,5)P2 was suppressed.
Ins(4,5)P2 is likely to be metabolised to either Ins4P or Ins5P. As detailed
earlier, Ins(4,5)P2 has been shown to be a weak substrate for the
Ins(l,4,5)P3/Ins(l,3,4,5)P4 5-phosphatase (Mitchell et al., 1989), however
this enzyme is not Li+-sensitive (Connolly et al., 1985; Seyfred et al., 1984)
nor is it likely to be inhibited by Ins4P since this enzyme is largely
unaffected by monophosphorylated compounds (Kennedy et al., 1990).
The possibility remains however, that Ins(4,5)P2 may be metabolised by a
novel Ins(4,5)P2 5-phosphatase such as that described in Dictyostelium
discoideum (Bominaar et al., 1991). Conversely involvement of a 4-
phosphatase in the metabolism of Ins(4,5)P2 is suggested by the presence
of Ins5P in rat cerebral cortex (Ackermann et al., 1987), a tissue in which
Ins(4,5)P2 has been detected.
The bell-shaped Li+ concentration-response curve observed for [3H]Ins4P
accumulation can be explained by the competitive inhibitory action of Li+
on the inositol monophosphatase enzyme, and their less potent
inhibitory effect on the Ins(l,4)P2/Ins(l,3,4)P3 1-phosphatase. At low
concentrations of Li+ inositol monophosphatase is strongly inhibited (Kj
< 1 mM, Gee et al., 1988; Hallcher and Sherman, 1980) resulting in a rapid
accumulation of [3H]Ins4P. At higher concentrations of LiCl however ,
the 1-phosphatase is effectively inhibited (Kj ~ 6 mM, Inhorn and
Majerus 1987), thus decreasing the supply of [3H]Ins4P and therefore its
accumulation. The formation of Ins(4,5)P2 from Ins(l,4,5)P3 by a Li+-
sensitive Ins(l,4,5)P3 1-phosphatase akin to that found in Dictyostelium
discoideum (Van Lookeren Campagne et al., 1988) could similarly
account for the bell-shaped Li+ concentration-response curve for
[3H]Ins(4,5)P2 accumulation.
210
[3H]Ins(4/5)P2 accumulation is stimulated in BTSM by muscarinic- and
histaminergic receptor stimulation. The former receptor appears to
couple more effectively to Ins(4,5)P2 generation. The accumulation of
this novel bisphosphate isomer is highly sensitive to Li+, indicating that
in vivo, in the absence of Li+, there may be a substantial flux of the
inositol headgroup through Ins(4,5)P2- The lack of effect of pre-treatment
with PDBu on the pattern of basal, Hist- or CCh-stimulated Ins(4,5)P2
accumulation renders it unlikely that PKC-stimulated, PLD-mediated
hydrolysis of PtdIns(4,5)P2 is the major source of Ins(4,5)P2 in this tissue.
However, a role for PLD hydrolysis, activated by an alternative
mechanism such as that described in human polymorphic nuclear
leukocytes (Perianin et al., 1993), in Ins(4,5)P2 production cannot be ruled
out. The most likely source of Ins(4,5)P2 in BTSM appears to be
Ins(l,4,5)P3. A Li+-sensitive Ins(l,4,5)P3 1-phosphatase could account for
the bell-shaped Li+ concentration-response curve observed for
[3H]Ins(4,5)P2 accumulation. This therefore may represent a novel
additional route for Ins(l,4,5)P3 metabolism especially at later time-points
of agonist stimulation when the 5-phosphatase activity decreases.
Ins(4,5)P2 is probably further metabolised to either Ins4P or Ins5P. While
the primary metabolite of Ins(4,5)P2 remains uncertain, it is clear that the
enzyme responsible for the dephosphorylation of this InsP2 is strongly
inhibited by Li+ ions.
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SUMMARY
Excessive bronchoconstriction is an important factor governing airways
calibre in conditions such as asthma and the pharmacological
manipulation of the contractile response of ASM plays a central role in
the treatment of this and many other respiratory diseases. Contraction is
initiated following stimulation of surface receptors by spasmogens and
the generation of Ins(l,4,5)P3- This second messenger plays a pivotal role
in pharmacomechanical coupling in ASM and is subject to rapid agonist-
stimulated metabolism via a complex cascade of reactions which to date
have been poorly studied in this tissue. A knowledge of the factors which
determine the intracellular concentration of Ins(l,4,5)P3 is of considerable
importance since it may facilitate the generation of therapeutic
modulators of ASM contraction and provide an understanding of the
mechanisms underlying the currently used bronchodilators. The aims of
this thesis were to study, in detail, the formation and metabolism of
Ins(l,4,5)P3 in an ASM model and to determine the factors which could
modulate this response.
A model system was established in which BTSM slices were labelled to
steady-state with wyo-[3H]inositol and subsequently stimulated with
agonist for various time-periods in the presence of Li+ ions to prevent the
breakdown of InsPi isomers. This protocol allowed accurate
quantification of InsPP accumulation following agonist-stimulation of
BTSM. An important finding of the initial studies was the lack of
demonstrable phosphoinositide hydrolysis following either membrane
depolarisation or physiological increases in [Ca2+]j. In addition, no
accumulation of InsPs was observed following activation of PKC with
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PDBu, indicating that PKC-stimulated Ptdlns-specific PLD activity is
unlikely to contribute significantly to the agonist-stimulated InsP
accumulation. The model therefore provided an appropriate system for
monitoring the metabolism of agonist-stimulated, PtdIns(4,5)P2-derived
Ins(l,4,5)P3. The muscarinic cholinoceptor agonist carbachol (CCh)
induced a rapid and transient accumulation of [3H]InsP3 accompanied by
secondary increases in [3H]InsP2 and delayed increases in [3H]InsPi.
Experiments utilising cell-free preparations of BTSM indicated that, as in
other tissues, Ins(l,4,5)P3 could be metabolised by two major pathways -
the 3-kinase and 5-phosphatase pathways - to yield a series of mutually
exclusive InsPP products. Further experiments were therefore
undertaken to determine the relative contributions of these two
pathways to agonist-stimulated Ins(l,4,5)P3 metabolism in BTSM.
Following prolonged (30 min) stimulation with a maximally effective
concentration of CCh the 5-phosphatase pathway accounted for 75 % of
the total metabolism of [3H]Ins(l,4,5)P3. Detailed time-course analysis
however revealed that the flux of [3H]Ins(l,4,5)P3 through the two
enzyme pathways varied during the agonist-stimulated response. The 5-
phosphatase pathway was highly dominant especially at early time-
points, accounting for more than 85 % of the total metabolism over the
first 5 sec following agonist-addition. The 3-kinase pathway became
increasingly important at later time-points.
Since the 3-kinase pathway provides many additional putative second
messenger and functional molecules the factors governing the regulation
of metabolism through the two pathways may be extremely important to
cell signalling and the contractile response. To gain a greater
understanding of the enzymes involved, kinetic studies of the Ins(l,4,5)P3
3-kinase and Ins(l,4,5)P3 5-phosphatase were undertaken. The 5-
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phosphatase activity was found to be predominantly particulate. The
similar affinity of the soluble and particulate 5-phosphatase activities
indicate that these enzymes may be identical and are likely to be Type la
isoforms. The particulate 5-phosphatase had a higher capacity and lower
affinity for Ins(l,4,5)P3 metabolism (Vmax = 45-50 nmol min-1 mg
protein-1; Km = 15-20 pM) than the soluble 3-kinase (Vmax = 323-360 pmol
min-1 mg protein-1; Km = 2-2.5 pM). The affinity of the 3-kinase however
was relatively low compared to studies obtained in most other tissues. A
finding of particular interest in the current study was that neither the 3-
kinase nor 5-phosphatase activities were significantly affected by
physiologically relevant increases in [Ca2+]free. The 3-kinase is generally
thought to be activated by Ca2+ via an increase in its Vmax- This
conclusion however is based on studies conducted in the absence of
calpain inhibitors. The 3-kinase has been shown to be a substrate for
calpain and sequencing studies have demonstrated that it contains
several putative calpain cleavage sites. The inclusion of calpain
inhibitors in the current study indicates that the intact enzyme, at least in
this model system, is insensitive to changes in [Ca2+]frce, and highlights
the possibility for activation of this enzyme following limited calpain-
mediated proteolysis. An important area of further research with clinical
applications may therefore be the study of regulators of calpain activity
and their effect on the ASM contractile response.
Stimulation of BTSM with a maximally effective concentration of
histamine (Hist) results in a decreased (~ 30 % ) [3H]InsP and Ins(l,4,5)P3
response compared to stimulation with a maximally effective
concentration of CCh. This decrease in the initial accumulation of
Ins(l,4,5)P3 is associated with a relatively greater metabolism of
Ins(l,4,5)P3 through the 3-kinase pathway. It is quite possible that the
214
'stimulation' of the 3-kinase simply reflects the higher affinity of this
enzyme for Ins(l,4,5)P3 rather than any direct modulation of the 3-kinase
or 5-phosphatase enzyme kinetics.
The Hist- and CCh-stimulated [3H]InsP responses displayed differential
sensitivity to both activation of PKC with PDBu, and (32-adrenoceptor
stimulation with either salmeterol (Salm) or salbutamol (Salb). Pre-
treatment of BTSM slices with PDBu resulted in 99 % and 76 % maximal
inhibition of the (30 min) Hist- and CCh-stimulated [3H]InsP responses
respectively. The mechanisms underlying the PKC-mediated selective
feedback inhibition of Hi receptor-PIC coupling are unknown but may
involve phosphorylation of the G-protein/PIC signal transducing
machinery. These data therefore support the suggestion that the H]
histaminergic and M3 muscarinic receptors are coupled to alternative G-
protein and/or PIC isozymes, and that a component of the desensitisation
of the InsP response to Hist is mediated via a PKC inhibitory pathway.
The Hist-stimulated [3H]InsP response, unlike the CCh-stimulated
[3H]InsP response, was also inhibited by pre-treatment with P2-
adrenoceptor agonists. Salm, a novel, long-acting P2-adrenoceptor
agonist was a considerably more potent inhibitor of the Hist-stimulated
[3H]InsP response (IC50 = 0.24 nM) than the short-acting P2-adrenoceptor
agonist Salb (IC50 = 10.8 nM). In order to determine whether the
differential effects of Salm and Salb on agonist-stimulated [3H]InsP
production underlie their differential relaxant responses the time-courses
of Salm- and Salb-mediated inhibition of Hist-stimulated [3H]InsP
accumulation were examined. Both agents resulted in a substantial but
short-term inhibition of the Hist-stimulated L3HJInsP response which
gradually recovered between 1 and 24 h following addition of the P2-
adrenoceptor agonist. A significant difference in the Salm- and Salb-
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mediated inhibition was only observed at the earliest time-point
measured (1 h). Since Salm has been shown, in an identical model, to
produce relaxation over a far longer time-period than Salb, this data
would suggest that the inhibition of agonist-stimulated phosphoinositide
hydrolysis may not be the major mechanism underlying |32-adrenoceptor-
mediated relaxation of ASM.
An important and unexpected finding encountered during the course of
these studies was the agonist-stimulated and Li+-sensitive accumulation
of a novel [3H]InsP2 isomer tentatively identified as [3H]Ins(4,5)P2- Since
the origins and metabolic fate of this isomer are currently unknown
further detailed experiments were conducted to try and determine its
possible routes of formation and metabolism. The CCh-stimulated
accumulation of this isomer only reached significant values at later time-
points (> 5 min) following agonist addition. The accumulation of
[3H]Ins(4,5)P2 indicates the possible existence of a Ptdlns-specific PLD
activity in BTSM or of a novel Ins(l,4,5)P3 1-phosphatase. Although the
first suggestion cannot be ruled out entirely, such an activity does not
appear to be stimulated following PKC activation (the dominant
mechanism underlying PLD activation in ASM) since treatment of BTSM
with PDBu was without effect on either basal [3H]Ins(4,5)P2 accumulation
or the relative amount of [3PI]Ins(4,5)P2 accumulation following Hist- or
CCh stimulation. [3H]Ins(4,5)P2 and [3H]Ins4P accumulation exhibited
bell-shaped Li+ concentration-response curves suggesting that similar
enzymes may be responsible for the formation and metabolism of these
two InsPs. The accumulation of [3H]Ins4P at low concentrations of Li+ is
due to the uncompetitive inhibition of the inositol monophosphatase
enzyme by Li+. At higher concentrations of Li+ the InsPP 1-phosphatase
is also inhibited thereby decreasing the supply of [3H]Ins4P from
216
[3H]Ins(l,4)P2. It is likely therefore that Ins(4,5)P2 is both formed and
metabolised by Li+-sensitive enzymes. Hence it is proposed that a novel
Li+-sensitive Ins(l,4,5)P3 1-phosphatase similar to that identified in
Dictyostelium discoideum, and a Li+-sensitive Ins(4,5)P2 4- or 5-
phosphatase exist in BTSM and account for observed concentration effects
of Li+ on the accumulation of [3H]Ins(4/5)P2- This data indicates the
presence therefore of a novel, albeit relatively minor, route of Ins(l,4,5)P3
metabolism in BTSM.
The studies documented in this thesis represent the first detailed analysis
of the InsPP isomers present in BTSM and have highlighted the potential
for the regulation of the pattern of InsPP accumulation by both PKA and
PKC. The complexity of the phosphoinositide signal transducing
pathways and their multiple regulatory mechanisms testify to the
importance of phosphoinositide signalling in ASM. Hist and CCh appear
to generate distinct patterns of InsPP accumulation in this tissue and
these responses display differential sensitivity to regulation by p2-
adrenoceptor agonists and PKC activation. These data imply that the two
agonists may utilise different G-protein or PIC isozymes, and hence a
future generation of highly specific G-protein and PIC inhibitors may
prove to be clinically relevant. In addition, a novel InsP2 isomer -
Ins(4,5)P2 - has been identified whose potential functional role is
currently unknown and which warrants further study.
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